The Cancer Research Society Division of Epidemiology fileThe Cancer Research Society Division of Epidemiology Department of Oncology McGill University REPORT OF ACTIVITIES 1995-2011

The Cancer Research Society

Division of Epidemiology

Department of Oncology

McGill University

REPORT OF ACTIVITIES

1995-2011

Director: Dr. Eduardo L. Franco

Prepared by

Gayle A. Shinder, PhD

Program Coordinator, Department of Oncology

Cancer Research Society Division of Epidemiology – Report of Activities, 1995-2011

2

Clockwise from top left: Gerald Bronfman Centre at 546 Pine Avenue West, Montreal, on McGill campus (the

home of the CRS Division of Epidemiology); Candida Pizzolongo and Eduardo Franco, the administrative secretary

and Director for the Division, respectively; Research Nurse Claude Richard (sitting), PhD student Andrea Spence,

and PhD student Tam Dang-Tan reviewing study documents; left to right: PhD student Javier Pintos, Inez

Nishimoto, a Visiting Trainee from Brazil, Eduardo Franco, and PhD student Nicolas Schlecht (circa 1999) .


3

TABLE OF CONTENTS

Page

1. Introduction 4

2. Prominence of the Research Program at the CRS Division of Epidemiology 5

3. Faculty and Staff 7

4. Research Interests 9

i. Cervical cancer and HPV-associated malignancies 10

ii. Upper aero-digestive tract cancers 11

iii. Prostate cancer 11

iv. Childhood malignancies 11

v. HIV epidemiology 11

vi. Epidemiologic methods 12

vii. Inflammation and cancer etiology and prognosis 12

viii. Other cancers: endometrial, esophageal 12

5. Research Collaborations 12

6. Funding History 14

7. Publications 20

8. Presentations 21

9. Education and Training 22

10. Conference Organization 28

11. Awards and Distinctions (to the CRS Division Director) 30

Appendix 1: Publications 1995-2011 31

Appendix 2: Invited Lectures and Session Leadership at Conferences and

Scientific Meetings 1995-2011 50

Appendix 3: Lectures and Seminars at Academic, Research and Clinical

Departments 1995-2011 66

Appendix 4: Abstracts and Short Communications 1995-2011 72


4

1. INTRODUCTION

In 1986 the Cancer Research Society provided an endowment of $1.5 M for the creation of the

Cancer Research Society (CRS) Division of Epidemiology at McGill University. The first

Director of the Division was Dr. Gerry Hill (1988-1989). In January 1990 this Division became

part of the newly created Department of Oncology which also incorporated the Divisions of

Cancer Research, Clinical Oncology, Radiation Oncology and Palliative Care. In 1991 Dr. John

Bailar became the Acting Director of the Division until 1995 when Dr. Eduardo Franco was

appointed as permanent Director.

In May 1992, thanks to an endowment from the Bronfman family, the Gerald Bronfman Centre

for Clinical Research in Oncology at 546 Pine Avenue West was officially opened. This

building not only became the focal point for oncology clinical trials at McGill and the location of

the Department’s administrative offices, it also became home to the CRS Division of

Epidemiology. The Division occupies a suite of offices on the first floor and basement of the

Gerald Bronfman Centre, for the Director, his administrative and research staff as well as

graduate students and fellows pursuing training in cancer epidemiology.

The CRS Division of Epidemiology is also known as the Division of Cancer Epidemiology

within the Department of Oncology, and the Cancer Epidemiology Unit within the McGill

Department of Epidemiology & Biostatistics. Its mission is threefold:

To conduct epidemiologic research on the etiology and prognosis of cancers of global

public health importance with an emphasis on proposing preventive practices.

To provide advanced training in cancer epidemiology and prevention to graduate

students and health professionals.

To provide epidemiologic oversight and expertise to clinical collaborators in oncology.

The Division also produced a regular newsletter containing summaries of the cancer

epidemiology and prevention literature on a quarterly basis to assist the CRS with its mail-out

funding campaigns. These layperson summaries, called “Facts and Stats in Cancer Epidemiology

and Prevention” were also regularly featured on the CRS website for many years. The “Facts and

Stats” series was regularly provided to the CRS from 1997 until 2004. A total of 26 quarterly

issues were written by the Division staff and students, each with two summaries of key articles

that had recently appeared in the medical literature and that were of broad interest to the

population. The series was discontinued in 2004 because the internet became then a ready source

of credible cancer information for patients and professionals.

Over the last fifteen years, the Division has focused its cancer epidemiology research programs

in eight areas:

1. Cervical cancer and HPV-associated malignancies

2. Upper aero-digestive tract cancers

3. Prostate cancer

4. Childhood malignancies (Wilms’ tumour)

5. HIV epidemiology

6. Epidemiologic methods


5

7. Inflammation and cancer etiology and prognosis

8. Other cancers: endometrial, esophageal

The following report outlines the academic activities of the CRS Division of Epidemiology since

1995 when Dr. Franco became the Director. It provides information on its research programs,

research productivity and dissemination of research findings through publications in international

journals, invited lectures and session chairmanship in national and international conferences,

invited seminars at academic, research and clinical departments worldwide, and offered poster

and oral presentations at national and international conferences. This report also provides

information on the Division’s involvement in teaching and training of undergraduate students,

graduate students at the Master’s and PhD level and postdoctoral fellows, in the field of cancer

epidemiology. The information presented here focuses on the work done by Dr. Franco and his

staff and trainees, as well as his collaborative work with other faculty members who are affiliated

with the program. Publications and presentations were not obtained from these other faculty

members since for the most part the ones relevant to this Division were done in collaboration

with Dr. Franco and are therefore already included in the list.

2. PROMINENCE OF THE RESEARCH PROGRAM AT THE CRS DIVISION OF

EPIDEMIOLOGY

Cervical cancer research: Our division is involved with many productive research tracks but

our cervical cancer prevention research program stands out because of its long-term history and

national and international prominence. Our cervical cancer research program at McGill is the

most productive in Canada and one of the top four in North America. Through Dr. Franco, the

Division is the recipient of a CIHR team grant on “HPV infection and associated diseases” that

brings together the most accomplished basic and clinical HPV scientists in Quebec. Our research

has provided much of the epidemiologic basis for the demonstration that human papillomavirus

(HPV) infection is the cause of cervical cancer. Our research has also proved the benefits of

HPV vaccination to prevent cervical cancer and of new molecular technologies to improve

cervical cancer screening. Because of the prominence of the Division’s program, Dr. Franco has

an extremely busy agenda as a guest speaker in national and international conferences and as

advisor to agencies such as NIH, CDC, WHO, PAHO, and IARC, as well as to governments and

industry. He is also a frequent advisor to teams involved with the health economics and health

technology related to cervical cancer prevention. Some of our most prominent studies and

activities are described below.

Dr. Franco brought to the CRS division the Ludwig-McGill cohort study of HPV infection and

cervical neoplasia (seed funding provided by the Ludwig Institute for Cancer Research and

subsequently funded by NIH, CIHR, and NCIC). This long-term molecular epidemiologic

investigation has been extremely productive, with 27 original papers, all of which are published

in high-impact journals, such as JAMA, JNCI, J Infect Dis, Int J Cancer, Cancer Epidemiol Biom

Prev and others, and has been highly cited. It was among the first to measure incidence and

clearance of HPV infections over time and to show the role of persistent HPV infection with

oncogenic viral genotypes in cervical carcinogenesis. It was also the only study so far to unveil

the role of HLA polymorphisms in mediating viral persistence.


6

The division has also conducted cohort studies of HPV infection among university students in

Montreal and case-control studies of biomarkers of cervical cancer risk. Findings from these

studies have been featured in prominent medical journals. One of these findings, the role of a p53

codon 72 polymorphism, resulted from our collaboration with McGill’s Greg Matlashewski, and

has inspired dozens of subsequent similar studies and review articles. Our study of HPV

transmission among university couples (HITCH cohort) is the first such investigation worldwide

and the initial findings are being used by health economists to analyze the cost-effectiveness of

male HPV vaccination.

As the momentum shifted to the HPV hypothesis in cervical cancer causation the biotechnology

sector began to develop tests for HPV DNA that could be used in cervical cancer screening. The

fear of malpractice litigation in the US favoured parallel use of this new test to compensate for

the high false-negative rate of Pap smears. As a prelude to our own trials of HPV testing, the

division contributed elegant demonstrations to show that the claims by the biotech industry that

there were major gains in sensitivity were biased (in one of the only statistical papers in the

history of the Amer J Obstet Gynecol [1999]). We were also the first to show that clinical trials

of HPV testing compared with Pap cytology had to compensate for verification bias in

colposcopy referrals to be able to reach valid conclusions (in a 2000 article in Cancer Epidemiol

Biom Prev describing a pioneer trial done in Newfoundland and in a 2003 JNCI Monograph

paper). Several subsequent trials began to use the approach we proposed.

In 2002 we launched the Canadian Cervical Cancer Screening Trial (CCCaST), a CIHR-funded

randomized controlled trial of over 11,000 women in Montreal and Newfoundland that was the

first to compare HPV testing directly to Pap cytology. The design and initial findings from this

RCT, the first in North America, have appeared in the IJC and in the NEJM and are assisting the

formulation of forthcoming guidelines in cervical cancer screening. A second generation study

expanding on the findings from CCCaST is now ongoing in British Columbia (a $6.5 million

study funded by CIHR) based on a design developed by the division (Dr. Franco is a

coinvestigator in the latter study). The CCCaST trial’s results have formed the basis for a change

in paradigm in cervical cancer screening in Canada. Provinces such as Quebec, Ontario, British

Columbia, and Newfoundland are beginning to reformulate their cervical cancer screening

guidelines to include HPV DNA testing as a primary technology.

Around 1995, when the pharmaceutical giants Merck and GSK (then SmithKline Beecham)

began to invest in developing HPV vaccines these companies sought our advice in their research

and development. We have since collaborated with GSK in the design and analysis of their phase

II trial of a bivalent (HPV types 16 and 18) vaccine. This trial’s design and sample size were

planned as per the results of the aforementioned Ludwig-McGill cohort study. Dr. Franco was a

lead author on both Lancet papers (2004 and 2006), which have accrued more than 1700

citations since. The Lancet editorial board elected the 2006 article among the most influential

achievements in medicine in 2007.

Most recently as we began to examine the possible impact of HPV vaccination on the prevalence

of cervical precancerous lesions in the population, we realized that a change in screening

paradigm (HPV DNA testing followed by Pap cytology to triage those who were HPV positive)

could fulfill the dual mission of being an adequate screening strategy as well as serving the role


7

of post-vaccination surveillance. We have published a few articles on the merits of this strategy

(e.g., Vaccine 2008, Arch Med Res 2009) and Dr. Franco has been invited to lecture

internationally dozens of times on this topic.

Research on other cancer and public health themes: The division has been successful in other

areas as well. Our studies of the etiology and prognosis of head and neck cancers and of

childhood cancers have unveiled findings that would not have been possible if it were not for our

tendency to innovate in study design. Our study of the possible harms from a needle exchange

program in Montreal aimed at curbing HIV transmission among IV drug users introduced novel

strategies of data analysis that enhance the validity of observational studies of controversial

associations.

Our research on diagnostic delays in oral cancer and more recently in childhood cancers have

pointed the way for provincial policies at curbing regional disparities and in identifying gaps in

deploying technical resources in oncology.

Our research program in prostate cancer etiology and prevention has turned out important

findings concerning the protective role of aspirin and other NSAIDs. We have also shown that,

contrary to medical belief, endometrial polyps are not true cancer precursors and have also

conducted a study that showed the considerable reduction in complications using robotic surgery

relative to conventional laparotomy or laparoscopic surgery.

In section 4, we list the various research projects and the student and fellows associated with

each.

3. FACULTY AND STAFF

Left to right: MSc student Steven Ades, secretary Candida Pizzolongo, MSc student Susie Lau, Research Nurse

Solange Piché, Research Nurse Claude Richard, PhD student Ann Burchell, Research Assistant Allita Rodrigues,

MSc student Tory Atwood, Division Director Eduardo Franco, MSc student Alexandra de Pokomandy, PhD

students Tam Dang-Tan and Andrea Spence, Database Manager Mario Matus, and PhD student Marie-Helene

Mayrand.


8

The Division currently has 12 research and academic staff, 11 associate or adjunct faculty and 1

visiting professor on sabbatical (Table 1). Due to financial constraints it has not been possible to

greatly expand the Division with full time faculty via tenure-stream appointments. However, in

2007 Dr. Agnihotram Ramanakumar joined the Division as a Research Biostatistician and was

appointed as Assistant Professor in January 2011. The addition of faculty members with joint

part-time appointments as well as adjunct and associate faculty has enriched the academic life of

the Division. Associate and adjunct faculty members come from McGill and Université de

Montréal as well as from academic institutions across Canada and in the United States. Several

of the adjunct and associate faculty are former graduate students and postdoctoral fellows who

have secured research positions at McGill or elsewhere (Paul Allison, Ann Burchell, Salaheddin

Mahmud, Helen Trottier).

Table 1 – Current research and academic staff of the CRS Division of Epidemiology RESEARCH AND ACADEMIC STAFF

1. Eduardo Franco, James McGill Professor and

Director (1995 – present)

2. Agnihotram Ramanakumar, Assistant Professor

(2007 – present)

3. Laurent Azoulay (Assistant Professor, joint part-

time appointment) (2008 – present)

4. Raghu Rajan (Associate Professor, joint part-time

appointment) (2003 – present)

5. Celia Greenwood (Associate Professor, joint part-

time appointment) (2009 – present)

6. Candida Pizzolongo (Administrative Secretary)

(1995- present)

7. Natalia Morykon (Research Nurse) (2008 –

present)

8. Amelia Rocamora (Research Nurse) (2009 –

present)

9. Allita Rodrigues (Medical Research Coordinator)

(2003 – present)

10. Jennifer Selinger (Epidemiologic Clerk) (2005 –

present)

11. Elizabeth Montpetit-Dubrule (Epidemiologic

Clerk) (2008 – present)

12. Sarah Penney (Epidemiologic Clerk) (2010 –

present)

Visiting Professor On Sabbatical

Edson D. Moreira Jr., Fed. Univ. Bahia, FIOCRUZ

(2011 – 2012)

ADJUNCT AND ASSOCIATE FACULTY

1. Paul Allison, Associate Professor and Dean,

Faculty of Dentistry (2002 – present)

2. Ann Burchell, Scientist, Ontario HIV Network

(2010 – present)

3. François Coutlée, Professor, Université de

Montréal (1999 – present)

4. Jocelyne Feine, Professor, McGill Faculty of

Dentistry (1997 – present)

5. Parviz Ghadirian, Professor, Université de

Montréal (1997 – present)

6. Mark Goldberg, Professor, McGill Department of

Medicine (1997 – present)

7. Salaheddin Mahmud, Assistant Professor,

University of Manitoba (2008 – present)

8. Greg Matlashewski, Professor and Chair, McGill

Microbiology and Immunology

(1999 – present)

9. Tom Rohan, Chair, Dept. Epidemiology, Albert

Einstein College of Medicine

(1997 – present)

10. Helen Trottier, Assistant Professor, Université de

Montreal (2009-present)

11. Sam Ratnam, Memorial University, Newfoundland

(2009 – present)

Past research and academic staff

Liliana Abruzzese (Research Nurse) (2002-2007)

Jonathan Assayag (Epidemiologic Clerk) (2008-2009)

Katia Bellegarde (Research Nurse) (2003-2008)

Myra Bernardin (Epidemiologic Clerk) (2003-2006)

Johanna Bleecker (Epidemiologic Clerk) (2006-2008)

Vicky D’Anjou-Pomerleau (Epidemiologic Clerk) (2006-2009)


9

Marie Désy (Part-time free lance biostatistician) (1997–2002)

Cristina Diaconu (Research Assistant) (2006-2008)

Eliane Duarte (Research Associate) (1997–2005)

Suzanne Dumais (Research Nurse) (1996-2009)

Gail Kelsall (Nurse-Interviewer) (1997–2010)

Eugene Lee (Epidemiologic Clerk) (2009-2011)

Mario Matus (Database and Website Manager) (2004-2007)

Jason Carlos Parente (Epidemiologic Clerk) (2003-2005)

Solange Piché (Research Nurse, Study-Interviewer) (2001-2006)

Claude Richard (Research Nurse) (2003-2009)

Nicole Rousseau (Research Assistant, Study-Interviewer) (2001-2004)

Cara Schwartz (Epidemiologic Clerk) (2004-2008)

Nathalie Slavtcheva (Research Nurse) (2001- 2011)

Amy Toporowski (Epidemiologic Clerk) (2010-2011)

Rita Zakarian (Research Assistant) (1995-1997)

4. RESEARCH INTERESTS

Research Assistant Allita Rodrigues (left) and Epidemiologic Clerk Cara Schwartz (right) preparing specimens for

analysis.

As described in section 2 above, the CRS Division of Epidemiology is involved in a wide range

of research studies which have been published in prominent journals. Some of these studies have

been important in guiding cancer screening and other prevention policies. Below is a list of

research studies conducted by Division members and trainees.


10

i. Cervical cancer and HPV-associated malignancies

Etiology, Natural History, and Transmission • Ludwig-McGill cohort (NIH, CIHR, NCIC) A. Negassa, H. Makni, M.C. Rousseau, N.

Schlecht, S. Yang, S. Kulaga, S. Mahmud, S. Lau, H. Trottier, A. Ramanakumar, R.

Ferguson, M. Chevarie-Davis

• McGill-Concordia cohort (CIHR) H. Richardson, K. Robinson, S. Mahmud, H. Trottier,

A. Ramanakumar, R. Ferguson, M. Smith

• HITCH cohort (CIHR, Merck, NIH) A. Burchell

• BCCR (CIHR) and other case-control and lab studies (CIHR, NCIC) A. Koushik, A.

Schaffer, S. Ades, H. Trottier, R. Ferguson

• Inuit cohort (FRSQ, CIHR) (led by P. Brassard)

Screening

• Newfoundland primary screening Study (NHRF) co-led by S. Ratnam

• Kinshasa (Congo) Screening Study (PATH) G. Lugoma, S. Mahmud, A. Ramanakumar

• CCCaST Trial (CIHR, Merck) M-H Mayrand

• PICCS study: Psychosocial impact of HPV screening results (CIHR) (led by Z. Rosberger)

• BC RCT (HPV-Focal) (CIHR) led by A. Coldman, G. Ogilvie

• PEACHS: Pap Efficacy And Cervical HPV Status Study Consortium L. Richardson, A.

Ramanakumar

HPV vaccination • Analysis of GSK’s phase 2b trial data and natural history studies (GSK) H. Trottier, A.

Ramanakumar, S. Mahmud

• RCT of Transmission Reduction and Prevention Using HPV Vaccine (TRAP-HPV study)

(Merck) Z. El-Khatib, A. Ramanakumar, T. Dang-Tan, A. Burchell

• Epidemiologic Approach to Evaluate the Potential for HPV Type Replacement Post-

Vaccination (GOC) J. Tota

Other preventive strategies • RCT of carrageenan-containing vaginal gel to prevent HPV infection (CATCH trial)

(CIHR) J. Tota, A. Burchell, A. Ramanakumar

Health Services and Cost-Effectiveness • ICCAS: Audit study of invasive cervical cancers in Montreal (CIHR) A. Spence

• Racial and Socioeconomic Disparities in Cervical Cancer Survival in the United States C.

Sirjoosingh

• Cost-effectiveness analysis of new screening technologies specific to Canada (NCIC) (led

by R. Rajan) C.V. Atwood

• New approaches in modeling (NIH) (led by S. Goldie) S. Mahmud

• Role of herd immunity in modelling HPV transmission (led by M. Brisson)

(Consultation to individual scientists, governments, WHO, NGOs, and industry)


11

HPV and Anogenital Cancers • HPV natural history and anal lesions in HIV-positive men under HAART (NCIC) A. de

Pokomandy, H. Trottier

ii. Upper aero-digestive tract cancers

Etiology

• Case-control study of UADT cancers in Brazil (Ludwig Institute, CRS) I. Nishimoto, J.

Pintos, J. Chen, N. Schlecht

• Bleomycin sensitivity and UADT cancer risk (MRC) N. Sadeghi

• Case-control study of HPV and oral cancers in Montreal (NCIC, IARC) J. Pintos

• Molecular and social variables in UADT cancers (Montreal, Brazil, S. Africa, UK, India)

(CIHR) (led by B. Nicolau, P. Allison, M.C. Rousseau)

Prognosis and early detection • HPV as prognostic marker of survival (FRSQ) J. Pintos

• Diagnostic delays in UADT cancers in Montreal P. Allison

• Diagnostic delays in UADT cancers in Brazil A. Carvalho

iii. Prostate cancer

Etiology and prognosis

• Cohort study of NSAID use and prostate cancer risk and prognosis (CIHR, USDOD, co-

led by A Aprikian) S. Mahmud

• Meta-analysis and regression of epidemiologic studies of NSAID use and prostate cancer

risk S. Mahmud

• Cross-sectional study of NSAID use and prostate cancer risk S. Mahmud

• Cohort study of statin use and prostate cancer risk and prognosis (CIHR) S. Mahmud

• Case-control study of NSAID use and prostate cancer (CIHR) led by M-E Parent, J.J.

Mansure

iv. Childhood malignancies

Etiology and prognosis • Case-control study of Wilms’ tumour in Brazil (CRS) C. Sharpe

• Prognostic factors of Wilms’ tumour recurrence and survival (Brazilian Research

Council) B. Camargo

• Diagnosis and treatment delays in childhood malignancies in Canada (CIHR) T. Dang-Tan

v. HIV epidemiology

Etiology and social aspects

• St-Luc cohort of IV drug users (NHRDP, CIHR) J Bruneau

• Quality of life of IV drug users (CIHR) S Brogly


12

vi. Epidemiologic methods

Measurement errors

• Influence on mediation by an intermediate causal factor (T Rohan)

• Determining that a factor is a necessary cause when it is measured with error (T Rohan)

Biases in assessing screening efficacy

• Verification bias in cervical cancer screening (S Walter)

• False gain in sensitivity in studies of adjunctive screening tests (S Walter)

Impact of study design • Monte-Carlo simulation study of the influence of study design variables on persistent

HPV infection (S Mahmud)

• Meta-analysis and meta-regression of HPV screening studies (MH Mayrand)

• Meta-analysis and meta-regression of epidemiologic studies of polio vaccines, simian

virus 40 and cancer (T Dang-Tan)

vii. Inflammation and cancer etiology and prognosis

• Post-operative complications and lung cancer survival (A Andalib)

viii. Other cancers: endometrial, esophageal

• Robotic surgery outcomes in endometrial cancer (A Ramanakumar)

• Endometrial polyps and endometrial cancer risk (A Ramanakumar)

• Barrett’s esophagus and natural history of esophageal cancer (S Al-Nasser)

5. RESEARCH COLLABORATIONS (past and present)

Pathologist Alex Ferenczy, one of our closest collaborators

The Division has collaborations with local, national and international researchers and clinician

scientists with a wide range of expertise including pathology, gynecologic oncology, head and

neck cancer, radiation oncology, cancer prevention and psychosocial oncology (see list below).

McGill and MUHC

1. Michal Abrahamowicz, McGill Epidemiology and MUHC

2. Armen Aprikian, MUHC Urology


13

3. Jocelyne Arseneau, McGill and MUHC Gyne Oncology

4. Paul Brassard, McGill Epidemiology and MUHC

5. Martin Black, McGill Otolaryngology, JGH

6. Sergio Faria, McGill and MUHC Radiation Oncology

7. Alex Ferenczy, McGill Pathology, JGH

8. Lorenzo Ferri, McGill and MUHC Surgery

9. Lucy Gilbert, McGill and MUHC Gyne Oncology

10. Walter Gotlieb, McGill Pathology, JGH

11. James Hanley, McGill Epidemiology

12. Karen Kost, MUHC Otolaryngology

13. Markus Martin, McGill and MUHC Gyne Oncology

14. Greg Matlashewski, McGill Microbiology, Cancer Centre

15. Robert Platt, McGill Epidemiology and MUHC

16. Michael Pollak, McGill Oncology, JGH

17. Zeev Rosberger, JGH Psychiatry, McGill Oncology

18. George Shenouda, McGill and MUHC Radiation Oncology

19. Pierre Tellier, McGill Family Medicine

20. Te Vuong, McGill and MUHC Radiation Oncology

U of M and CHUM

1. François Coutlée, U of M, Notre-Dame

2. Pierre Drouin, U of M, Notre-Dame

3. Marie-Josée Dupuis, U of M, St-Luc

4. Parviz Ghadirian, U of M, Hotel-Dieu

5. Diane Provencher, U of M, Notre-Dame

6. Isabel Rodrigues, U of M, Cité de la Santé

7. Michel Roger, U of M, Notre-Dame

Elsewhere in Montreal

1. Jacques Archambault, IRCM

2. Patricia Goggin, INSPQ

3. Marc Steben, INSPQ

4. Marie-Elise Parent, INRS-Inst Armand-Frappier

Other Canada

1. Marc Brisson, Laval University

2. Melanie Drolet, Laval University

3. Vincent Fradet, Laval University

4. Sam Ratnam, Newfoundland Public Health Laboratory

5. Gail Eyssen, University of Toronto

6. Andrew Coldman, BC Cancer Agency

USA

1. Anna Giuliano, University of Arizona, Tucson

2. Sue Goldie, Harvard U, Boston

3. Laura Koutsky, University of Washington, Seattle


14

4. Shalini Kulasingam, University of Minnesota, Minneapolis

5. Tom Rohan, Albert Einstein College of Medicine, NY

6. Nicolas Schlecht, Albert Einstein College of Medicine, NY

7. Tom Wright, Columbia University, New York

Outside North America

1. Marly Cardoso, University of São Paulo

2. Silvia Franceschi, IARC, Lyon

3. Luiz Kowalski, Cancer Hospital, São Paulo

4. Rui Medeiros, University of Porto, Portugal

5. Luisa Villa, Ludwig Institute for Cancer Research, São Paulo

6. FUNDING HISTORY

In addition to the invaluable support from the CRS endowment, our research has been funded by

the Canadian Institutes of Health Research (CIHR), the US National Institutes of Health,

National Cancer Institute of Canada, and Fonds de la recherche en santé du Québec (FRSQ). A

detailed listing of all our funded projects is provided below.

0.00

500,000.00

1,000,000.00

1,500,000.00

2,000,000.00

2,500,000.00

1994

-95

1995

-96

1996

-97

1997

-98

1998

-99

1999

-00

2000

-01

2001

-02

2002

-03

2003

-04

2004

-05

2005

-06

2006

-07

2007

-08

2008

-09

2009

-10

2010

-11

2011

-12

2012

-13

2013

-14

2014

-15

PI Co-PI Co-Investigator CRS-Division

Figure 1 – Funding History


15

Dr. Franco as Principal Investigator or Co-PI (amounts in Canadian dollars unless stated

otherwise)

1. Determinants of persistence of cervical HPV infection: A prospective study (E Franco, L

Villa [Co-PIs]). Ludwig Institute for Cancer Research (approx. $472,000 [US$ 349,700],

1993-1998).

2. Cancer attributable risks due to tobacco smoking in North America. Health Canada ($10,000,

contract, 1994-95).

3. Molecular diagnosis of HPV in cervical cancer screening (L Villa, E Franco [co-PIs], several

others). Brazilian Ministry of Planning ($230,000, 1998-00).

4. Molecular epidemiology of persistent HPV infection (E Franco, L Villa, A Ferenczy, T

Rohan). National Institutes of Health (NCI Grant # RO1 CA70269, approx. $ 890,000 [US$

641,058], 1996-99; renewed 1999-03: approx. $1,200,000 [US$799,961]; renewed 2003-05:

US$250,000).

5. Persistent HPV infection and cervical intraepithelial neoplasia (E Franco, A Ferenczy, M

Arella, F Coutlée). Medical Research Council of Canada (Grant #MT-13649, $408,690,

1996-01), Canadian Institutes of Health Research (Grant MOP-53111, $199,678, 2002-05).

6. Natural history of HPV infection and cervical neoplasia in a high risk area (E Franco, A

Ferenczy, G Matlashewski, T Rohan, R Platt). Medical Research Council of Canada (Grant

#MA-13647, $51,360, 1996-98, renewed 1999-01: grant MOP-49396, $63,260, renewed

2001-04: $122,739, renewed 2004-07: $122,242, renewed 2007-10: $167,670).

7. Case-control study of HPV and oral cancer (E Franco, M Black, J Feine, P Ghadirian).

National Cancer Institute of Canada (Grant # 8147, $136,535, 1997-00, renewed 2000-01,

$20,438).

8. p53 polymorphism and susceptibility to human papillomavirus associated cervical cancer (G.

Matlashewski, E Franco [co-PIs]). National Cancer Institute of Canada (Grant # 09259,

$280,700, 1998-01, renewed 2001-02, $44,100).

9. Report on the epidemiology and prevention of cervical cancer in Canada. Cancer Bureau,

Laboratory Centre for Disease Control, Health Canada ($6,000, contract, 1999).

10. Antioxidant nutrients among a Brazilian population (A Giuliano, E Franco [co-PIs], J

Marshall, D Roe, L Villa, N Craft) National Institutes of Health (NCI Grant # RO1CA81310,

approx. $1.3 million [US$ 870,000], 2000-03, Subcontract US$75,656 (CA$98,254.59);

Renewed under the title “Effect of oxidant load on HPV persistence and CIN”, 2004-08,

approx. $1.2 million, Subcontract approximately CA$111,000).

11. Biomarkers of cervical cancer risk (E Franco, F Coutlée, G Matlashewski, M. Pollak, M

Roger) Canadian Institutes of Health Research (CIHR grant #MOP-42532, $418,119, 2000-

04; renewed 2005-08, $313,587).

12. Efficacy trial of HPV versus Pap testing for screening cervical cancer precursors (E Franco,

F Coutlée, S Ratnam, S Walter, E Duarte, I Rodrigues, R Rajan, M Steben). Canadian

Institutes of Health Research (CIHR grant #MCT-54063, $1,071,837, 2002-07).


16

13. PAP Cytology Screening Failure: Influences of the Patient, Physician, and Laboratory (E

Franco, E Duarte-Franco, F Coutlée, A Ferenczy, P Ghadirian, M Dawes, M Deschamps, P

Drouin). Canadian Institutes of Health Research (grants # IHS-61108, $48,545, 2002-03 and

MOP-64454 $312,945, 2003-07).

14. Diagnostic and treatment delays in childhood cancers in Canada (E Franco, M Greenberg, R

Barr, H Morrison, L Mery). Canadian Institutes of Health Research (grant MOP-64455,

$55,498, 2003-05).

15. Non-steroidal anti-inflammatory drug use and prostate cancer risk and prognosis (A

Aprikian, E Franco [co-PIs], R Platt, D Skarsgaard, P Beck, J Tonita). Canadian Institutes of

Health Research (grant MOP-64441, $163,660, 2003-05) (declined) United States

Department of Defense (grant W81XWH-04-1-0175, US$ 307,804, 2004-2006).

16. HPV infection and transmission among couples through heterosexual activity (the HITCH

cohort) (E Franco, F Coutlée, J Hanley, P Tellier). Canadian Institutes of Health Research

(grant# MOP68893, $546,544, 2004-09; renewed 2009-13, $577,824).

17. CIHR Team in HPV infection and associated diseases (E Franco, F Coutlée [co-PIs], M

Roger, G Matlashewski, P Brassard, Z Rosberger, A Al-Moustafa, J Archambault, P Davies,

B Duval, R Rajan). Canadian Institutes of Health Research (grant #83320, $2,242,318, 2007-

13).

18. Randomized Controlled Trial of the Efficacy of Carrageenan as a Topical Microbicide

Against HPV Infection (E Franco, A. Burchell, F Coutlée, P Tellier). Canadian Institutes of

Health Research (grant #MOP-106610, $668,050, 2010-15).

19. HITCH: A Study of HPV Transmission in Young Couples (E Franco, A. Burchell, F Coutlée,

M. Roger, P Tellier, J Hanley). US National Institutes of Health (grant R01AI073889, US$

431,632, 2010-14).

As Co-Investigator (amounts in Canadian dollars unless stated otherwise)

1. The relationship of hormone replacement therapy to HPV prevalence and minor grade

cytologic atypia in postmenopausal women (M Gelfand, A Ferenczy, E Franco). Jewish

General Hospital's Intramural Research Funds ($59,000, 1994-97).

2. Prévalence et incidence de l'infection VIH chez les usagers de drogue par injection à

Montréal: la cohorte Saint-Luc (F Lamothe, J Bruneau, J Soto, J Vincelette, E Franco, B Van

Caloen). National Health Research and Development Program, Health and Welfare Canada

(Grant #AIDS 6605-2936, $492,762, 1994-96).

3. In vivo effects of 60 Hz MFs on brain tumor promotion (R Mandeville, M Lis, D Oth, E

Franco). U.S. National Institutes of Health (Grant #1 R01 ES07049-01, $480,000, 1994-97).

4. Modelisation comportamentale qualitative chez les usagers de drogue a Montreal (J Bruneau,

B Van Caloen, F Lamothe, E Franco, J Soto, J Vincelette). National Health Research and

Development Program, Health Canada (Grant #AIDS 6605-4832, $96,013, 1996-97).

5. Molecular epidemiology of persistent human papillomavirus infection - Toronto (T Rohan, D

Harnish, E Franco). National Cancer Institute of Canada (Grant #7332, $171,000, 1996-98).


17

6. Quebec Family Cancer Network (P Ghadirian, A Aprikian, W Foulkes, E Franco, D Labuda,

A Lacroix, A Masson, M Plante, D Provencher, F Rousseau, J Simard, P Tonin). Fonds de la

recherche en santé du Québec (Grant #960067, $180,000 / year, 1996-98).

7. Efficacy of the combination Papanicolaou smear and HPV testing in primary cervical

screening: a prospective cohort study in Newfoundland (S Ratnam, E Franco, A Ferenczy).

Newfoundland Cancer Treatment and Research Foundation ($6,000) and Memorial

University of Newfoundland ($6,000) (1997-99).

8. Role of syringe access & risk factors on HIV Transmission (M Schechter, J Bruneau, F

Lamothe, E Franco, and several others). National Institutes of Health (NIDA Grant # RO1

DA11591-01, approx. $3M [US$ 2,129,340], 1998-01; approx. half for the Montreal team).

9. Rôle du virus herpes simplex type 2 dans les lésions prénéoplasiques et néoplasiques du col

utérin (F Coutlée, E Franco, D Provencher). Fonds de la recherche en santé du Québec (grant

#980927, $117,594, 1998-00).

10. Infrastructure for oral health research and pain control (J Lund, J Feine, C Bushnell, A

Vainio, R Melzack, E Franco, R Cohen, Z Rosberger). Canada Foundation for Innovation

(grant #NA, $139,691 from CFI and $210,000 from provincial government and institutional

partnership, 1999-00).

11. Canadian Cancer Etiology Research Network (G Eyssen, E Franco, M Jain, P Levallois, L

Marrett, J McLaughlin, M Pollak, N Birkett, S Buehler). National Cancer Institute of Canada

(grant #72016057, $1.5 million, 2000-05).

12. Le virus du papillome humain chez les Inuits du Québec: un projet pilote (P Brassard, E

Franco, F Coutlée). Fonds de la recherche en santé du Québec (grant #004051, $15,000,

2000-01).

13. Le virus du papillome humain et le cancer du col uterin dans une population Inuit du nouveau

Québec (P Brassard, F Coutlée, E Franco). Fonds de la recherche en santé du Québec (grant

#13-1027-014013, $117,050, 2001-03).

14. Anal intraepithelial lesions in HIV-seropositive men under HAART (F Coutlée, E Franco, D

Rouleau). National Cancer Institute of Canada (grant # 012030, $396,285, 2001-04; renewed

2004-08, $325,000).

15. HPV DNA Detection by Hybrid Capture as a Predictor of Recurrent VIN (F Coutlée, P

Gauthier, E Franco). Canadian Cancer Etiology Research Network of the National Cancer

Institute of Canada (grant #02-05-02, $19,934, 2002).

16. A phase II study of pre-operative radiation therapy and chemotherapy using Intensity-

Modulated Radiation Therapy (IMRT) for patients with unresectable rectal cancer (G

Shenouda, T Vuong, P Gordon, T Falco, M Wexler, S Meterissian, B Stein, E Franco, B

Lesperance). National Cancer Institute of Canada (grant # 013148, $88,455, 2002-05).

17. Characterization of the human papillomavirus infection among a population of Inuit women

in Québec. (P Brassard, E Franco, F Coutlée, M Roger). Canadian Institutes of Health

Research (CIHR grant #MOP57749, $496,752, 2002-07).


18

18. Clinical & cost-effectiveness of cervical cancer screening. (S Goldie, K Kuntz, M Weinstein,

T Wright, E Franco, J Palefsky, A Moscicki, K Freedberg). National Institutes of Health

(NIH-NCI Grant # R01CA93435, US$1,006,318, 2002-05, subcontract to E. Franco:

$137,565).

19. Economic evaluation of population screening for cervical cancer using HPV testing in

Canada (R Rajan, E Franco, J Penrod). National Cancer Institute of Canada (grant # 014033,

$190,141, 2003-06).

20. Development and validation of new statistical methods for modeling intermediate events in

survival analysis (M Abrahamowicz, A Ciampi, A Benedetti, E Franco, M Klein, L Pilote, R

Platt, J Siemiatycki) Canadian Institutes of Health Research (grant# ATF66665, $158,263,

2004-06; renewed $54,787, 2006-07).

21. Prognostic value of clinical correlates of cancer cachexia: A prospective, multicenter,

population-based study (A Vigano, V Baracos, S Cohen, MA Dalzell, E Franco, N

Macdonald, S Thirlwell). Canadian Institutes of Health Research (grant# MOP-67043,

$211,925, 2004-07).

22. CIHR training program in applied Oral Health Research (J Feine, P Allison, E Franco, W

Fraser, M Frenette, D Grenier, A Kolta, G Lavigne, J Lund, M Mckee). Canadian Institutes

of Health Research (grant #QTA-68723, $1.76M, July 2004 –June 2010).

23. Molecular analysis of HPV infection in precancerous and cancerous lesions of the uterine

cervix (F Coutlée, E Franco, G Matlashewski). Canadian Institutes of Health Research

(grant# MOP-67155, $289,371, 2004-07).

24. The life course approach to the aetiology of squamous cell carcinoma in the upper

aerodigestive tract (P Allison, E Franco, R Fuhrer, G Humphris, B Nicolau, A Sacker).

Canadian Institutes of Health Research (grant #69062, $434,063, October 2004 – September

2007).

25. The psychosocial impact of Pap versus HPV testing on Canadian women screened for

cervical cancer (Z Rosberger, P DiDio, E Duarte, E Franco, B Knauper, MH Mayrand).

Canadian Institutes of Health Research (grant MOP-74685, $160,000, 2005-08).

26. A randomized controlled trial of the effectiveness of a coping strategies intervention for

people with head and neck cancer (P Allison, LJ Edgar, J Feine, E Franco, B Nicolau, R

Rajan). Canadian Institutes of Health Research (grant #MCT-75475, $471,139, April 2005 –

March 2009).

27. Developing a transdisciplinary international collaboration to study the aetiology of squamous

cell carcinoma in the upper aerodigestive tract using the life course approach (P Allison, EL

Franco, F Fuhrer, G Humphris, BF Nicolau, A Sacker), Canadian Institutes of Health

Research (grant #OPD-74405, $24,600, April 2005 – March 2006).

28. A randomised controlled evaluation of HPV testing for cervical cancer screening (A

Coldman, P Davies, R Martin, J Matsic, D Van Niekerk, G Ogilvie, T Ehlen, G Stuart, E

Franco, S Peacock, M Krajden), Canadian Institutes of Health Research (grant MCT-82072,

$6,268,935, 2006-13).


19

29. The life course approach to studying the etiology of head and neck cancer: HeNCe life study

(B Nicolau, P Allison, R Burk, F Coutlée, E Franco, G Humphris, J O’Loughlin, A Sacker, N

Schlecht), Canadian Institutes of Health Research (grant MOP-81172, $478,236, 2006-10).

30. Inuit women's understanding of human papillomavirus: implications for health education and

prevention in Nunavik, Québec (P Brassard, E Franco, ME Macdonald), Social Sciences and

Humanities Research Council (grant #NA, $39,995, 2007-08).

31. Natural history of oropharyngeal cancer precursors: a pilot study (MC Rousseau, Nicolau B,

P Allison, T Belbin, M Black, F Coutlée, E Franco, M Hier, N Schlecht), Canadian Institutes

of Health Research (grant #MOP-93739, $306,721, 2008-11).

32. Quebec Research Program for Prostate Cancer Prevention (ME Parent, P Karakiewicz, MH

Roy-Gagnon, J Siemiatycki, J Lavoué, E Franco, A Aprikian, M Abrahamowicz, F Saad, M

Goldberg), GRePEC Competition 2010, Cancer Research Society and Fonds de la recherche

en santé du Québec ($4,728,203, 2010-15).

33. Rôle de l'infection au virus du papillome humain (VPH) dans les cancers des voies aéro-

digestives supérieures (B Nicolau, MC Rousseau [Co-PIs], P Allison, E Franco, F Coutlée, D

Soulières, N Schlecht, A Sacker, S Rogato), Ministère du Développement économique, de

l’Innovation et de l’Exportation du Quebec (operating grant, $103,055, 2011-14).

Other Grants (Dr. Franco as only applicant) (amounts in Canadian dollars)

1. Programme de soutien à la tenue d'événements scientifiques à caractère international (grant

support to the 16th

World Congress of Epidemiology to be held in Montreal). Fonds de la

recherche en santé du Québec ($10,000, 2000-02).

2. Grant support for plenary session "Epidemiology as a transdisciplinary science" during the

XVI World Congress of Epidemiology. The Robert Wood Johnson Foundation ($17,143,

2001-02).

3. Grant support for the XVI World Congress of Epidemiology. Réseau de recherche en santé

bucco-dentaire du Québec ($10,000, 2001-02).

4. Grant support for the XVI World Congress of Epidemiology. National Cancer Institute of

Canada ($10,000, 2002).

5. Grant support for the XVI World Congress of Epidemiology. Canadian Institutes of Health

Research ($25,000, 2002-03).

6. Grant support for the XVI World Congress of Epidemiology. Institute of Population and

Public Health, Toronto, Canada ($10,000, 2002-03).

7. Grant support for the XVI World Congress of Epidemiology. Health Canada, Ottawa,

Canada ($5,000, 2002).

8. Grant support for the XVI World Congress of Epidemiology. Ministère de la Recherche,

Science et Technologie du Québec, Québec, Canada ($10,500, 2002-03).

9. Grant support for the XVI World Congress of Epidemiology. Canadian International

Development Agency ($75,000, 2002-03).


20

10. Grant support for the XVI World Congress of Epidemiology. International Development

Research Centre ($5,000, 2002-03).

Industry Support (non-peer-reviewed unrestricted grants) (amounts in Canadian and US dollars)

1. Supplement to Economic Evaluation of Population Screening for Cervical Cancer Using

HPV Testing in Quebec (Merck-Frosst Co., CA$78,000, 2004-08).

2. Support for the Canadian Cervical Cancer Screening Trial (Merck-Frosst Co., CA$25,000,

2005-07).

3. Support for the HPV infection and transmission among couples through heterosexual activity

(the HITCH cohort) (Merck-Frosst Co., CA$60,276.71 and US$414,032.94, 2006-09)

7. PUBLICATIONS (see Appendix 1 for list of publications 1995-2011)

Table 2 – Publications (until mid-August 2011)

Period Full

papers

Other

papers

Total

papers Chapters Books

Journal

Supplements

Technical

Reports

1995-99 35 14 49 14 1 0 8

2000-04 64 16 80 13 1 1 4

2005-09 76 30 106 15 0 8 5

2010-present 44 3 47 6 0 1 1

Total 219 63 282 48 2 10 18

Annual Average 13.3 3.8 17.1 2.9 0.1 0.6 1.1

Average since

2005 18.5 5.1 23.5 3.2 0.0 1.4 0.9

Table 3 - Publications in top-tier journals (impact factors > 10)

Journal Title

Period

1995-99 2000-04 2005- Total

Journal of the National Cancer Institute 2 5 2 9

New England Journal of Medicine 1 1

British Medical Journal 2 2

Public Library of Science-Medicine 1 1

The Lancet (includes Lancet Oncology) 4 4 8


21

8. PRESENTATIONS

Left to right: Biostatistician and faculty member Agnihotram Ramanakumar, Division Director Eduardo Franco,

PhD student Tam Dang-Tan, Post-doctoral Fellow Salah Mahmud, and PhD student Ann Burchell attending an

international congress.

Dr. Franco has been a frequent invited speaker and chairperson at many local, national and

international conferences on cancer research and public health (Appendix 2), and in academic,

research and clinical departments worldwide (Appendix 3). In addition, members of the

Division present their research findings as offered oral or poster presentations (Appendix 4).

Table 4 below is a summary of the number of invited lectures, guest seminars and offered

presentations from the Division from 1995 to the present (the first two columns reflect only Dr.

Franco’s engagements and the rightmost column includes all offered communications by

Division staff and students).

Table 4 – Presentations (until mid-September 2011)

Period

Invited

Lectures and

Session

Chairmanship

Invited

Seminars in

Universities

and Hospitals

Offered

Communications

1995-99 38 26 81

2000-04 72 25 101

2005-09 164 42 95

2010-present 70 11 45

Total 344 104 322

Annual Average 20.8 6.3 19.5

Annual Average since 2005 36.0 8.2 21.5


22

9. EDUCATION AND TRAINING

The CRS Division of Epidemiology is responsible for the teaching of cancer epidemiology and

prevention to McGill students at the undergraduate and graduate level and for training the next

generation of cancer epidemiology researchers.

Since Dr. Franco joined McGill and the CRS Division in 1995 he has supervised 45 graduate

students and post-doctoral fellows. A total of 24 MSc and 10 PhD McGill epidemiology theses

were successfully defended primarily under his supervision at McGill, four of which received the

Dean’s Honour List award. One of his PhD students (Marie-Helene Mayrand) received the

Principal’s dissertation award of 2007, which is McGill’s highest accolade for theses (only one is

given every year).

Our trainees have gone on to successful academic and research positions nationally and

internationally and achieved associate or full professorship status. Examples follow:

Canadian institutions: McGill University (Paul Allison [Dean of Dentistry], Université de

Montreal (Anita Koushik, Helen Trottier, Julie Bruneau, Marie-Helene Mayrand), Université du

Quebec (Marie-Claude Rousseau, Belinda Nicolau, Javier Pintos), University of Toronto (Ann

Burchell), University of Manitoba (Salah Mahmud), Queen’s University (Harriet Richardson),

University of Alberta (Ghislain Lugoma), Public Health Agency of Canada (Tory Atwood, Rhea

Ferguson, Candace Sirjoosingh).

U.S. institutions: Harvard University (Susan Brogly), Albert Einstein College of Medicine

(Nicolas Schlecht, Abdissa Negassa), University of Chicago (Nader Sadeghi).

Other institutions (Brazil): University of Sao Paulo (Luciana Tomita, Rosario Latorre),

University of Rio Grande do Sul (Bernadete Nonnenmacher).

The division has regularly hosted guest researchers on sabbatical from Brazil and Portugal who

spend from 1 to 12 months during the summer and fall months at our McGill unit.

Since 1995, Dr. Franco has taught the only graduate-level cancer epidemiology and prevention

course in Montreal, a popular 2-credit offering that attracts 15-25 students every year. He began

to teach in 2009 a new course on best practices in publishing clinical research, expanding on his

editorial board service and experience in teaching such a course internationally. He also guest

lectures in several undergraduate and graduate courses in cancer biology and clinical oncology

every year at McGill.

Dr. Franco is frequently invited to give short courses on cancer epidemiology and scientific

publishing. He has taught such courses in Canada, Brazil, Chile, Venezuela, Saudi Arabia,

Turkey, Portugal, Thailand, and in the US.

He received the Faculty Honour List for Educational Excellence in the Faculty of Medicine at

McGill in 2000.


23

Courses taught by E. Franco

A day in graduate course EPIB 671, the Cancer Epidemiology and Prevention course taught by Dr. Franco at McGill

since 1992.

McGill University, Departments of Epidemiology & Biostatistics and Oncology

Coordinator and main lecturer in EPIB-641 (Cancer Epidemiology and Prevention), 1 credit

(1992-2003), EPIB-671, 2 credits (2004-present)

Coordinator and only lecturer in EPIB-645 (Publishing in Epidemiologic and Clinical

Research), 1 credit (2009-10).

Lecturer in 516-504A (Cancer Biology), 3 credits, 1992-present

Lecturer in 513-637L (Infectious Disease Epidemiology), 3 credits, 1992-96

Lecturer in 516-614B (Environmental Carcinogenesis), 3 credits, 1995-99, 2006-present.

Lecturer in 513-642B (Health Technology Assessment Applied to Screening), 3 credits, 1998

Lecturer in the oncology residency training course (Cancer Epidemiology and Prevention),

1995-97

Instructor and planner in the new curriculum’s integrated small group sessions (Breast

cancer), 1996, 2000

Tutor in 513-606 (Basic Epidemiology), 4 credits, 1997-2008

Lecturer, Introduction to Cancer Prevention, to medical students, 12 hours, 2002.

Lecturer in EPIB 676/678/615 (Infectious Disease Epidemiology), 3 credits, 2007-present

Lecturer in 516-635D (Experimental and Clinical Oncology), 4 credits, 2007-present.

Co-organizer and moderator, Oncology Research Journal Club, 1 hour/month, 2003-present.

Université du Québec, Institut Armand-Frappier (Laval, Canada)

Lecturer in graduate level biostatistics course (VIM 6003), 0.25 credits, 1990-96;

Lecturer in viral carcinogenesis (VIM 6006), 2 hs, 1991-97.


24

Université de Montreal (Montreal, Canada)

Lecture on microbial etiology of cancer (Cours MSO 6023: Epidemiologie des infections), 3

hs, 2002-05.

Lecture on molecular epidemiology (Cours MSO 6005: Épidémiologie Sociale), 3 hs, 2004.

Courses taught elsewhere

In addition to the above teaching engagements in Montreal, Dr. Franco has also served as quest

lecturer or organizer of short courses nationally and internationally, as follows:

Guest Faculty Member, Course on Cancer Epidemiology and Prevention, Annual Summer

Programme in Public Health, Faculdade de Saúde Pública, Universidade de São Paulo, Brazil

(1-week course, every February, 1996-2004)

Guest Lecturer, Survival analysis and logistic regression, Epi-Info: A course for Teachers of

Epidemiology and Computing, Centers for Disease Control and Prevention, Atlanta, USA

(May 17-20, 1999)

Organizer and Instructor, Course on Cancer Epidemiology and Prevention, 5th Eastern

Mediterranean Regional Scientific Meeting of the International Epidemiological Association,

Manama, Bahrain (October 23-25, 2000)

Organizer and Instructor, Course on Cancer Epidemiology and Prevention, Instituto Português

de Oncologia Francisco Gentil and Liga Portuguesa Contra o Cancro, Porto, Portugal

(December 10-12, 2001; December 2-4, 2002; March 15-17, 2006; July 2-4, 2008)

Main Instructor, Course on Cancer Epidemiology and Prevention, Instituto Nacional do

Cancer, Ministério da Saúde, Rio de Janeiro, Brazil (October 21-24, 2003)

Instructor, Course on Cohort Studies in Cancer Epidemiology and Prevention, co-sponsored

by the Postgrado Regional en Ciencias Veterinarias Tropicales, Instituto Costarricense contra

el Cancer, and Proyecto Epidemiologico Guanacaste, Sam Jose, Costa Rica (November 24-25,

2003)

Organizer and Instructor, Satellite Course on Cancer Epidemiology and Prevention, 6th

Brazilian Congress of Epidemiology (VI Congresso Brasileiro de Epidemiologia) (June 20,

2004)

Organizer and Main Instructor, Satellite course “From Study design to final publication: How

to succeed in clinical research”, 3rd International Symposium on HPV and Cancer, Lisbon,

Portugal (October 13, 2004)

Organizer and Main Instructor, Course on Epidemiologic Methods in Oncology, Instituto

Português de Oncologia Francisco Gentil, Porto, Portugal (November 30, 2004)

Organizer and Main Instructor, Satellite Course on the Epidemiology of Breast and

Gynecologic Cancers, Sociedade Portuguesa de Ginecologia e Obstetricia, Porto, Portugal

(December 1, 2004)

Instructor, Satellite Course “Cancer Epidemiology and Prevention Update”, 17th

World

Congress of Epidemiology, International Epidemiological Association, Bangkok, Thailand

(August 21, 2005).

Instructor, Satellite Course “Reading, writing, and publishing scientific articles”, 17th

World

Congress of Epidemiology, International Epidemiological Association, Bangkok, Thailand

(August 21, 2005).


25

Organizer and Instructor, Satellite Workshop “Reading, writing, and publishing in

Epidemiological and Clinical Research”, 7th

Scientific Meeting, IEA-Eastern Mediterranean

Region, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

(November 29, 2007).

Co-Organizer and Lecturer, Satellite Course “Epidemiologic Research and New Directions”,

XVIII IEA World Congress of Epidemiology, Porto Alegre, Brazil (September 20-21, 2008).

Organizer and Lecturer, Satellite Course “Reading, writing, and publishing in

Epidemiological and Clinical Research”, XVIII IEA World Congress of Epidemiology, Porto

Alegre, Brazil (September 21, 2008).

Organizer and Lecturer, Satellite Course “Reading, writing, and publishing in Oncology

Research”, XVIII Congresso Brasileiro de Cancerologia, Curitiba, Brazil (October 31, 2009).

Organizer and Lecturer, Satellite Course “Writing and publishing in Clinical and Public

Health Research in Oncology”, 5th General Assembly of the Asian Pacific Organization for

Cancer Prevention, Istanbul, Turkey (April 3, 2010).

Organizer and Lecturer, Satellite Course “Publishing in Clinical and Public Health Research”,

26th

International Papillomavirus Conference, Montreal, Canada (July 8, 2010).

Organizer and Lecturer, Workshop “Epidemiologia del Cancer”, Universidad de Los Andes,

Santiago, Chile (October 28, 2010).

Organizer and Lecturer, Workshop “Publicación Cientifica”, Universidad de Los Andes,

Santiago, Chile (October 29, 2010).

Organizer and Lecturer, Workshop “Epidemiologia e prevenção do cancer”, Universidade

Federal do Maranhão, São Luis, Brazil (April 6, 2011).

Organizer and Lecturer, Workshop “Melhores práticas para publicação de artigos científicos

em pesquisa clínica”, Universidade Federal do Maranhão, São Luis, Brazil (April 7-8, 2011).

Organizer and Lecturer, Workshop “Best Practices in Publishing Clinical and Public Health

Research”, EUROGIN Congress, Lisbon, Portugal (May 11, 2011).


Research”, 19th Congress of the International Society for STD Research, Quebec City,

Canada (July 13, 2011).


Research”, Department of Clinical Epidemiology and Biostatistics, McMaster University,

Hamilton, Canada (September 9, 2011).

Course taught by A. Ramanakumar

2008-2010 Course Teacher-Statistical methods in Oncology - for MD residents of Radiation

Oncology, Gynecological Oncology, McGill University.

Graduate Students, Postdoctoral Fellows and Other Trainees of E. Franco

Current

MSc

1. Hani Al-Marzouki (MSc, 2011-, Otolaryngology)

2. Amin Andalib (MSc, 2010-)

3. Myriam Chevarie-Davis (MSc, 2010-)

4. Saleh Al-Nasser (MSc, 2010-, Surgery)


26

5. Lyndsay Richardson (MSc, 2009-11) thesis submitted

6. J. João Mansure (MSc, 2009-)

7. Maaike deVries (MSc, 2009-)

PhD

1. Sandra Isidean (PhD, 2011-)

2. Joseph Tota (PhD, 2008-)

3. Andrea Spence (PhD, 2001-) thesis submitted

Postdoctoral Fellows

1. Ziad El-Khatib (Postdoctoral Fellow, 2011-)

2. Fabiano Santos (Postdoctoral Fellow, 2011-)

Past

MSc

1. Candace Sirjoosingh (MSc, 2008-10) (Max E. Binz Fellowship)

2. Rhea Ferguson (MSc, 2008-10) (CIHR’s Banting and Best Graduate Scholarship)

3. Alexandra de Pokomandy (MSc, 2005-09) (Dean’s Honour List)

4. Carmen Victoria (Tory) Atwood (MSc, 2002-06)

5. Steven Ades (MSc, 2002-05)

6. Keira Robinson (MSc, 2002-04)

7. Suzie Lau (MSc, 2001-08, part-time)

8. Andrea Schaffer (MSc, 2001-04)

9. Cara Flamer (MSc, did not complete, 2001-04)

10. Jun Chen (MSc, 1999-02)

11. Seungmi Yang (MSc, 1999-02)

12. Julie Bruneau (MSc, 1998-03)

13. Hela Makni (MSc, 1998-99)

14. Susan Brogly (MSc, 1998-99) (Dean’s Honour List)

15. Nader Sadeghi (MSc, did not complete, 1996-98)

16. Sophie Kulaga (MSc, 1996-97)

17. Marie-Claude Rousseau (MSc, 1995-97) (MRC scholarship) (Dean’s Honour List)

18. Harriet Richardson (MSc, 1993-96) (MRC scholarship)

19. Javier Pintos (MSc, 1993-96)

PhD

1. Ann Burchell (PhD, 2003-09) (Tomlinson and NCIC scholarships)

2. Tam Dang-Tan (PhD, 2002-08) (CIHR scholarship)

3. Marie Hélène Mayrand (PhD, 2002-07) (FRSQ and NCIC scholarships) (Principal’s

Dissertation Award)

4. Anita Koushik (PhD, 1999-04) (CIHR and NCIC scholarships)

5. Nicolas Schlecht (PhD, 1999-02) (MRC scholarship) (Dean’s Honour List)

6. Susan Brogly (PhD, 1999-02) (NHRDP scholarship)

7. Marie-Claude Rousseau (PhD, 1998-03) (MRC scholarship) (Dean’s Honour List)

8. Harriet Richardson (PhD, 1997-03) (MRC scholarship)


27

9. Javier Pintos (PhD, 1997-02)

Postdoctoral Fellows

1. Ann Burchell (2009)

2. Tam Dang-Tan (2008-09)

3. Helen Trottier (2004-08)

4. Belinda Nicolau (jointly with Dentistry) (2002-05)

5. Salah Mahmud (2002-05)

6. Ghislain Lugoma (2000-01, 2003-04)

7. Paul Allison (jointly with Dentistry) (1998-99)

8. Abdissa Negassa (1997-98)

Co-supervision of students, clinical fellows and trainees from other departments and faculties

1. Adam Probert (MSc Dept Genetics)

2. Adi Yoskovitch (MSc, Dept Otolaryngology)

3. Michael Haben (MSc, Dept Otolaryngology)

4. Angela Lambrinos (MSc, Dept Psychiatry)

5. Larissa Vilela (MSc, Dentistry)

6. Paul Allison (PhD, Dentistry)

7. Lixie Zhong (Graduate trainee, Dept Medicine)

8. Janet Li (Clinical Fellow, Dept ObGyn)

9. Marie-Christine Roy (Clinical Fellow, Dept ObGyn)

10. Stephanie Klam (Clinical Fellow, Dept ObGyn)

11. Tamar Perry (Clinical Fellow, Dept ObGyn, JGH)

12. Thuy Nguyen (Clinical Fellow, Dept ObGyn)

Students, clinical fellows and trainees from other institutions

1. Anne-Karine Belizaire (MSc, U. Quebec)

2. Ines Nishimoto (MSc, University of São Paulo)

3. Michaela Smith (MSc, Queen’s University)

4. Alvaro Piazzetta (PhD, University of São Paulo and Harvard U.)

5. Beatriz Camargo (PhD, University of São Paulo)

6. Bernadete Nonnenmacher (PhD, Univ Rio Grande do Sul)

7. Joao Candeias (PhD, University of São Paulo)

8. Luciana Tomita (PhD, University of São Paulo)

9. Maria Clara Bicho (PhD, University of Lisbon)

10. Paulo Maciag (PhD, University of São Paulo)

11. Ricardo Ribeiro (PhD, University of Porto)

12. Rosario Latorre (PhD, University of São Paulo)

13. Andre Carvalho (PDF, University of São Paulo)

14. Andrea Abib (Trainee, National Cancer Institute, Rio de Janeiro)

15. Andrea Trevisan (Trainee, Ludwig Institute, São Paulo)


28

10. CONFERENCE ORGANIZATION

Dr. Franco has assisted the organizing or scientific program committees for 38 local, national,

and international conferences. The ones listed below are of particular note because they were

held in Montreal:

Member, Scientific Program Committee, First International Conference on Human

Papillomavirus Infection and Cervical Cancer, Montreal, Canada (July 1998).

Chair, Organizing Committee, 16th World Congress of Epidemiology, International

Epidemiological Association, Montreal, Canada (August 2002).

Member, Candidacy Planning Committee (subsequently, Local Host Committee), World

Cancer Congress of the Union Internationale Contre le Cancer, Montreal, Canada (August

2012).

Member, Local Organizing Committee, 26th International Papillomavirus Conference,

Montreal, Canada (July 2010).

Member, Local Host Committee, 3rd North American Congress of Epidemiology, Montreal,

Canada (June 2011).

In addition, Dr. Franco has also served in the organization of the following Canadian conferences

held outside of Montreal:

Member, Local Organizing Committee, 14th International Papillomavirus Conference,

Quebec City, Canada (July 1995).

Member, Canadian Advisory Board, 15th Biennial Congress of the International Society for

Sexually Transmitted Diseases Research, Ottawa, Canada (July 2003).

Member, Planning Committee, Pan-Canadian Forum on Cervical Screening, Health Canada,

Ottawa, Canada (November 2003).

Member, International Organizing Committee, 22nd International Papillomavirus Conference,

Vancouver, Canada (May 2005).

Convocation Ceremony at

McGill: Dr. Franco with his

graduating PhD students (left to

right): Marie-Claude Rousseau,

Susan Brogly, Anita Koushik, and

Ann Burchell


29

Member, 60th Anniversary Cancer Research Conference Program Committee, National

Cancer Institute of Canada, Toronto (November 2007).

Member, Advisory Committee, First Canadian Cancer Research Conference, Canadian

Cancer Research Alliance, Toronto, Canada (November 2011).

Finally, he has also served in the following international congresses:

Member, Planning Committee, 3rd International EUROGIN Congress, European Research

Organization on Genital Infection and Neoplasia, Paris, France (March 1997).

Member, International Organizing Committee, 16th International Papillomavirus Conference,

Siena, Italy (September 1997).

Member, International Organizing Committee, International Workshop on Environmental

Cancer Epidemiology, organized by the International Agency for Research on Cancer, World

Health Organization, Rio de Janeiro, Brazil (September 1998).

Member, Scientific Committee, 17th International Papillomavirus Conference, Charleston,

USA (January 1999).

Member, Scientific Committee, 4th Brazilian Congress of Oral Cancer, Sao Paulo, Brazil

(May 1999).

Chair, Scientific Committee, 4th International EUROGIN Congress, European Research

Organization on Genital Infection and Neoplasia, Paris, France (April 2000).

Member, International Advisory Committee, 18th International Papillomavirus Conference,

Barcelona, Spain (July 2000).

Member, Scientific Committee, 2nd International Symposium on HPV and Cancer, Lisbon,

Portugal (May 2001).

Member and Vice-Chair, Local Organizing Committee, 19th International Papillomavirus

Conference, Florianópolis, Brazil (October 2001).

Member, Scientific Advisory Committee, 6th International Symposium on Impact of

Biotechnology on Predictive Oncology, International Society for Preventive Oncology, Paris,

France (February 2002).

Member, International Programme Committee, 5th International EUROGIN Congress,

European Research Organization on Genital Infection and Neoplasia, Paris, France (April

2003).

Member, Organizing Committee, 7th International Congress of the International Society for

Preventive Oncology, Nice, France (February 2004).

Member, Scientific Committee, 3rd International Symposium on HPV and Cancer, Lisbon,

Portugal (October 2004).

Member, International Programme Committee, 8th International Congress of the International

Society for Preventive Oncology, St. Gallen, Switzerland (February 2006).

Member, Organizing Committee, 6th International EUROGIN Congress, European Research

Organization on Genital Infection and Neoplasia, Paris, France (April 2006).

Member, International Scientific Committee, 24th International Papillomavirus Conference

and Clinical Workshop, Beijing, China (November 2007).

Member, Program Committee, EUROGIN 2007 Congress, European Research Organization

on Genital Infection and Neoplasia, Monte-Carlo, Monaco (October 2007).

Member, Scientific Committee, XVIII IEA World Congress of Epidemiology, Porto Alegre,

Brazil (September 2008).


30


on Genital Infection and Neoplasia, Nice, France (November 2008).

Member, International Scientific Committee, 25th International Papillomavirus Conference

and Clinical Workshop, Malmo, Sweden (May 2009).

Member, International Scientific Committee, 35th European Congress of Cytology, Lisbon,

Portugal (September 2009).


on Genital Infection and Neoplasia, Monte-Carlo, Monaco (February 2010).

Member, Executive Scientific Committee, World Cancer Congress of the Union

Internationale Contre le Cancer (UICC), Shenzhen, China (August 2010).

Member, Scientific Programme Committee, First Turkish HPV Conference, Izmir, Turkey

(November 2010).


on Genital Infection and Neoplasia, Lisbon, Portugal (May 2011).

Member, International Organizing Committee and Public Health Workshop Planning

Committee, 27th International Papillomavirus Conference and Clinical Workshop, Berlin,

Germany (September 2011).

11. AWARDS AND DISTINCTIONS (to the CRS Division Director)

The research carried out at the CRS Division of Epidemiology has produced many dividends that

have permitted its Director to be distinguished with several national and international

recognitions. These are as follows:

Fellow of the Royal Society of Canada (2011).

McLaughlin-Gallie Award, Royal College of Physicians and Surgeons of Canada (2011)

Lifetime Achievement Award of the American Society for Colposcopy and Cervical

Pathology (ASCCP) (2010)

Honorary President for the EUROGIN Congress (more than 2000 delegates), Monte-Carlo,

Monaco, February 2010.

Women in U.S. Government’s Presidential Leadership Award (2008)

Distinguished Services Award of EUROGIN Society (2006)

Canadian Cancer Society’s O. Harold Warwick Prize in cancer control research (2004)

McGill University’s James McGill Chair (2002, 2009)

CIHR Distinguished Scientist (2000)

Educational Excellence at McGill University (2000)

Twice Montreal's "Ambassadeur du Palais des Congrés" (2000, 2007)

FRSQ's "Chercheur National" Award (1999, ranked first among all candidates)

Elected representative (2002-05) for North America in the Council of the International

Epidemiological Association


31

APPENDIX 1

PUBLICATIONS

1995-2011


32

PUBLICATIONS

(*) corresponding author, (

§) denotes a student of E. Franco as first author

Peer-reviewed

1. Sharpe C(§), Franco E(*), Camargo B, Lopes L, Barreto J, Johnsson R, Mauad M. Parental exposures to

pesticides and risk of Wilms' tumor in Brazil. American Journal of Epidemiology 141: 210-217, 1995.

2. Ferenczy A(*), Choukroun D, Falcone T, Franco EL. The effect of cervical loop electrosurgical excision on

subsequent pregnancy outcome: North-American experience. American Journal of Obstetrics & Gynecology

172: 1246-1250, 1995.

3. Franco EL. Editorial: Cancer causes revisited: Human papillomavirus and cervical neoplasia. Journal of the

National Cancer Institute 87: 779-780, 1995. (peer-reviewed)

4. Franco EL(*), Villa LL, Ruiz A, Costa MC. Transmission of cervical human papillomavirus infection by

sexual activity: Differences between low and high oncogenic risk types. Journal of Infectious Diseases 172:

756-763, 1995.

5. Siemiatycki J(*), Krewski D, Franco E, Kaiserman M. Associations between cigarette smoking and each of

21 types of cancer: A multi-site case-control study. International Journal of Epidemiology 24: 504-514, 1995.

6. Kowalski LP(*§), Franco EL, Andrade J. Factors influencing regional lymph node metastasis from laryngeal

carcinoma. Annals of Otology, Rhinology & Laryngology 104: 442-447, 1995.

7. Foulkes WD, Brunet JS, Kowalski LP, Narod SA, Franco EL(*). Family history of cancer is a risk factor for

squamous cell carcinoma of the head and neck in Brazil: a case-control study. International Journal of Cancer

63: 769-773, 1995.

8. Sharpe CR(§), Franco EL(*). Etiology of Wilms' tumor. Epidemiologic Reviews 17: 415-432, 1995.

9. Franco E(*), Bergeron J, Villa L, Arella M, Richardson L, Arseneau J, Stanimir G. Human papillomavirus

DNA in invasive cervical carcinomas and its association with patient survival: a nested case-control study.

Cancer Epidemiology, Biomarkers & Prevention 5: 271-275, 1996.

10. Franco EL. Mechanistic reasoning in socio-behavioral epidemiology: The influence of race and ethnicity on

cancer survival. Epidemiology 7: 326-327, 1996.

11. Sharpe C(§), Franco E(*). Use of dipyrone during pregnancy and risk of Wilms' tumor. Epidemiology 7: 533-

535, 1996.

12. Ferenczy A(*), Franco E, Arseneau J, Wright T, Richart R. Diagnostic performance of Hybrid Capture

human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study. American

Journal of Obstetrics & Gynecology 175: 651-656, 1996.

13. Ferenczy A(*), Robitaille J, Franco E, Arseneau J, Richart R, Wright T. Conventional cervical cytologic

smears vs ThinPrep smears: A paired comparison study on cervical cytology. Acta Cytologica 40: 1136-1142,

1996.

14. Payment P(*), Siemiatycki J, Richardson L, Renaud G, Franco E, Prevost M. A prospective epidemiological

study of gastrointestinal health effects due to the consumption of drinking water. International Journal of

Environmental Health Research 7: 5-31, 1997.

15. Ferenczy A(*), Gelfand M, Franco E, Mansour N. Human papillomavirus infection in postmenopausal

women with and without hormone therapy. Obstetrics and Gynecology 90: 7-11, 1997.

16. Coelho FR(*§), Franco EL, Kowalski LP, Zeferino LC, Brentani MM, Abrão FS. Carcinoma espinocelular do

colo uterino submetido a cirurgia radical isolada ou em combinação com radioterapia: Análise multivariada de

fatores prognósticos. Acta Oncologica Brasileira 17: 68-87, 1997.

17. Coutlée F(*), Mayrand M, Provencher D, Franco E. The future of hpv testing in clinical laboratories and

applied virology research. Clinical and Diagnostic Virology 8: 123-141, 1997.

18. Mandeville R(*), Franco E, Ghali S, Nadon L, Rocheleau N, Mercier G, Désy M, Gaboury L. Evaluation of

the potential carcinogenicity of 60 Hz linear sinusoidal continuous-wave magnetic fields in Fischer F344 rats.

FASEB Journal 11: 1127-1136, 1997.

19. Bruneau J(*§), Lamothe F, Franco E, Lachance N, Désy M, Soto J, Vincelette J. High rates of HIV-1

infection among drug users participating in needle exchange programs in Montreal: Results of a cohort study.

American Journal of Epidemiology 146: 994-1002, 1997.

20. Bruneau J(*§), Franco E, Lamothe F. Assessing harm reduction strategies: The dilemma of observational

studies. American Journal of Epidemiology 146: 1007-1010, 1997.


33

21. Allison P(§), Franco E, Feine J(*). Predictors of professional diagnostic delays for upper aerodigestive tract

carcinoma. European Journal of Cancer (Part B: Oral Oncology) 34:127-132, 1998.

22. Allison P(§), Franco E, Black M, Feine J(*). The role of professional diagnostic delays in the prognosis of

upper aerodigestive tract carcinoma. European Journal of Cancer (Part B: Oral Oncology) 34: 147-153, 1998.

23. Velly AM(§), Franco EL(*), Schlecht N, Pintos J, Kowalski LP, Oliveira BV, Curado MP. Relationship

between dental factors and risk of upper aero-digestive tract cancer. European Journal of Cancer (Part B: Oral

Oncology) 34: 284-291, 1998.

24. Nguyen TN(§), Bourdeau JL, Ferenczy A(*), Franco EL. Clinical significance of histiocytes in the detection

of endometrial adenocarcinoma and hyperplasia. Diagnostic Cytopathology 19: 89-93, 1998.

25. Pintos J(§), Franco EL(*), Kowalski LP, Oliveira BV, Curado MP. Use of wood stoves and risk of cancers of

the upper aero-digestive tract: a case-control study. International Journal of Epidemiology 27: 936-940, 1998.

26. Coelho FR(§*), Franco EL, Kowalski LP, Abrao FS. Preoperative irradiation therapy and radical

hysterectomy: prognostic value of tumor regression after initial irradiation of squamous cell carcinoma of the

cervix. Sao Paulo Medical Journal (Revista Paulista de Medicina). 116: 1700-1709, 1998.

27. Franco EL(*), Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a

necessary cause of cervical cancer. Journal of the National Cancer Institute 91: 506-511, 1999.

28. Pintos J(§), Franco EL(*), Bergeron J, Arella M, Black M. Human papillomavirus and prognoses of patients

with cancers of the upper aero-digestive tract. Cancer 85: 1903-1909, 1999.

29. Sharpe C(§), Franco E(*), Camargo B, Lopes L, Barreto J, Johnsson R, Mauad M. The influence of parental

age on the risk of Wilms’ tumor. Paediatric & Perinatal Epidemiology 13:138-143, 1999.

30. Coutlée F(*), Gravitt P, Richardson H, Hankins C, Franco E, Lapointe N, Voyer H. Nonisotopic detection

and typing of human papillomavirus DNA in genital samples by the line blot assay. Journal of Clinical

Microbiology 37: 1852-1857, 1999.

31. Schlecht N(§), Franco EL(*), Pintos J, Kowalski LP. Effect of smoking cessation and tobacco type on the risk

of cancers of the upper aero-digestive tract in Brazil. Epidemiology 10: 412-418, 1999.

32. Franco EL(*), Ferenczy A. Assessing gains in diagnostic utility when human papillomavirus testing is used

as a Pap smear adjunct for triaging women with cervical cytological abnormalities. American Journal of

Obstetrics & Gynecology 181: 382-386, 1999.

33. Franco EL(*), Villa LL, Sobrinho J, Prado JM, Rousseau MC, Désy M, Rohan TE. Epidemiology of acquisition

and clearance of cervical human papillomavirus infection in women from a high risk area for cervical cancer.

Journal of Infectious Diseases 180: 1415-1423, 1999.

34. Franco E(*), Villa L, Rohan T, Ferenczy A, Petzl-Erler M, Matlashewski G. Design and methods of the Ludwig-

McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in

Brazil. Pan American Journal of Public Health 6: 223-233, 1999.

35. Schlecht N(§), Franco EL(*), Pintos J, Negassa A, Kowalski LP, Oliveira BV, Curado MP. Interaction

between tobacco and alcohol consumption on the risk of cancers of the upper aero-digestive tract in Brazil.

American Journal of Epidemiology 150: 1129-1137, 1999.

36. Mandeville R(*), Franco E, Sidrac-Ghali S, Paris-Nadon L, Rocheleau N, Mercier G, Desy M, Devaux C,

Gaboury L. Evaluation of the potential promoting effect of 60 Hz magnetic fields on N-ethyl-N-nitrosourea

induced neurogenic tumors in female F344 rats. Bioelectromagnetics 21: 84-93, 2000.

37. Richardson H(§), Franco E(*), Pintos J, Bergeron J, Arella M, Tellier P. Determinants of low-risk and high-

risk cervical human papillomavirus infections in Montreal University students. Sexually Transmitted Diseases

27: 79-86, 2000.

38. Rousseau MC(§), Franco EL(*), Villa LL, Sobrinho J, Termini L, Prado JM, Rohan TE. A cumulative case-

control study of risk factor profiles for oncogenic and non-oncogenic cervical human papillomavirus

infections. Cancer Epidemiology, Biomarkers & Prevention 9: 469-476, 2000.

39. Makni H(§), Franco E(*), Kaiano J, Villa L, Lebrecque S, Dudley R, Storey A, Matlashewski G. P53

polymorphism in codon 72 and risk of HPV-induced cervical cancer: effect of inter-laboratory variation.

International Journal of Cancer 87: 528-533, 2000.

40. Klam S(§), Arseneau J, Mansour N, Franco E, Ferenczy A(*). Comparison of endocervical curettage and

endocervical brushing. Obstetrics & Gynecology 96: 90-94, 2000.

41. Ratnam S, Franco EL(*), Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer

precursors. Cancer Epidemiology, Biomarkers & Prevention 9, 945-951, 2000.

42. Brogly SB(§), Bruneau J(

§*), Lamothe F, Vincelette J, Franco EL. Risk behaviour change and HIV infection

among injection drug users in Montreal. AIDS 14: 2575-2582, 2000.


34

43. Maciag PC(§), Schlecht NF, Souza PA, Franco EL, Villa LL(*), Petzl-Erler ML. Major histocompatibility

complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian

women. Cancer Epidemiology, Biomarkers and Prevention 9: 1183-1191, 2000.

44. Villa LL(*), Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, Franco EL. Molecular variants of

human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. Journal of General

Virology 81, 2959–2968, 2000.

45. Ferenczy A, Franco EL. Cervical-cancer screening beyond the year 2000. Lancet Oncology 2: 27-32, 2001.

46. Bruneau J(§*), Lamothe F, Soto, J, Lachance N, Vincelette J, Vassal A, Franco E. Sex-specific determinants

of HIV infection among injection drug users in Montreal. Canadian Medical Association Journal 164: 767-

776, 2001.

47. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human

papillomavirus infection. Canadian Medical Association Journal 164: 1017-1025, 2001.

48. Rohan TE(*), Burk RD, Franco EL. Towards a reduction of the global burden of cervical cancer. Clinical

Journal of Women's Health 1: 103-106, 2001.

49. Yoskovitch A(§), Frenkiel S, Franco E, Coutlée F, Nachtigal D, Rochon L. Analysis of human papillomavirus

in Schneiderian papillomas as compared to chronic sinusitis and normal nasal mucosa. Journal of

Otolaryngology 30: 167-172, 2001.

50. Schlecht NF(§), Pintos J, Kowalski LP, Franco EL(*).Effect of type of alcoholic beverage on the risks of

upper aerodigestive tract cancers in Brazil. Cancer Causes & Control 12: 579-587, 2001.

51. Kornegay JR(*), Shepard AP, Hankins C, Franco E, Lapointe N, Richardson H, Canadian Women's HIV

Study Group, Coutleé F. Nonisotopic detection of human papillomavirus dna in clinical specimens using a

consensus PCR and a generic probe mix in an enzyme-linked immunosorbent assay format. Journal of

Clinical Microbiology 39: 3530–3536, 2001.

52. Healey SM(§), Aronson KJ, Mao Y, Schlecht NF, Mery LS, Ferenczy A, Franco EL(*). Oncogenic human

papillomavirus infection and cervical lesions in aboriginal women in Nunavut, Canada. Sexually Transmitted

Diseases 28: 694-700, 2001.

53. Rousseau MC(§), Pereira JS, Prado JCM, Villa LL, Rohan TE, Franco EL(*). Cervical coinfection with

human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. Journal of

Infectious Diseases 184:1508–1517, 2001.

54. Schlecht NF(§), Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE,

Ferenczy A, Villa LL, Franco EL(*). Persistent human papillomavirus infection as a predictor of cervical

intraepithelial neoplasia. Journal of the American Medical Association 286: 3106-3114, 2001.

55. Schlecht NF(§), Franco EL(*), Rohan TE, Kjær SK, Schiffman M, Moscicki AB, Duffy SW, for the MARSH

International Collaborative Group. Repeatability of sexual history in longitudinal studies: determinants of

reporting error at follow-up interviews. Journal of Epidemiology and Biostatistics 6: 393-407, 2001.

56. Ferenczy A(*), Franco EL. Persistent human papillomavirus infection and cervical neoplasia. Lancet

Oncology 3: 11–16, 2002.

57. Brogly SB(§), Bruneau J, Lamothe F, Vincelette J, Franco EL. HIV positive notification and behaviour

changes in Montreal injection drug users. AIDS Education and Prevention 14: 17-28, 2002.

58. Coutleé F(*), Gravitt P, Kornegay JR, Hankins C, Richardson H, Lapointe N, Voyer H, Canadian Women's

HIV Study Group, Franco E. Use of PGMY primers in L1 consensus PCR improves detection of human

papillomavirus DNA in genital samples. Journal of Clinical Microbiology 40: 902-907, 2002.

59. Carvalho AL(§), Pintos J, Schlecht NF, Oliveira BV, Fava AS, Curado MP, Kowalski LP, Franco EL.

Predictive factors for diagnosis of advanced-stage squamous cell carcinoma of the head and neck. Archives of

Otolaryngology and Head & Neck Surgery 128: 313-318, 2002.

60. Maciag PC(§), Schlecht NF, Souza PSA, Rohan TE, Franco EL, Villa LL(*). Polymorphisms of the human

leukocyte antigen DRB1 and DQB1 genes and the natural history of human papillomavirus infection. Journal

of Infectious Diseases 186: 164–172, 2002.

61. Macaskill P(*), Walter SD, Irwig L, Franco EL. Assessing the gain in diagnostic performance when

combining two diagnostic tests. Statistics in Medicine 21: 2527-2546, 2002.

62. Tran-Thanh D, Koushik A, Provencher D, Drouin P, Dubuc-Lissoir J, Gauthier P, Allaire G, Kornegay J,

Franco E, Coutlée F(*). Detection of Human Herpes Virus type 6 DNA in precancerous lesions of the uterine

cervix. Journal of Medical Virology 68: 606–610, 2002.

63. Franco EL, Duarte-Franco E, Rohan TE. Evidence-based policy recommendations on cancer screening and

prevention. Cancer Detection and Prevention 26: 350-361, 2002.


35

64. Nishimoto IN(§), Pintos J, Schlecht NF, Torloni H, Carvalho AL, Kowalski LP, Franco EL(*). Assessment of

control selection bias in a hospital-based case-control study of upper aero-digestive tract cancers. Journal of

Cancer Epidemiology and Prevention (formerly J Epidemiol Biostat) 7: 131-141, 2002.

65. Schlecht NF(§), Trevisan A, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL(*). Viral load as

a predictor of the risk of cervical intraepithelial neoplasia. International Journal of Cancer 103: 519-524, 2003.

66. Li J(§), Rousseau MC, Franco EL, Ferenczy A(*). Is colposcopy warranted in women with external

anogenital warts? Journal of Lower Genital Tract Disease 7: 22-28, 2003.

67. Tran-Thanh D, Provencher D, Koushik A, Duarte-Franco E, Kessous A, Drouin P, Wheeler C, Dubuc-Lissoir

J, Gauthier P, Allaire G, Vauclair R, DiPaolo J, Gravitt P, Franco E, Coutlée F(*). Herpes Simplex Virus type

II is not a cofactor to human papillomavirus in cancer of the uterine cervix. American Journal of Obstetrics &

Gynecology 188: 129-134, 2003.

68. Nonnenmacher B(§*

), Pintos J, Bozzetti MC, Mielzinska-Lohnas I, Lorincz AT, Ikuta N, Schwartsmann G, Villa

LL, Schiller JT, Franco E. Epidemiologic correlates of antibody response to human papillomavirus among

women at low risk of cervical cancer. International Journal of STD & AIDS 14: 258–265, 2003.

69. Brogly S(§), Mercier C, Bruneau J(

§*), Palepu A, Franco E. Towards more effective public health

programming for injection drug users: development and evaluation of the injection drug user quality of life

scale. Substance Use & Misuse 38: 965-992, 2003.

70. Franco EL. Primary screening of cervical cancer with human papillomavirus tests. Journal of the National

Cancer Institute Monographs 31: 89-96, 2003.

71. Richardson H(§), Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, Coutlée F, Franco EL(*).

The natural history of type-specific human papillomavirus infections in female university students. Cancer

Epidemiology, Biomarkers & Prevention 12: 485-490, 2003.

72. Rousseau MC(§), Villa LL, Costa MC, Abrahamowicz M, Rohan TE, Franco EL(*). Occurrence of cervical

infection with multiple human papillomavirus types is associated with age and cytological abnormalities.

Sexually Transmitted Diseases 30: 581-587, 2003.

73. Goldie SJ(*), Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history

model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18

vaccine. International Journal of Cancer 106: 896-904, 2003.

74. Schlecht NF(§), Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JCM, Ferenczy A, Rohan TE,

Villa LL, Franco EL(*). Human papillomavirus infection and time to progression and regression of cervical

intraepithelial neoplasia. Journal of the National Cancer Institute 95: 1336-1343, 2003.

75. Ferenczy A(*), Coutlée F, Franco E, Hankins C. Human papillomavirus and HIV coinfection and the risk of

neoplasias of the lower genital tract: a review of recent developments. Canadian Medical Association Journal

169: 431-434, 2003.

76. Rousseau MC(§), Abrahamowicz M, Villa LL, Costa MC, Rohan TE, Franco EL(*). Predictors of cervical

coinfection with multiple human papillomavirus types. Cancer Epidemiology, Biomarkers & Prevention 12:

1029-1037, 2003.

77. Schlecht NF(§), Platt RW, Negassa A, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL(*).

Modeling the time dependence of the association between human papillomavirus infection and cervical cancer

precursor lesions. American Journal of Epidemiology 158: 878–886, 2003.

78. Rohan TE(*), Burk RD, Franco EL. Toward a reduction of the global burden of cervical cancer. American

Journal of Obstetrics & Gynecology 189: S37-S39, 2003.

79. Giuliano AR(*), Siegel EM, Roe DJ, Ferreira S, Baggio ML, Galan L, Duarte-Franco E, Villa LL, Rohan TE,

Marshall JR, Franco EL. Dietary intake and risk of persistent human papillomavirus (HPV) infection: The

Ludwig-McGill HPV natural history study. Journal of Infectious Diseases 15: 1508-1516, 2003.

80. Franco E, Schlecht N, Saslow D. The epidemiology of cervical cancer. Cancer Journal 9: 348-359, 2003.

81. Monsonego J, Bosch FX, Coursaget P, Cox JT, Franco E, Frazer I, Sankaranarayanan R, Schiller J, Singer A,

Wright T, Kinney W, Meijer C, Linder J. Cervical cancer control, priorities and new directions. International

Journal of Cancer 108: 329-333, 2004.

82. Mahmud S(§*

), Franco E, Aprikian A. Prostate cancer and use of non-steroidal anti-inflammatory drugs:

Systematic review and meta-analysis. British Journal of Cancer 90: 93-99, 2004.

83. Roy MC(§), Mayrand MH, Franco EL, Arseneau J, Ferenczy A(*). Electrofulguration for low-grade

squamous intraepithelial lesions of the cervix (CIN1). Journal of Lower Genital Tract Disease 8: 10-15, 2004.

84. Aho J, Kornegay JR, Healey S, Roger M, Dion F, Gaudreault D, Shepard AP, Franco EL, Coutlée F(*).

Evaluation of a convenient enzyme immunoassay to assess the quality of genital specimens submitted for the

detection of human papillomavirus DNA by consensus PCR. Journal of Clinical Virology 29: 127-133, 2004.


36

85. Koushik A(§), Platt RW, Franco EL(*). P53 codon 72 polymorphism and cervical neoplasia: A meta-analysis

review. Cancer Epidemiology, Biomarkers & Prevention 13: 11-22, 2004.

86. Pinto AP(*§), Schlecht NF, Pintos J, Kaiano J, Franco EL, Crum CP, Villa LL. Prognostic significance of

lymph node variables and human papillomavirus DNA in invasive vulvar carcinoma. Gynecologic Oncology

92: 856-865, 2004.

87. Goldie SJ(*), Kohli M, Grima D, Weinstein M, Wright TC, Bosch FX, Franco E. Projected clinical benefits

and cost-effectiveness of a human papillomavirus 16/18 vaccine. Journal of the National Cancer Institute 96:

604-615, 2004.

88. Bruneau J(§*

), Brogly SB, Tyndall MW, Lamothe F, Franco EL. Intensity of drug injection as a determinant

of sustained injection cessation among chronic drug users: the interface with social factors and service

utilization. Addiction 99: 727–737, 2004.

89. Vuong T(*), Franco E, Lehnert S, Lambert C, Portelance L, Nasr E, Faria S, Hay J, Larsson S, Shenouda G,

Souhami L, Wong F, Freeman C. Silver leaf nylon dressing to prevent radiation dermatitis in patients

undergoing chemotherapy and external beam radiotherapy to the perineum. International Journal of Radiation

Oncology, Biology and Physics 59: 809-814, 2004.

90. Duarte-Franco E(*), Franco EL. Cancer of the Uterine Cervix. BMC Womens Health 4 (Suppl 1): S13 (1-

10), 2004.

91. Duarte-Franco E(*), Franco EL. Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal

cancers. BMC Womens Health 4 (Suppl 1):S14 (1-9), 2004.

92. Siegel EM, Craft N, Roe D, Duarte-Franco E, Villa LL, Franco EL, Giuliano AR(*). Temporal variation and

identification of factors associated with endogenous retinoic acid isomers in serum from Brazilian women.


93. Harper DM(*), Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De

Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G; GlaxoSmithKline

HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection

with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:

1757-1765, 2004.

94. Healey SM(§*), Aronson K, Mao Y, Franco EL. Human papillomavirus and cervical dysplasia in Nunavut:

prelude to a screening strategy. International Journal of Circumpolar Health. 63 Suppl 2:199-201, 2004.

95. Dang-Tan T(§), Mahmud S, Puntoni R, Franco EL(*). Polio vaccines, Simian Virus 40, and human cancer:

The epidemiologic evidence for a causal association. Oncogene 23: 6535-6540, 2004.

96. Franco EL, Correa P, Santella RM, Wu X, Goodman SN, Petersen GM. Role and limitations of epidemiology

in establishing a causal association. Seminars in Cancer Biology 14: 413-426, 2004.

97. Stuart G(*), Taylor G, Bancej CM, Beaulac J, Colgan T, Franco EL, Kropp RY, Lotocki R, Mai V,

McLachlin CM, Onysko J, Martin RE. Report of the 2003 Pan-Canadian Forum on Cervical Cancer

Prevention and Control. Journal of Obstetrics and Gynaecology of Canada 26: 1004-1014, 2004.

98. Sichero L, Franco EL, Villa LL(*). Different p105 promoter activities among natural variants of human

papillomavirus type 18. Journal of Infectious Diseases 191: 739-742, 2005.

99. Spence A(§), Franco E, Ferenczy A(*). The role of human papillomaviruses in cancer: evidence to date.

American Journal of Cancer 4: 49-64, 2005.

100. Franco EL, Harper DM. Vaccination against human papillomavirus infection: A new paradigm in cervical

cancer control. Vaccine 23: 2388-2394, 2005.

101. Richardson H(§), Abrahamowicz M, Tellier P, Kelsall G, du Berger R, Ferenczy A, Coutlée F, Franco EL(*).

Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in

a cohort of university students. Cancer Epidemiology Biomarkers & Prevention 14: 1149-1156, 2005.

102. Coutlée F(*), Rouleau D, Ferenczy A, Franco E. The laboratory diagnosis of genital human papillomavirus

infections. Canadian Journal of Infectious Diseases and Medical Microbiology 16: 83-91, 2005.

103. Koushik A(§), Ghosh A, Duarte-Franco E, Forest P, Voyer H, Matlashewski G, Coutlée F, Franco EL(*), for

the Biomarkers of Cervical Cancer Risk (BCCR) Study Team. The p53 codon 72 polymorphism and risk of

high-grade cervical intraepithelial neoplasia. Cancer Detection and Prevention 29: 307-316, 2005.

104. Kowalski LP(§*

), Nishimoto IN, Carvalho AL, Oliveira BV, Curado MP, Fava AS, Torloni H, Franco EL.

Looking beyond tobacco and alcohol: The role of lifestyle and other environmental risk factors for laryngeal

cancer. Applied Cancer Research 25: 10-19, 2005.

105. Vilela LD(§), Nicolau B, Mahmud S, Edgar L, Hier M, Black M, Franco EL, Allison P(*). Comparison of

psychosocial outcomes in head and neck cancer patients receiving a coping strategies intervention and control

subjects receiving no intervention. Journal of Otolaryngology 35: 88-96, 2006.


37

106. Burchell AN(§), Richardson H, Mahmud SM, Trottier H, Tellier PP, Hanley J, Coutlée F, Franco EL(*).

Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation

and empirical data from a cohort study of young women in Montreal, Canada. American Journal of

Epidemiology 163:534-543, 2006.

107. Mahmud SM (§*

), Tanguay S, Bégin LR, Franco EL, Aprikian AG. Non-steroidal anti-inflammatory drug use

and prostate cancer in a high-risk population. European Journal of Cancer Prevention 15: 158-164, 2006.

108. Monsonego J(*), Pintos J, Semaille C, Beumont M, Dachez R, Zerat L, Bianchi A, Franco E. Human

papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia.

International Journal of Gynecological Cancer 16:591-598, 2006.

109. Mayrand MH(§), Duarte-Franco E, Coutlée F, Rodrigues I, Walter SD, Ratnam S, Franco EL(*), for the

CCCaST Study Group. Randomized controlled trial of human papillomavirus testing versus Pap cytology in

the primary screening for cervical cancer precursors: Design, methods and preliminary accrual results of the

Canadian cervical cancer screening trial (CCCaST). International Journal of Cancer 119:615-623, 2006.

110. Goffin F, Mayrand MH, Gauthier P, Alobaid A, Lussier C, Provencher D, Drouin P, Franco EL, Coutlée

F(*).High-risk human papillomavirus infection of the genital tract of women with a previous history or current

high-grade vulvar intraepithelial neoplasia. Journal of Medical Virology 78:814-819, 2006.

111. Harper DM(*), Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins DD,

Schuind A, Clemens SAC, Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle

vaccine against human papillomavirus types 16 and 18. Follow-up from a randomized controlled trial in

young women. Lancet 367: 1247-1255, 2006.

112. Alotaibi L, Provost N, Gagnon S, Franco EL, Coutlée F(*). Diversity of cutaneous human papillomavirus

types in individuals with and without skin lesion. Journal of Clinical Virology 36: 133-140, 2006.

113. Coutlée F(*), Rouleau D, Petignat P, Ghattas G, Kornegay JR, Schlag P, Boyle S, Hankins C, Vézina S, Coté

P, Macleod J, Voyer H, Forest P, Walmsley S, Franco E. Enhanced Detection and typing of Human

Papillomavirus DNA in Anogenital Samples with PGMY primers and the Linear Array HPV Genotyping

Test. Journal of Clinical Microbiology 44: 1998-2006, 2006.

114. Trottier H(§), Franco EL(*). The epidemiology of genital human papillomavirus infection. Vaccine 24: S1/4-

15, 2006.

115. Sangwa-Lugoma G(§), Mahmud S, Nasr S, Liaras J, Kayembe P, Tozin R, Drouin P, Lorincz A, Ferenczy A,

Franco EL(*). Visual inspection as a cervical cancer screening method in a primary health care setting in

Africa. International Journal of Cancer 119: 1389-1395, 2006.

116. Trottier H(§), Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL,

Franco EL(*). Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer

Epidemiology, Biomarkers and Prevention 15: 1274-1280, 2006.

117. Khouadri S, Villa LL, Gagnon S, Koushik A, Richardson H, Ferreira S, Tellier P, Simao J, Matlashewski G,

Roger M, Franco EL, Coutlée F(*). Human papillomavirus type 33 polymorphisms and high-grade squamous

intraepithelial lesions of the uterine cervix. Journal of Infectious Diseases 194: 886-894, 2006.

118. Schlecht NF(§), Trevisan A, Baggio ML, Galan L, Duarte-Franco E, Greenberg MD, Rohan TE, Ferenczy A,

Villa LL, Franco EL(*). Lack of agreement between cervicography and cytology and the effect of human

papillomavirus infection and viral load. Journal of Lower Genital Tract Disease 10: 229-237, 2006.

119. Frazer IH(*), Cox JT, Mayeaux EJ, Franco EL, Moscicki AB, Palefsky J, Ferris D, Ferenczy A, Villa L.

Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediatric

Infectious Disease Journal 25: S65–S81, 2006.

120. Burchell AN(§), Winer RL, Sanjosé S, Franco EL. Epidemiology and transmission dynamics of genital

human papillomavirus infection. Vaccine 24S3: 52-61, 2006.

121. Franco EL(*), Cuzick J, Hildesheim A, Sanjose S. Issues in planning cervical cancer screening in the era of

HPV vaccination. Vaccine 24S3: 171-177, 2006.

122. Franco EL(*), Bosch FX, Cuzick J, Schiller J, Garnett G, Meheus A, Wright TC. Knowledge gaps and

priorities for research on prevention of HPV infection and cervical cancer. Vaccine 24S3: 242-249, 2006.

123. Wright TC, Bosch FX, Franco EL, Cuzick J, Schiller J, Garnett G, Meheus A. HPV Vaccines and screening

in the prevention of cervical cancer: Conclusions from a 2006 Workshop of International Experts. Vaccine

24S3: 251-261, 2006.

124. Trottier H(§), Franco EL. Human papillomavirus and cervical cancer: burden of illness and basis for

prevention. American Journal of Managed Care 12: S462-472, 2006.


38

125. Siegel EM, Craft N, Duarte-Franco EF, Villa LL, Franco EL, Giuliano AR(*). Associations between serum

carotenoids and tocopherols and type-specific HPV persistence: the Ludwig-McGill Cohort Study.

International Journal of Cancer 120: 672–680, 2007.

126. Gagnon S, Hankins C, Money D, Pourreaux K, Canadian Women's HIV Study Group, Franco EL, Coutlée

F(*). Polymorphism of the L1 capsid gene and persistence of human papillomavirus type 52 infection in

women at high-risk or infected by HIV. Journal of Acquired Immunodeficiency Syndrome 44: 61-65, 2007.

127. Kohli M, Ferko N(*), Martin A, Franco EL, Jenkins D, Gallivan, S, Sherlaw-Johnson C, Drummond M.

Estimating the long-term impact of a prophylactic human papillomavirus (HPV) 16/18 vaccine on the burden

of cervical cancer in the UK. British Journal of Cancer 96: 143-150, 2007.

128. Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, Villa LL(*). High grade cervical

lesions are caused preferentially by non-European variants of HPVs 16 and 18. International Journal of

Cancer 120: 1763-1768, 2007.

129. Al-Qahtani K(§), Brousseau V, Paczesny D, Domanowski G, Hamid Q, Hier M, Black M, Franco E, Kost K.

Koilocytosis in oral squamous cell carcinoma: what does it mean? Journal of Otolaryngology 36: 26-31, 2007.

130. Schaffer A(§), Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L,

Gotlieb W, Ferenczy A, Coutlée F, Pollak M, Franco EL(*). Insulin-like growth factor-I and risk of high-

grade cervical intraepithelial neoplasia. Cancer Epidemiology, Biomarkers and Prevention 16: 716-722, 2007.

131. Petignat P(*), Faltin DL, Bruchim I, Tramèr MR, Franco EL, Coutlée F. Are self-collected samples

comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic

review and meta-analysis. Gynecologic Oncology 105: 530-535, 2007.

132. Mahmud S(§), Robinson K, Richardson H, Tellier PP, Ferenczy A, Roger M, Coutlée F, Franco EL(*). HLA

polymorphisms and cervical human papillomavirus infection in a cohort of Montreal university students.

Journal of Infectious Diseases 196: 82–90, 2007.

133. Franco EL, Ferenczy A. Cervical cancer screening following the implementation of prophylactic human

papillomavirus vaccination. Future Oncology 3: 319-327, 2007.

134. Brogly SB(*), Watts DH, Ylitalo N, Franco EL, Seage III GR, Oleske J, Eagle M, Van Dyke R.

Reproductive health of adolescent girls perinatally infected with HIV. American Journal of Public Health 97:

1047-1052, 2007.

135. Kim JJ(*), Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ. Multi-Parameter Calibration

of a Natural History Model of Cervical Cancer. American Journal of Epidemiology 166:137-150, 2007.

136. Ferenczy A(*), Franco EL. Prophylactic human papillomavirus vaccines: Potential for sea change. Expert

Reviews on Vaccines 6: 511-525, 2007.

137. Goldie SJ(*), Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O’Shea MKH, Bosch FX, Sanjosé S,

Franco EL. Cost-effectiveness of HPV 16,18 Vaccination in Brazil. Vaccine 25: 6257-6270, 2007.

138. Dang-Tan T(§), Franco EL(*). Diagnosis delays in childhood cancer: A review. Cancer 110: 703-713, 2007.

139. Spence A(§), Goggin P, Franco EL(*). Process of care failures in invasive cervical cancer: Systematic review

and meta-analysis. Preventive Medicine 45:93-106, 2007.

140. Mahmud SM(§), Koushik A, Duarte-Franco E, Costa J, Fontes G, Bicho M, Coutlée F, Franco EL(*).

Haptoglobin phenotype and risk of cervical neoplasia: a case-control study. Clinica Chimica Acta 385: 67-72,

2007.

141. Khouadri S, Villa LL, Gagnon S, Koushik A, Richardson H, Matlashewski G, Roger M, Ferenczy AS, Franco

EL, Coutlée F(*). Viral load of episomal and integrated forms of human papillomavirus type 33 in high-grade

squamous intraepithelial lesions of the uterine cervix. International Journal of Cancer 121: 2674–2681, 2007.

142. Mayrand MH(§), Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F,

Franco EL(*), for the CCCaST Study Group. Human Papillomavirus DNA versus Papanicolaou Screening

Tests for Cervical Cancer. New England Journal of Medicine 357: 1579-1588, 2007.

143. Coutlée F(*), Rouleau D, Ghattas G, Hankins C, Vézina S, Coté P, Macleod J, Pokomandy A, Money D,

Walmsley S, Voyer H, Brassard P, Franco E. Confirmatory real-time PCR assay for human papillomavirus

(HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV

genotyping test. Journal of Clinical Microbiology 45: 3821-3823, 2007.

144. Ramanakumar AV, Urgency for epidemiological evidence from developing world to know the cancer

related risks better. Journal of Cancer Res Ther 3 (1): 34-39, 2007.

145. Ramanakumar AV, PARENT ME, SIEMIATYCKI J. Residential Fuel Exposures and Risks of Lung

Cancer: An Evidence from two population based case-control studies in Montreal. American Journal of

Epidemiology 165(6):634-642, 2007.


39

146. Pintos J(§), Black MJ, Sadeghi N, Ghadirian P, Zeitouni AG, Viscidi RP, Herrero R, Coutlée F, Franco

EL(*). Human papillomavirus infection and oral cancer: A case-control study in Montreal, Canada. Oral

Oncology 44: 242-250, 2008.

147. Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination.

Vaccine 26S: A16-A23, 2008.

148. Ades S(§), Koushik A, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W,

Ferenczy A, Coutlée F, Roger M, Franco EL(*). Selected class i and class ii hla alleles and haplotypes and

risk of high-grade cervical intraepithelial neoplasia. International Journal of Cancer 122: 2820-2826, 2008.

149. Trottier H(§), Mahmud S, Prado JCM, Sobrinho JS, Costa MC, Rohan TE, Villa LL, Franco EL(*). Type-

specific duration of human papillomavirus infection: implications for human papillomavirus screening and

vaccination. Journal of Infectious Diseases 197:1436-1447, 2008.

150. Azizi N, Brazete J, Hankins C, Money D, Fontaine J, Koushik A, Rachlis A, Pourreaux K, Ferenczy A,

Franco EL, Coutlée F. Influence of human papillomavirus type 16 (HPV-16) E2 polymorphism on

quantification of HPV-16 episomal and integrated DNA in cervicovaginal lavages from women with cervical

intraepithelial neoplasia. Journal of General Virology 89: 1716-1728, 2008.

151. Dang-Tan T(§), Trottier H, Mery LS, Morrison HI, Barr RD, Greenberg ML, Franco EL(*). Delays in

Diagnosis and Treatment among Children and Adolescents with Cancer in Canada. Pediatric Blood & Cancer

51: 468-474, 2008.

152. Walter SD(*), Franco EL. Use of latent class models to accommodate inter-laboratory variation in assessing

genetic polymorphisms associated with disease risk. Biomed Central Genetics 8: 9(1):51, 2008.

153. Souza PSA, Maciag PC, Ribeiro K, Petzl-Erler ML, Franco EL, Villa LL(*). Interaction between

polymorphisms of the Human Leukocyte Antigen and HPV-16 variants on the risk of invasive cervical cancer.

Biomed Central Cancer .8: 246, 2008.

154. Gohy L, Gorska I, Rouleau D, Ghattas G, Pokomandy A, Vézina S, Coté P, Macleod J, Allaire G, Hadjeres R,

Kornegay JR, Franco EL, HIPVIRG Study Group, Coutlée F(*). Genotyping of human papillomavirus dna in

anal biopsies and anal swabs collected from hiv-seropositive men with anal dysplasia. Journal of Acquired

Immunodeficiency Syndrome 49:32-39, 2008.

155. Rogoza RM, Ferko N, Bentley J, Meijer C, Berkhof J, Wang KL, Downs L, Smith JS, Franco EL.

Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer

vaccination: A multi-regional health economic analysis. Vaccine 26S: F46-F58, 2008.

156. Franco EL, Tsu V, Herrero R, Lazcano E, Hildesheim A, Muñoz N, Murillo R, Sanchez G, Andrus JK.

Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the

Caribbean. Vaccine 26S: L88-L95, 2008.

157. Muñoz N, Franco EL, Herrero R, Andrus JK, Quadros C, Goldie S, Bosch FX. Recommendations for

cervical cancer prevention in Latin America and the Caribbean. Vaccine 26S: L96-L107, 2008.

158. Hamlin-Douglas LK, Coutlée F, Roger M, Franco EL, Brassard P. Prevalence and Age-Distribution of Human

Papillomavirus (HPV) Infection in a Population of Inuit Women in Nunavik, Quebec. Cancer Epidemiology,

Biomarkers, and Prevention 17: 3141-3149, 2008.

159. Ramanakumar AV, Nadon L, Siemiatycki J. Exposures in painting related occupations and risk of selected

cancers: results from a case-control study in Montreal. American Journal of Industrial Medicine 51(6):419-

427, 2008.

160. Ramanakumar AV, Parent ME, Latreille B, Simiatycki J. Risk of Lung Cancer following exposure to

titanium dioxide, carbon black and talc: results from two case-control studies in Montreal. International

Journal of Cancer 122(1):183-189, 2008.

161. Meijer CJLM(*), Berkhof J, Castle PE, Hesselink A, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J,

Dillner J, Heideman DAM, Snijders PJF. Guidelines for human papillomavirus DNA test requirements for

primary cervical cancer screening in women 30 years and older. International Journal of Cancer 124: 516-520,

2009.

162. Trottier H(§), Mahmud SM, Lindsay L, Jenkins D, Quint W, Wieting SL, Schuind A, Franco EL(*), for the

GSK HPV-001 Vaccine Study Group. Persistence of an incident human papillomavirus infection and timing

of cervical lesions in previously unexposed young women. Cancer Epidemiology, Biomarkers, and Prevention

18: 854-862, 2009.

163. De Pokomandy A(§), Rouleau D, Ghattas G, Vézina S, Coté P, Macleod J, Allaire G, Franco EL, Coutlée

F(*), for the HIPVIRG Study Group. Prevalence, clearance and incidence of anal human papillomavirus

infection in HIV-infected men: the HIPVIRG Cohort Study. Journal of Infectious Diseases 199: 965-973,

2009.


40

164. Coutlée F(*), Trottier H, Simon G, Koushik A, Richardson H, Roger M, Ferenczy A, Franco EL. Low-risk

human papillomavirus type 6 DNA load and integration in cervical samples from women with squamous

intraepithelial lesions. Journal of Clinical Virology 45: 96-99, 2009.

165. Coutlée F(*), Mayrand MH, Roger M, Franco EL. Detection and typing of Human Papillomavirus nucleic

acids in biological fluids. Public Health Genomics 12:308-318, 2009.

166. Franco EL(*), Coutlée F(*), Ferenczy A. Integrating HPV vaccination in cervical cancer control

programmes. Public Health Genomics 12: 352-361, 2009.

167. Franco EL, Olsen J, Saracci R, Detels R. Epidemiology’s contributions for a Nobel prize recognition.

Epidemiology 20: 632-634, 2009.

168. Rosen NO, Knäuper B, Pagé G, DiDio P, Morrison E, Mayrand MH, Franco EL, Rosberger Z(*).

Uncertainty-inducing and Reassuring Facts about HPV: A Descriptive Study of French-Canadian Women.

Health Care for Women International 30:892-902, 2009.

169. Franco EL(*), Mahmud SM, Tota J, Ferenczy A, Coutlée F. The expected impact of HPV vaccination on the

accuracy of cervical cancer screening: The need for a paradigm change. Archives of Medical Research 40:

478-485, 2009.

170. Kulasingam S(*), Rajan R, St-Pierre Y, Atwood CV, Myers E, Franco EL. Human papillomavirus testing

with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. BMC Medicine 7:69,

2009 (doi:10.1186/1741-7015-7-69).

171. Xuan Z. Stephen DW. Ramanakumar AV. Properties of the Projected Length of Curve (PLC) and Area

Swept out by the Curve (ASC) Indices for the Receiver Operating Characterstic (SROC) Curve. International

Journal of Biostatistics 5 (1) Article 11, 2009.

172. Rosen NO, Knäuper B, DiDio P, Morrison E, Tabing R, Feldstein A, Amsel R, Mayrand MH, Franco EL,

Rosberger Z(*). The impact of intolerance of uncertainty on anxiety after receiving an informational

intervention about HPV: A randomized controlled study. Psychology and Health 25: 651-668, 2010.

173. Burchell AN(§), Tellier PP, Hanley J, Coutlée F, Franco EL(*). Human papillomavirus infections among

couples in new sexual relationships. Epidemiology 21(1):31-7, 2010.

174. Tomita LY(§), Longatto A, Costa MC, Andreoli MAA, Villa LL, Franco EL, Cardoso MA(*). Diet and

serum micronutrients in relation to cervical neoplasia and cancer among low-income Brazilian women.

International Journal of Cancer 126(3): 703-714, 2010.

175. Burchell AN(§), Tellier PP, Hanley J, Coutlée F, Franco EL(*). Influence of partner’s infection status on

prevalent human papillomavirus among persons with a new sex partner. Sexually Transmitted Diseases 37:

34-40, 2010.

176. Franco EL, Tota J. Human papillomavirus infection and risk of cervical precancer: Using the right methods

to answer the right questions. American Journal of Epidemiology 171: 164-168, 2010.

177. Dang-Tan T(§), Trottier H, Mery LS, Morrison HI, Barr RD, Greenberg ML, Franco EL(*). Determinants of

Delays in Treatment Initiation in Children and Adolescents Diagnosed with Leukemia or Lymphoma in

Canada. International Journal of Cancer 126: 1936-1943, 2010.

178. Ramanakumar VA(§), Thomann P, Candeias JM, Ferreira S, Villa LL, Franco EL(*). Use of the

normalized absorbance ratio as an internal standardization approach to minimize measurement error in

enzyme-linked immunosorbent assays for human papillomavirus infection. Journal of Clinical Microbiology

48: 791-796, 2010.

179. Ogilvie GS(*), van Niekerk D, Krajden M, Martin RE, Ehlen TG, Ceballos K, Peacock S, Smith L, Kan L,

Cook DA, Mei W, Stuart GCE, Franco EL, Coldman AJ. A Randomized Controlled Trial of Human

Papilloma Virus (HPV) Testing For Cervical Cancer Screening: Trial Design and Preliminary Results (HPV

FOCAL Trial). Biomed Central Cancer 10(1):111, 2010.

180. Hamlin-Douglas LK, Coutlée F, Roger M, Hanley J, Franco EL, Brassard P(*). Determinants of human

papillomavirus infection among Inuit women of Northern Quebec, Canada. Sexually Transmitted Diseases 37:

377-381, 2010.

181. Cornut G, Gagnon S, Hankins C, Money D, Pourreaux K, , Franco EL, Coutlée F(*), for the Canadian

Women’s HIV Study Group. Polymorphism of the capsid L1 gene of human papillomavirus types 31, 33 and

35. Journal of Medical Virology 82: 1168-1178, 2010.

182. Huh W(*), Einstein MH, Herzog TJ, Franco EL. What is the Role of HPV Typing in the United States Now

and in the Next Five Years in a Vaccinated Population? Gynecologic Oncology 117: 481-485, 2010.

183. Rabachini T, Trottier H, Franco EL, Villa LL(*). Validation of dot blot hybridization and denaturating high

performance liquid chromatography as reliable methods for TP53 codon 72 genotyping in molecular

epidemiologic studies. Biomed Central Genetics 11:44, 2010.


41

184. Mahmud SM(*), Franco EL, Aprikian AG. Use of Non-steroidal anti-inflammatory drugs and prostate cancer

risk: A meta-analysis. International Journal of Cancer 127: 1680-1691, 2010.

185. Siegel EM, Salemi JL, Craft NE, Villa LL, Ferenczy A, Franco EL, Giuliano AR(*). No association between

endogenous retinoic acid and human papillomavirus clearance or incident cervical lesions in Brazilian

women. Cancer Prevention Research 3: 1007-1014, 2010.

186. Siegel EM, Salemi JL, Villa LL, Ferenczy A, Franco EL, Giuliano A(*). Dietary consumption of antioxidant

nutrients and risk of incident cervical intraepithelial neoplasia. Gynecologic Oncology 118: 289-294, 2010.

187. Tota J(§), Mahmud SM, Ferenczy A, Coutlée F, Franco EL(*). Promising strategies for cervical cancer

screening in the post-HPV vaccination era. Sexual Health 7: 376-382, 2010.

188. Alvarez J, de Pokomandy A, Rouleau D, Ghattas G, Vézina S, Coté P, Macleod J, Allaire G, Hadjeres R,

Franco EL, Coutlée F(*).Episomal and integrated Human papillomavirus type 16 loads and anal

intraepithelial neoplasia in HIV-seropositive men. AIDS 24: 2355-2363, 2010.

189. Perri T(§), Rahimi Kurosh, Ramanakumar AV, Wou K, Pilavdzic D, Franco EL, Gotlieb WH, Ferenczy A(*).

Are endometrial polyps true cancer precursors? American Journal of Obstetrics and Gynecology 203: 232e1-

e6, 2010.

190. Trottier H(§), Ferreira S, Thomann P, Costa MC, Sobrinho JS, Prado JCM, Rohan TE, Villa LL, Franco

EL(*). HPV infection and re-infection in adult women: the role of sexual activity and natural immunity.

Cancer Research 70: 8569–8577, 2010.

191. Mayrand MH(*), Franco EL. Integrating novel primary and secondary prevention strategies: The next

challenge for cervical cancer control. Future Oncology 6: 1725-1733, 2010.

192. Ramanakumar AV(§), Goncalves O, Richardson H, Tellier P, Ferenczy A, Coutlée F, Franco EL(*).

Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and

transient infections in young women. BMC Infectious Diseases 10: 326, 2010.

193. Ang C, Guiot MC, Ramanakumar AV, Roberge D, Kavan P. Clinical Significance of Molecular

Biomarkers in Glioblastoma. Canadian Journal of Neurological Sciences. 37 (5): 625-630, 2010.

194. Dufresne S, Sauthier P, Mayrand MH, Petignat P, Provencher D, Drouin P, Gauthier P, Dupuis MJ, Michon

B, Ouellet S, Hadjeres R, Ferenczy A, Franco EL, Coutlée F(*). Human Papillomavirus (HPV) DNA triage

of women with Atypical Squamous Cells of Undetermined Significance (ASCUS) with AMPLICOR HPV

and Hybrid Capture 2 Assays for the Detection of High-grade Lesions of the Uterine Cervix. Journal of

Clinical Microbiology 49: 48-53, 2011.

195. Cerigo H, MacDonald ME, Franco EL, Brassard P(*). Awareness and knowledge about human

papillomavirus among Inuit women in Nunavik, Quebec. Journal of Community Health 36: 56-62, 2011.

196. Mahmud SM(*§), Franco EL, Turner D, Platt RW, Beck P, Skarsgard D, Tonita J, Sharpe C, Aprikian AG.

Use of Non-Steroidal Anti-Inflammatory Drugs and Prostate Cancer Risk: A population-based nested case-

control study. Public Library of Science – One 6(1):e16412, 2011.

197. Tomita LY(§), Roteli-Martins CM, Villa LL, Franco EL, Cardoso MA(*), for the BRINCA Study Team.

Associations of dietary dark green and deep yellow vegetables and fruits with cervical intraepithelial

neoplasia: modification by smoking. British Journal of Nutrition 105: 928-937, 2011.

198. Ferguson R(§), Ramanakumar AV, Richardson H, Tellier PP, Coutlée F, Franco EL, Roger M(*).Human

leukocyte antigen (HLA)-E and HLA-G polymorphisms in human papillomavirus infection susceptibility and

persistence. Human Immunology 72(4):337-341, 2011.

199. de Pokomandy A(§), Rouleau D, Ghattas G, Trottier H, Vézina S, Coté P, Macleod J, Allaire G, Hadjeres R,

Franco EL, Coutlée F(*). HAART and Progression to High-Grade Anal Intraepithelial Neoplasia in Men Who

Have Sex with Men and Are Infected with HIV. Clinical Infectious Diseases 52:1174-1181, 2011.

200. Sénécal M(*), Brisson M, Maunsell E, Ferenczy A, Franco EL, Ratnam S, Coutlée F, Palefsky JM, Mansi

JA. Loss of quality of life associated with genital warts: baseline analyses from a prospective study. Sexually

Transmitted Infection 87:209-215, 2011.

201. Coutlée F(*), Ratnam S, Ramanakumar AV, Insinga RR, Bentley J, Escott N, Ghatage P, Koushik A,

Ferenczy A, Franco EL. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia

and invasive cervical cancer in Canada. Journal of Medical Virology 83:1034-1041, 2011.

202. Brisson M(*), Van De Velde N, Franco EL, Drolet M, Boily MC. Incremental impact of adding boys to

current hpv vaccination programmes: role of herd immunty. Journal of Infectious Diseases 204(3): 372-376,

2011.

203. Vanni T(§*), Legood R, Franco EL, Villa LL, Luz PM, Schwartsmann G. Economic evaluation of strategies

for managing women with equivocal cytological results in Brazil. International Journal of Cancer 129(3): 671-

679, 2011.


42

204. Sangwa-Lugoma G(§), Ramanakumar AV, Mahmud S, Liaras J, Kayembe PK, Tozin RR, Lorincz A, Franco

EL(*). Prevalence and determinants of high-risk human papillomavirus infection in women from a sub-

Saharan African community. Sexually Transmitted Diseases 38(4): 308-315, 2011.

205. Ramanakumar AV, Parent ME, Richardson L, Simiatycki J. Exposures in painting related occupations and

risk of lung cancer among men: results from two case-control studies in Montreal. Occupation and

Environmental Medicine Jan: 68(1) 44-51, 2011.

206. Richardson LA(§), Tota J, Franco EL(*). Optimizing Technology for Cervical Cancer Screening in High-

Resource Settings. Expert Review of Obstetrics & Gynecology (in press).

207. Drolet M, Brisson M(*), Maunsell E, Franco EL, Coutlée F, Ferenczy A, Fisher W, Mansi J. The

psychosocial impact of an abnormal cervical smear result: a prospective and comparative study. Psycho-

Oncology (in press).

208. Drolet M, Brisson M(*), Maunsell E, Franco EL, Coutlée F, Ferenczy A, Ratnam S, Fisher W, Mansi J. The

impact of anogenital warts on health-related quality of life: a 6-month prospective study. Sexually

Transmitted Diseases (in press).

209. Cerigo H, Macdonald ME, Franco EL, Brassard P(*). Inuit Women’s Attitudes and Experiences towards

Cervical Cancer and Prevention Strategies in Nunavik, Quebec. International Journal of Circumpolar Health

(in press).

210. Siegel E, Patel N, Lu B, Lee J-H, Nyitray AG, Craft NE, Frenkel K, Villa LL, Franco EL, Giuliano AR(*).

Biomarkers of oxidant load and type-specific clearance of prevalent oncogenic human papillomavirus

infection: Markers of immune response?. International Journal of Cancer (in press).

211. Toporowski A, Harper S, Fuhrer R, Buffler PA, Detels R, Krieger N, Franco EL(*). Burden of Disease,

Health Indicators, and Challenges for Epidemiology in North America. International Journal of Epidemiology

(in press).

212. Burchell AN(§*), Coutlée F, Tellier PP, Hanley J, Franco EL. Genital transmission of human papillomavirus

in recently-formed, heterosexual couples. Journal of Infectious Diseases (in press).

213. Legault V, Burchell A, Goggin P, Nicolau B, Forest P, Mayrand MH, Franco EL, Coutlée F(*). Generic

Microtiter Plate Assay for Triaging Clinical Specimens prior to Genotyping of HPV DNA via Consensus

PCR. Journal of Clinical Microbiology (in press).

214. Tota JE(§), Chevarie-Davis M, Richardson LA, deVries M, Franco EL(*). Epidemiology and burden of HPV

infection and related diseases: Implications for prevention strategies. Preventive Medicine (in press).

215. Gilbert L, Basso O, Sampalis O, Karp I, Martins C, Feng J, Piedimonte S, Quintal L, Ramanakumar AV,

Takefman J, Artho G, Krishnamurthy S, for the DOVE Study Group. Targeting symptomatic women for

early diagnosis of ovarian cancer: potential and pitfalls. Lancet Oncology (in press).

Peer-reviewed articles, E. Franco authorship as part of study group

1. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, Cohen C; American Cancer Society

Advisory Groups. American Cancer Society guideline for the early detection of cervical neoplasia and cancer.

CA Cancer Journal for Clinicians 52: 342-362, 2002.

2. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B, Pintos

J, Fernandez L, Idris A, Sanchez MJ, Nieto A, Talamini R, Tavani A, Bosch FX, Reidel U, Snijders PJ, Meijer

CJ, Viscidi R, Munoz N, Franceschi S; IARC Multicenter Oral Cancer Study Group. Human papillomavirus

and oral cancer: the International Agency for Research on Cancer multicenter study. Journal of the National

Cancer Institute 95: 1772-1783, 2003.

3. Tomita LY, Almeida LC, Roteli-Martins C, D'Almeida V, Cardoso MA; BRINCA Study Team. Dietary

predictors of serum total carotene in low-income women living in São Paulo, southeast Brazil. Public Health

Nutrition 12: 2133-2142, 2009.

4. Luciani S, Vardy L, Paci E, Adewole I, Sasco A, Calvacante T; ICCC-3 Session C Group. Cancer prevention

and population-based screening. Tumori 95: 597-609, 2009.

Invited editorials, non-peer-reviewed articles, letters, etc.

1. Franco EL. Recent advances in the molecular epidemiology of cervical cancer. Sao Paulo Medical Journal 113

(2, suppl.): 28-29, 1995.


43

2. Franco EL. Invited Editorial: A personal view of the epidemiological presentations in the 14th International

Papillomavirus Conference, Quebec City. Papillomavirus Report 6: 147-150, 1995.

3. Franco EL(*), Syrjänen K, De Wolf C, Patnick J, Ferenczy A, McGoogan E, Bosch X, Singer A, Muñoz N,

Meheus A, Monsonego J. Meeting report: New developments in cervical cancer screening and prevention.


4. Latorre MR(§), Franco EL. Epidemiologia dos tumores na infância. Acta Oncologica Brasileira 16: 201-219,

1996.

5. Franco EL. Invited editorial: Understanding the epidemiology of genital infection with oncogenic and non-

oncogenic human papillomaviruses: A promising lead for primary prevention of cervical cancer. Cancer

Epidemiology, Biomarkers & Prevention 6: 759-761, 1997.

6. Franco EL. Invited editorial: Defining safe drinking water. Epidemiology 8: 607-609, 1997. Reprinted in

Infectious Diseases in Clinical Practice 7: 63-65, 1998.

7. Richardson H(§), Franco EL(*). Human Papillomavirus infection and cervical cancer: an update. Mature

Medicine Canada 1: 26-28, 1998.

8. Franco EL. Invited editorial: “A epidemiologia do câncer no Brasil: onde estamos e para onde devemos ir.”

Revista da Sociedade Brasileira de Cancerologia 1: 10-13, 1998.

9. Bruneau J(*§), Lamothe F, Franco E. Letter to the Editor: Re: High rates of HIV infection among injection

drug users. American Journal of Epidemiology 148: 716-717, 1998.

10. Latorre MR(§), Franco EL. Epidemiologia dos sarcomas. Acta Oncologica Brasileira 18: 3-14, 1998.

11. Franco EL. Invited editorial: “Ponto de vista: A epidemiologia do câncer no Brasil.” Revista Médicos 2: 96-

100, 1999.

12. Franco EL. Invited Letter to the Editor: Being a medical scientist: it takes love and dedication to research, not a

title. McGill Journal of Medicine 5: 2-3, 1999.

13. Bruneau J(*§), Franco E. Letter to the Editor: Re: High rates of HIV-1 infection among drug users participating

in needle exchange programs in Montreal. American Journal of Epidemiology 150: 326, 1999.

14. Franco EL, Schlecht NF. Authors’ response to “Invited Commentary: More evidence of increased risks of

cancer among alcohol drinkers. American Journal of Epidemiology 150: 1141, 1999.

15. Schlecht NF(§), Franco EL(*). Letter to the Editor: Authors’ response to “Re: Interaction between tobacco and

alcohol and the risk of cancers of the upper aero-digestive tract in Brazil.” American Journal of Epidemiology

152: 193-194, 2000.

16. Sharpe CR(§), Franco EL(*). Letter to the Editor: Re: The influence of parental age on the risk of Wilms’

tumour. Paediatric and Perinatal Epidemiology 14: 284-285, 2000.

17. Bosch FX, Muñoz N, Sanjosé S, Franco EL, Lowy DR, Schiffman M, Franceschi S, Kjær S, Meijer CJLM,

Frazer IH, Cuzick J. Letter to the editor Re:. Cervical carcinoma and human papillomavirus: on the road to

preventing a major human cancer. Journal of the National Cancer Institute 93: 1349-1350, 2001.

18. Franco EL, Duarte-Franco E, Ferenczy A. Reply to E Ellison: Re: The merits of new alternatives to the

Papanicolaou test. Canadian Medical Association Journal 165:739-40, 2001.

19. Duarte-Franco E, Franco EL(*). Determinants of patient survival in cervical cancer: an overview. CME

Journal of Gynecologic Oncology 6: 173-183, 2001.

20. Mayrand MH(§), Franco EL(*). Screening elderly women for urogenital cancers: When should we stop giving

older women Pap tests? Geriatrics & Aging 5: 39-42, 2002.

21. Villa LL, Amestoy G, Franco E. Introduction. Virus Research 189: 161, 2002.

22. Villa LL, Bernard HU, Kast M, Hildesheim A, Amestoy G, Franco E. Past, present, and future of HPV

research: highlights from the 19th International Papillomavirus Conference-HPV 2001. Virus Research 189:

163-173, 2002.

23. Gilbert L, Krishnamurthy S, Tan SL, Franco EL. Letter to the Editor Re: Estrogen replacement therapy and

risk of ovarian cancer in post-menopausal women. Journal of the American Medical Association 288: 2538-

2539, 2002.

24. Wolf JK, Franco EL, Arbeit JM, Shroyer KR, Wu TC, Runowicz CD, Tortolero-Luna G, Herrero R, Crum CP.

Innovations in understanding the biology of cervical cancer. Cancer 98 (Suppl): 2064-2069, 2003.

25. Franco EL. Invited Commentary: Are we ready for a paradigm change in cervical cancer screening? Lancet

362: 1866-1867, 2003.

26. Franco EL, Duarte-Franco E, Ferenczy A. Prospects for controlling cervical cancer at the turn of the century.

Salud Publica de Mexico 45 (suppl. 3): S367-375, 2003.

27. Franco EL. Invited Editorial: Male circumcision and AIDS in Africa: Primum non nocere versus the collective

good. Epidemiology 15: 133-134, 2004.


44

28. Franco EL. Invited Editorial: Randomized controlled trials of hpv testing and Pap cytology: Toward evidence-

based cervical cancer prevention. International Journal of Cancer 110: 1-2, 2004.

29. Mahmud S(§), Franco EL(*). Invited Editorial: An overview of epidemiologic and public health research on

HPVs presented at the 21st International Papillomavirus Conference in Mexico City. Papillomavirus Report 15:

121-123, 2004.

30. Franco EL, Duarte-Franco EF. Invited Commentary: Screening every three years, instead of annually, would

result in a small increase in risk of cervical cancer (Sawaya et al., N Engl J Med 2003; 349:1501-1509).

Evidence-Based Obstetrics & Gynecology 6: 204-205, 2004.

31. Lau S(§), Franco EL(*). Management of low-grade cervical lesions in young women. Canadian Medical

Association Journal 173: 771-774, 2005.

32. Franco EL. Invited Commentary: Epidemiology as a tool to reveal inequalities in breast cancer care. Public

Library of Science-Medicine 3(3): e48, 2006.

33. Franco EL, Lau S. LSIL in young women: Inaction is not an option. Canadian Medical Association Journal

174: 813, 2006.

34. Franco EL(*), Ferenczy A. Invited Commentary: Is human papillomavirus testing with cytological triage a

more logical approach in cervical cancer screening? Lancet Oncology 7: 527-529, 2006.

35. Franco EL, Mayrand MH, Trottier H. Cervical cancer prevention: Promises and perils in a changing landscape.

Oncology Exchange 5: 9-13, 2006.

36. Franco EL, Trottier H. Invited Editorial: A new window into the natural history of human papillomavirus

infection: A view from the ALTS (Atypical Squamous Cells of Undetermined Significance/Low-Grade

Squamous Intraepithelial Lesions Triage Study) trial. Journal of Infectious Diseases 195: 1560-1562, 2007.

37. Sichero L, Trottier H, Ferreira S, Duarte-Franco E, Franco EL, Villa LL(*). Re: Human papillomavirus type 16

and 18 variants: race-related distribution and persistence. Journal of the National Cancer Institute 99: 653-654,

2007.

38. Franco EL. Invited Commentary: Which is the more useful screening tool for cervical cancer, HPV or Pap?

Parkhurst Exchange 15: 123-125, 2007

39. Ferenczy A(*), Franco EL. HPV: Answering your worried patients' questions. Contemp OB/GYN 52:48-54,

2007.

40. Franco EL. Invited commentary: Health inequity could increase in poor countries if universal HPV vaccination

is not adopted. British Medical Journal 335: 378-379, 2007.

41. Petignat P(*), Franco EL, Coutlée F. Letter: Response to Pretorius and Belinson. Gynecologic Oncology 107:

596-597, 2007.

42. Kim JJ(*), Franco EL, Stout NK, Goldie SJ. Letter: The authors reply re: Multi-Parameter Calibration of a

Natural History Model of Cervical Cancer. American Journal of Epidemiology 166: 983-984, 2007.

43. Franco EL, de Pokomandy A, Spence AR, Burchell AN, Trottier H, Mayrand MH, Lau S. Letter: Vaccination

against human papillomavirus. Canadian Medical Association Journal 177: 1524-1525, 2007.

44. Franco EL. Expected Impact of HPV Vaccination on Cervical Cancer Screening Practices: Time to Rethink

Preventive Strategies. African Organisation for Research and Training In Cancer (AORTIC) Newsletter 9: 15-

16, 2007.

45. Brogly SB(*), Franco EL, Watts DH, Van Dyke R. Letter: Reproductive health of adolescent girls perinatally

infected with HIV. American Journal of Public Health 97: 1930, 2007.

46. Gorska-Flipot I, Sawicki J, Gaboury LA, Krajinovic M, Labuda D, Brukner I, Rouleau D, Ghattas G, Franco

EL, Coutlée F. Newly isolated HPV-97 related to HPV-18 and 45 is highly prevalent in HIV positive males

from the Montreal area. International Journal of Cancer 122: 1195-1197, 2008.

47. Franco EL, Duarte-Franco E. Invited Commentary: Ovarian cancer and oral contraceptives. Lancet 371: 277-

278, 2008.

48. Franco EL, Trottier H. Invited Editorial: Reassessing the epidemiology of human papillomavirus infection:

Back to basics. Sexually Transmitted Diseases 35: 283-285, 2008.

49. Franco EL, Mayrand MH, Ratnam S. Letter: Human Papillomavirus DNA versus Papanicolaou Screening

Tests for Cervical Cancer. New England Journal of Medicine 358: 643, 2008.

50. Franco EL, Spence AR. Invited Commentary: Smoking and human papillomavirus infection: the pursuit of

credibility for an epidemiologic association. International Journal of Epidemiology 37: 547-548, 2008.

51. Franco EL, Paavonen J. Foreword: Human papillomavirus vaccination and screening as the new paradigm in

cervical cancer prevention. Therapy 5: 261-263, 2008.

52. Franco EL, Drummond M. Foreword: Cost-effectiveness Analysis: An Essential Tool to Inform Public Health

Policy in Cervical Cancer Prevention. Vaccine 26S: F1-F2, 2008.


45

53. Bosch FX; Editors (Bosch FX, Stanley M, Wright TC, Franco EL, Herrero R, Munoz N, Cuzick J, Garland

SM). A scientific response to prevent cervical cancer in the world. Vaccine 26 Suppl 10: v-vi, 2008.

54. Bosch FX; Editors (Franco EL, Herrero R, Munoz N, Cuzick J, Garland SM, Bosch FX, Stanley M, Wright

TC). A scientific response to prevent cervical cancer in the world. Vaccine 26 Suppl 11: v-vi, 2008.

55. Franco EL, Coutlée F. Invited Editorial: Prognostic value of measuring load of human papillomavirus DNA in

cervical samples: an elusive target. Journal of the National Cancer Institute 101:131-133, 2009.

56. Franco EL. Invited Commentary: Is the UK ready to embrace HPV testing? Lancet Oncology 10: 643-644,

2009.

57. Franco EL. Invited Editorial: Managing low grade and borderline cervical abnormalities: The dilemma of

choosing between conservative and aggressive policies remains. British Medical Journal 339: b3014, 305-306,

2009.

58. Franco EL, Wallace S. Foreword: How multidisciplinary research advanced the mission of cervical cancer

prevention. Public Health Genomics 12: 264-267, 2009.

59. Franco EL. Invited Editorial: A new generation of studies of human papillomavirus DNA testing in cervical

cancer screening. Journal of the National Cancer Institute 101: 1600-1601, 2009.

60. Tota J(§)

, Franco EL(*). Effectiveness of cervical cancer screening at different ages. Womens Health 5: 613-

616, 2009.

61. Franco EL, Turgeon GA. Invited Editorial: Radiodiagnostic Imaging in Pregnancy and the Risk of Childhood

Malignancy: Raising the Bar. Public Library of Science – Medicine 7(9): e1000338, 2010.

doi:10.1371/journal.pmed.1000338.

62. Franco EL. Invited Editorial: Persistent HPV infection and cervical cancer risk: Is the scientific rationale for

changing the screening paradigm enough? Journal of The National Cancer Institute 102: 1451-1453, 2010.

63. Franco EL. Foreword. Future Medicine, in press, 2011.

Manuscripts submitted

1. Ferko N(*), Kohli MA, Buitendyk M, Bosch FX, Standaert BA, Franco EL. Clustering countries according to

correlates of cervical cancer risk: An approach for improving the coverage of health economic models of

cervical cancer prevention strategies. (submitted for publication).

2. Lau S(§), Vaknina Z, Ramana-Kumar AV, Halliday D, How J, Gotlieb R, Deland C, Eniu I, Franco EL,

Gotlieb WH(*). Outcomes and cost following the introduction of a robotics program for cancer surgery in

Canada. (submitted for publication).

3. Trevisan A(§*), Schlecht NF, Ramanakumar AV, Villa LL, Franco EL, for the Ludwig-McGill Study

Group. HPV16 viral load measurement as a predictor of infection clearance. (submitted for publication).

4. Ferguson R(§), Ramanakumar AV, Koushik A, Coutlée F, Franco EL, Roger M(*), for the Biomarkers of

Cervical Cancer Risk (BCCR) Study Team. Human leukocyte antigen G polymorphism is associated with an

increased risk of invasive cancer of the uterine cervix. (submitted for publication).

5. Walter SD(*), Riddell CA, Rabachini T, Villa LL, Franco EL(*). Accuracy of p53 codon 72 polymorphism

status determined by multiple laboratory methods: a latent class model analysis. (submitted for publication).

6. Mahmud SM(§*), Sangwa-Lugoma G, Nasr SH, Liaras J, Kayembe PK, Tozin RR, Drouin P, Lorincz A,

Ferenczy A, Franco EL. Comparison of Human Papillomavirus Testing and Cytology for Cervical Cancer

Screening in a Primary Health Care Setting in the Democratic Republic of Congo. (submitted for publication).

7. Ribeiro R(§*), Monteiro C, Azevedo A, Cunha V, Ramanakumar AV, Fraga AM, Pina FM, Lopes CMS,

Medeiros R, Franco EL. Performance of an adipokine pathway-based multilocus genetic risk score for

prostate cancer risk prediction. (submitted for publication).

Books

Franco EL, Monsonego J (eds.) New developments in cervical cancer screening and prevention. Blackwell Science,

Oxford, 1997, 470 pages, ISBN 0-632-04765-8 (personal authorship of individual chapters listed below).

Franco EL, Rohan TE (eds.) Cancer Precursors: Epidemiology, Detection, and Prevention. Springer-Verlag, New

York, 2002, 430 pages, ISBN 0-387-95188-1 (personal authorship of individual chapters listed below).


46

Journal Supplements

1. Villa LL, Amestoy G, Franco E (Guest Editors). Special Issue: 19th International Papillomavirus Conference,

Florianopolis, Brazil, 1–7 September 2001. Virus Research 189: 161-314, 2002 (personal authorship of two

articles listed above).

2. Bosch FX, Cuzick J, Schiller J, Garnett G, Meheus A, Franco E, Wright T (Co-Editors). HPV Vaccines and

Screening in the Prevention of Cervical Cancer. Vaccine, Volume 24, Supplement 3, 31 August 2006, ISSN

0264-410X (personal authorship of four articles listed above).

3. Franco EL, Paavonen J (Guest Editors). Special Focus Issue – HPV vaccination. Future Therapy 5(3) May

2008.

4. Franco EL. (Guest Editor) HPV Today: Special issue on Canada. No. 15, June 2008. Bypass Ediciones,

Madrid, Spain.

5. Bosch FX, Wright T, Ferrer E, Munoz N, Franco EL, Herrero R, Bruni L, Garland S, Cuzick J, Louie K,

Stanley M. (Co-Editors). Prevention of Cervical Cancer: Progress and Challenges on Hpv Vaccination and

Screening. Vaccine Vol. 26, Supp. 10, 2008, ISSN 0264-410X.

6. Bosch FX, Munoz N, Herrero R, Bruni L, Garland S, Cuzick J, Louie K, Wright T, Stanley M, Ferrer E, Franco

EL. (Co-Editors). Prevention of Cervical Cancer in the Latin American and Caribbean Region. Vaccine Vol.

26, Supp. 11, 2008, ISSN 0264-410X. (personal authorship of two articles listed above).

7. Bosch FX, Garland S, Louie K, Munoz N, Franco EL, Herrero R, Bruni L, Wright T, Stanley M, Ferrer E,

Cuzick J. (Co-Editors). Prevention of Cervical Cancer in the Asia-Pacific Region. Vaccine Vol. 26, Supp. 12,

2008, ISSN 0264-410X.

8. Franco EL, Drummond MF (Guest Editors). Health economics of HPV vaccination for cervical cancer

prevention: Historical developments and practical applications. Vaccine Vol. 26, Supp. 5, 2008.

9. Franco EL (Guest Editor). Special issue on Cervical Cancer Prevention and HPV Vaccines. Public Health

Genomics Vol. 12, No. 5-6, 2009.

10. Franco EL (Guest Editor). Human Papillomavirus Vaccines. Future Medicine, in press, 2011.

Book Chapters and Monographs

1. Franco EL. Epidemiologia do cancer mamario e ginecologico. In: Abrao F (ed.) Tratado de oncologia genital e

mamaria. Editora Roca, Sao Paulo, 1995 (pp. 3-16).

2. Franco EL. Epidemiology of anogenital warts and cancer. In: Reid R, Lorincz A (eds.) Human

Papillomaviruses I. Obstetrics and Gynecology Clinics of North America, W.B. Saunders, Philadelphia, 23:

597-623, 1996.

3. Franco EL. Epidemiology in the study of cancer. In: Bertino JR et al. (eds.), Encyclopedia of Cancer, Vol. 1.

Academic Press, San Diego, 1997 (pp. 621-641).

4. Franco EL, Monsonego J. Introduction. In: Franco EL, Monsonego J (eds.) New developments in cervical

cancer screening and prevention. Blackwell, Oxford, 1997 (pp. xiii-xiv).

5. Franco EL, Villa LL, Richardson H, Rohan T, Ferenczy A. Epidemiology of cervical human papillomavirus

infection. In: Franco EL, Monsonego J (eds.) New developments in cervical cancer screening and prevention.

Blackwell, Oxford, 1997 (pp. 14-22).

6. Franco EL. Statistical issues in studies of human papillomavirus infection and cervical cancer. In: Franco EL,

Monsonego J (eds.) New developments in cervical cancer screening and prevention. Blackwell, Oxford, 1997

(pp. 39-50).

7. Ferenczy A, Franco EL. HPV DNA testing using liquid-based cytology. In: Franco EL, Monsonego J (eds.)

New developments in cervical cancer screening and prevention. Blackwell, Oxford, 1997 (pp. 348-353).

8. Villa LL, Rahal P, Franco EL(*). Molecular variant analysis as a tool in natural history studies of human

papillomavirus infection and cervical neoplasia. In: Franco EL, Monsonego J (eds.) New developments in

cervical cancer screening and prevention. Blackwell, Oxford, 1997 (pp. 379-385).

9. Franco EL. Rapporteurs’ summary of presentations. In: Franco EL, Monsonego J (eds.) New developments in

cervical cancer screening and prevention. Blackwell, Oxford, 1997 (pp. 453-461).

10. Franco EL. Highlights and consensus. In: Franco EL, Monsonego J (eds.) New developments in cervical

cancer screening and prevention. Blackwell, Oxford, 1997 (pp. 462-464).

11. Franco EL. Epidemiology of uterine cancers (chapter 14). In: Meisels A, Morin C (eds.) Cytopathology of the

uterus, 2nd Edition. American Society of Clinical Pathologists, Chicago, 1997 (pp. 301-324).


47

12. Latorre MR(§), Franco EL(*). Epidemiologia do câncer de ovário. In: Abrao F (ed.) Cancer do ovário. Editora

Roca, Sao Paulo, 1997 (pp. 51-64).

13. Allison PJ(§), Franco E, Locker D, Feine JS. The role of delays and anatomical site in determining disease

stage among oral and oropharyngeal cancers. In: Varma AK (ed.) Oral Oncology, Vol V, ICOC Press, New

Delhi, 1997 (pp. 112-115).

14. Latorre MR(§), Franco EL(*). Epidemiologia. In: Lopes AL (ed.) Sarcomas de partes moles. MEDSI Editora,

Sao Paulo, 1998 (pp. 3-18).

15. Franco EL. Statistical issues in human papillomavirus testing and screening. In: Carr J (ed.) Human

Papillomavirus. Clinics in Laboratory Medicine, W.B. Saunders, Philadelphia, 2000 (pp 345-367).

16. Carvalho AL(§), Schlecht NF, Pintos J, Oliveira BV, Fava AS, Curado MP, Kowalski LP, Franco EL. Factors

influencing patient and professional delay in oral cancer diagnosis. In: Varma AK, Roodenburg JLN (eds.) Oral

Oncology, Vol VII, ICOC Press, The Hague, 2001 (pp. 31-34).

17. Carvalho AL(§), Pintos J, Schlecht NF, Oliveira BV, Fava AS, Curado MP, Kowalski LP, Franco EL.

Incidence of second primary tumours in a cohort of head and neck cancer patients in Brazil. In: Varma AK,

Roodenburg JLN (eds.) Oral Oncology, Vol VII, ICOC Press, The Hague, 2001 (pp. 72-74).

18. Rohan TE, Franco EL. Introduction. In: Franco EL, Rohan TE (eds.) Cancer Precursors: Epidemiology,

Detection, and Prevention. Springer-Verlag, New York, 2002 (pp. 1-3).

19. Franco EL, Rohan TE. Assessing epidemiologic relations and the role of measurement errors. In: Franco EL,

Rohan TE (eds.) Cancer Precursors: Epidemiology, Detection, and Prevention. Springer-Verlag, New York,

2002 (pp. 60-74).

20. Franco EL, Ferenczy A. Cervix. In: Franco EL, Rohan TE (eds.) Cancer Precursors: Epidemiology, Detection,

and Prevention. Springer-Verlag, New York, 2002 (pp. 249-286).

21. Franco EL, Ferenczy A. Endometrium. In: Franco EL, Rohan TE (eds.) Cancer Precursors: Epidemiology,


22. Franco EL, Rohan TE. Evidence-based policy recommendations on screening and prevention. In: Franco EL,

Rohan TE (eds.) Cancer Precursors: Epidemiology, Detection, and Prevention. Springer-Verlag, New York,

2002 (pp. 389-403).

23. Rohan TE, Franco EL. Prospects. In: Franco EL, Rohan TE (eds.) Cancer Precursors: Epidemiology,


24. Rousseau MC(§), Franco EL(*). Détection des infections à HPV. In: Aubin F, Pretet JL, Mougin C (eds.)

Papillomavirus humains, biologie et pathologie tumorale. Editions Médicales Internationales, Paris, 2003 (pp.

601-626).

25. Carvalho A(§), Pintos J, Schlecht N, Oliveira B, Fava A, Curado MP, Kowalski LP, Franco EL. Age and

alcohol consumption influence prognosis of head and neck cancer patients. In: Varma AK, Reade P (eds.) Oral

Oncology, Vol 9, MacMillan Press, India, 2003 (pp. 101-103).

26. Tortolero-Luna G, Franco EL. Epidemiology of cervical, vulvar, and vaginal cancer: Unresolved issues and

future research. In: Gershenson DM, Gore M, Quinn MJ, Thomas G (Eds.). Gynecologic cancer: Controversies

in management. Elsevier Science and Churchill Livingstone (pp. 3-30), ISBN:044307142X, 2004.

27. Franco EL. The Role of Viruses in Oncogenesis: Human Papillomaviruses and Cervical Cancer as a Paradigm.

In: Knobler S, O'Connor S, Lemon S (eds.). The Infectious Etiology of Chronic Diseases: Defining the

Relationship, Enhancing the Research, and Mitigating the Effects. National Academy Press, Washington, D.C.

2004, pp. 17-28 (ISBN 0-309-08994-8).

28. Duarte-Franco E, Franco EL(*). Cancer of the Colon and Rectum: Epidemiology and Risk factors. In: Rossi

BM (ed.) Cancer of the Colon, Rectum and Anus, Lemar and Tecmedd, Sao Paulo, 2005, pp. 3-22, ISBN

858665303-9.

29. Duarte-Franco E, Franco EL(*). Cancer of the Anus: Epidemiology and Risk Factors. In: Rossi BM (ed.)

Cancer of the Colon, Rectum and Anus, Lemar and Tecmedd, Sao Paulo, 2005, pp. 665-678, ISBN 858665303-

9.

30. Franco EL, Duarte-Franco E, Ferenczy A. Perspectivas para controlar el cáncer cervicouterino en el siglo XXI.

In: Alonso PA, Lazcano-Ponce E, Hernández-Avila M (eds.) Cáncer Cervicouterino: Diagnóstico, Prevención y

Control. Editora Medica Panamericana, Mexico DF, 2005, pp. 251-262, ISBN 9687988509.

31. Burchell AN(§), Franco EL(*). Epidemiology of oncogenic and nononcogenic HPV types, and the evidence for

differences in their sexual transmissibility. In: Monsonego J (ed.) Emerging issues on HPV infections: From

science to practice. Karger AG, Basel, 2006, pp. 20-33, ISBN 3-8055-8120-3.

32. Duarte-Franco E, Franco EL(*). Epidemiologia do cancer mamario e ginecologico. In: Abrao F (ed.) Tratado

de oncologia genital e mamaria. 2a. Edição, Editora Revinter, Sao Paulo, 2006, pp. 1-25, ISBN 85-372-0005-0.


48

33. Rohan TE, Henson D, Franco EL, Albores-Saavedra J. Cancer Precursors. In: Schottenfeld D, Fraumeni J

(eds.) Cancer Epidemiology and Prevention, 3rd edition, Oxford University Press, 2006; pp. 21-46, ISBN-13:

978-0-19-514961-6 and ISBN-10: 0-19-514961-0.

34. Koushik A(§), Franco EL(*). Chapter 18: Epidemiology and the role of human papillomaviruses. In: Jordan

JA, Singer A (eds.) The Cervix, 2nd Edition, Blackwell, Oxford, 2006, pp. 259-276, ISBN-13: 978-1-4051-

3137-7, ISBN-10: 1-4051-3137-3.

35. Spence A(§), Franco EL(*). Chapter 26: Screening for cervical cancer using HPV tests. In: Jordan JA, Singer A

(eds.) The Cervix, 2nd Edition, Blackwell, Oxford, 2006, pp. 373-386, ISBN-13: 978-1-4051-3137-7, ISBN-10:

1-4051-3137-3.

36. Franco EL, Mahmud S, Dean AG. Epidemiological Methods: A View from the Americas. In: Holland W,

Olsen J, Florey C (eds.) The Development of Modern Epidemiology. Oxford University Press, 2007, pp. 275-

287, ISBN 978-0-19-856954-1.

37. Mayrand MH(§), Franco EL(*). Chapter 8: Prevention of uterine cancers. In: Meisels A, Morin C (eds.)

Modern Uterine Cytopathology. American Society of Clinical Pathologists, ASCP Press, Chicago, 2007, pp.

136-154.

38. Spence A(§), Franco EL(*). Chapter 9: Epidemiology of uterine cancers. In: Meisels A, Morin C (eds.) Modern

Uterine Cytopathology. American Society of Clinical Pathologists, ASCP Press, Chicago, 2007, pp. 155-168.

39. Franco EL. Human Papillomavirus and Cervical Cancer: Integrating the New Prevention Strategies. In: AACR

Education Book 2008, American Association for Cancer Research, San Diego, 2008, pp. 367-373.

40. Trottier H(§), Franco EL(*). A prevenção do câncer do colo do útero na era da vacinação contra o HPV

(“Prevention of cervical cancer in the era of HPV vaccination”. In: Coelho F et al. (eds.) Câncer do Colo do

Útero. Tecmedd Editora, Sao Paulo, 2008, pp. 162-168, ISBN 978-85-99276-25-9.

41. Trottier H(§), Franco EL(*). Impact potentiel de la vaccination HPV dans les programmes de dépistage du

cancer du col utérin. In: Monsonego J (ed.) Traité des infections et pathologies génitales à papillomavirus.

Editions Springer, Paris, 2008, ISBN 978-2-287-72064-2.

42. Tota J (§), Franco EL(*). Chapter 12: HPV Infection and Cervical Carcinogenesis: Epidemiology and

Prevention. In: Ayhan A, Gultekin M, Dursum P (eds.) Textbook of Gynaecological Oncology, European

Society of Gynecologic Oncology, Gunes Publishing, Ankara, 2009, pp 49-52, ISBN 978-975-277-267-0.

43. Trottier H(§), Franco EL(*).Chapter 23. Infectious diseases and cancer: HPV. In: Krämer A, Kretzschmar M,

Krickeberg K (eds.) Modern infectious disease epidemiology: Concepts, methods, mathematical models, and

public health. Springer 2010, ISBN 978-0-387-93834-9.

44. Burchell AN(§), Franco EL(*). Chapter 6: The impact of immunization on cancer control: The example of

HPV vaccination. In: Elwood JM, Sutcliffe SB (eds.) Cancer Control. Oxford University Press, Oxford, UK,

2010, pp 101-128, ISBN 978-0-19-955017-3.

45. Coutlée F, Franco EL(*). Chapter 10: Infectious Agents. In: Rothman N, Hainaut P, Schulte P, Smith M,

Boffetta P, Perera F (eds.) Molecular Epidemiology: Principles and Practices. International Agency for

Research on Cancer, Scientific Publication, Lyon, in press.

46. De Pokomandy A(§), Franco EL(*). Chapter 20: HPV Infection and Cervical Carcinogenesis: Epidemiology

and Prevention. In: Gultekin M, Dursum P (eds.) Textbook of Gynaecological Oncology, European Society of

Gynecologic Oncology (in press).

47. Chevarie-Davis M(§), Franco EL(*). Chapter: Screening and vaccination in cervical cancer control and

prevention. In: Goldman MB, Troisi R, Rexrode KM (Eds). Women and health, 2nd

edition, Elsevier (in press).

48. Ramanakumar AV. Assessment of cervical cancer prevention and treatment strategies in low-resource

countries: challenges and revelations. Poverty in India (editor: Chatarjee A) (in press).

Technical Reports

1. Franco EL. Risk of cancer attributable to active and passive tobacco smoking: A review of North American

studies since 1985. A report prepared under contract (4844) with Health Canada, 1995.

2. Franco EL, Bosch X, De Wolf C, Ferenczy A, McGoogan E, Meheus A, Muñoz N, Patnick J, Singer A,

Syrjänen K. New developments in cervical cancer screening and prevention. Technical report with

recomendations and conclusions from the Joint Experts’ Workshop. World Health Organization and European

Research Organization on Genital Infection and Neoplasia, 1996.

3. Monsonego J, Franco EL (eds.). Cervical cancer control: General statements and guidelines. EUROGIN-WHO

Monograph, UNESCO, Paris, 1997.


49

4. Lamothe F, Bruneau J, Franco E, Vincelette J, Lachance N. Prevalence, incidence, and risk factors for hepatitis

C infection among injection drug users participating in the Saint-Luc Cohort. A report prepared under contract

(5498) with the Laboratory Centre for Disease Control, Health Canada, 1997.

5. Franco EL. Epidemiology of HPV infection: Current concepts. In: Sauder D (ed.) Human Papillomavirus

Infection: Current perspectives in clinical management. Pharmacotherapeutic Strategies, 3M Pharmaceuticals

and Meducom International, Guelph, Canada, 1998.

6. Franco EL, Duarte-Franco E. Chapter on Cervical Cancer. Women's Cancer Information Monograph. Cancer

Bureau, Laboratory Centre for Disease Control, Health Canada, 1999.

7. Duarte-Franco E, Franco EL. Cancer of the Uterine Cervix. Chapter 4.1.G, Women’s Health Status Report,

Health Canada, 2004

8. Duarte-Franco E, Franco EL. Other Gynecological Cancers. Chapter 4.1.H, Women’s Health Status Report,

Health Canada, 2004

9. Franco EL (Contributing Author). Chapter on Genital Human Papillomavirus Infections. Canadian Guidelines

on Sexually Transmitted Infections, 2006. Public Health Agency of Canada, Ottawa, ISBN 0-662-42798-X.

10. Franco EL. Editorial: The research contributions of Canada to cervical cancer prevention. HPV Today, No. 15,

June 2008, pp.2.

11. Mayrand MH(§), Franco EL(*). The Canadian Cervical Cancer Screening Trial (CCCaST). HPV Today, No.

15, June 2008, pp.2.

12. Franco EL. Invited Expert review on: Comparison of linear array and line blot assay for detection of human

papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined

significance and low-grade squamous intraepithelial lesion triage study. Castle PE, Gravitt PE, Solomon D, et

al. J Clin Microbiol 2008;46:109-17. Sexually Transmitted Diseases Diagnostics Initiative, World Health

Organization, Issue no.24: Jan-Mar 2008.

13. Franco EL. Commentary: Screening HPV vaccinated generations. HPV Today, No. 23 (in press).

Book Reviews

1. Franco EL. Book review: "Emerging viruses: by S. Morse." Invited review in Epidemiology 6: 87-88, 1995.

2. Franco EL. Epidemiology in a rapidly changing world. Invited Book reviews: "Infectious diseases in an age of

change: by Roizman B." and “Climate change and human health: by McMichael AJ et al.” Epidemiology 8:

332-334, 1997.

3. Franco EL. Letter to Jan (a eulogy to Jan Walboomers). European Journal of Gynaecological Oncology 21:

540, 2001.

4. Franco EL. Book review: "Abramson JH, Gahlinger PM. Computer Programs for Epidemiologists" Invited

review in Epidemiology 14: 503-504, 2003.

5. Franco EL. Book review: "Vogelstein B, Kinzler KW. The genetic basis of human cancer” Invited review in

Geriatrics Today: Journal of the Canadian Geriatrics Society 6: 117, 2003.

Invited Foreword for a Book

Rosenblatt A, Guidi HGC. Human Papillomavirus: A Practical Guide for Urologists. Springer-Verlag, Berlin, 2009.

ISBN: 978-3-540-70973-2


50

APPENDIX 2

INVITED LECTURES AND SESSION

LEADERSHIP AT CONFERENCES AND

SCIENTIFIC MEETINGS

1995-2011


51

INVITED LECTURES AND SESSION LEADERSHIP AT CONFERENCES AND

SCIENTIFIC MEETINGS

Most with published abstracts, unrelated to the ones listed under offered abstracts in Appendix 4

1. “Recent advances in the molecular epidemiology of cervical cancer.” 1st International Symposium on Clinical

Epidemiology, Sao Paulo, Brazil (May 26, 1995).

2. Panel Discussant: Opportunities for cancer epidemiology research in Latin America. 1st International

Symposium on Clinical Epidemiology, Sao Paulo, Brazil (May 26, 1995).

3. Panel Discussant: Workshop on Attributable Risks of Diseases due to Smoking in Canada, Health Protection

Branch, Health Canada, Ottawa, Canada (March 30, 1995).

4. “The role of epidemiology in studying the natural history of HPV-induced cancers.” Opening Lecture, 14th

International Papillomavirus Conference, Quebec City, Canada (July 24, 1995).

5. Discussant: Symposium on HPV Vaccine Development Issues. Sponsored by Merck Research Laboratories,

Quebec City, Canada (July 24, 1995).

6. Panel Discussant and presenter: “HPV infection and the natural history of cervical cancer: Emerging

technologies for secondary prevention,” 3rd International Working Group on National Cancer Control

Programs, sponsored by the World Health Organization, Sydney, Australia (May 1, 1996).

7. Session vice-chair, Discussant and Presenter: “The epidemiology of human papillomavirus infection,”

International Joint Experts Meeting on Cervical cancer Screening and New Developments, sponsored by

EUROGIN and WHO, Geneva, Switzerland (June 17, 1996).

8. “Statistical issues in studies of HPV and cancer,” International Joint Experts Meeting on Cervical cancer

Screening and New Developments, sponsored by EUROGIN and WHO, Geneva, Switzerland (June 18,

1996).

9. “Molecular variant analysis as a tool in natural history studies of HPV and cervical cancer,” International

Joint Experts Meeting on Cervical cancer Screening and New Developments, sponsored by EUROGIN and

WHO, Geneva, Switzerland (June 19, 1996).

10. Session Chairman: “Importance of epidemiology in cancer information system.” 7th Annual Meeting of

Cancer Registries, Salvador, Brazil (August 8, 1996).

11. “Human papillomavirus and uterine cervical cancer.” 7th Annual Meeting of Cancer Registries, Salvador,

Brazil (August 8, 1996).

12. “Role of tumour registries in cancer research.” 7th Annual Meeting of Cancer Registries, Salvador, Brazil

(August 9, 1996).

13. "Study designs to assess the role of HPV testing in cervical cancer screening". Workshop on HPV testing in

cervical cancer screening, Brazilian Ministry of Science and Technology and Ludwig Institute for Cancer

Research, Sao Paulo, Brazil (November 6, 1996).

14. Cochair: Session “Cervical cancer control: Consensus and guidelines.” 3rd International Congress on Lower

Genital Tract Infections and Neoplasia, Paris, France (March 25, 1997).

15. Cochair: Session “Epidemiology and pathogenesis of cervical neoplasia and HPV infection.” 3rd International

Congress on Lower Genital Tract Infections and Neoplasia, Paris, France (March 27, 1997).

16. Cochair: Session “Latin-American round table.” 3rd International Congress on Lower Genital Tract Infections

and Neoplasia, Paris, France (March 25, 1997).

17. “Epidemiological issues in natural history and screening studies of HPV and cancer.” 3rd International

Congress on Lower Genital Tract Infections and Neoplasia, Paris, France (March 26, 1997).

18. “Epidemiology of HPV infection and cervical neoplasia: an update.” Pre-Congress Course, 16th International

Papillomavirus Workshop, Siena, Italy (September 5, 1997).

19. Rapporteur: Session “Adéquation des méthodes épidemiologiques.” Réunion Scientifique de l’Association des

Epidémiologistes de Langue Française; Epidémiologie et évaluation en toxicomanie. Lausanne, Switzerland

(September 26, 1997).

20. Keynote speaker: “Epidemiology in pediatric oncology.” 1st International Meeting of Pediatric Oncology and

Pediatric Oncology Nursing, S.A. Hospital de Niños “JM de los Rios” and International Association of

Parents of Children with Cancer, Caracas, Venezuela (November 19, 1997).

21. “Software for statistical analysis in pediatric oncology.” 1st International Meeting of Pediatric Oncology and

Pediatric Oncology Nursing, S.A. Hospital de Niños “JM de los Rios” and International Association of

Parents of Children with Cancer, Caracas, Venezuela (November 19, 1997).


52

22. “Pediatric tumour registries.” 1st International Meeting of Pediatric Oncology and Pediatric Oncology

Nursing, S.A. Hospital de Niños “JM de los Rios” and International Association of Parents of Children with

Cancer, Caracas, Venezuela (November 19, 1997).

23. “Role of HPV in the etiology and prevention of cervical cancer.” 1998 Preventive Oncology Seminar:

Challenges and Controversies in Cancer Screening, Cancer Care Ontario and Canadian Cancer Society,

Toronto, Canada (April 28, 1998).

24. Moderator, Session on HPV epidemiology. First International Conference on Human Papillomavirus Infection

and Cervical Cancer, Montreal, Canada (July 8, 1998).

25. “Epidemiologic principles in screening.” First International Conference on Human Papillomavirus Infection

and Cervical Cancer, Montreal, Canada (July 9, 1998).

26. “Natural history of HPV infections.” First International Conference on Human Papillomavirus Infection and

Cervical Cancer, Montreal, Canada (July 10, 1998).

27. "Looking beyond tobacco and alcohol: The challenge of identifying new risk factors for head and neck

cancer." Session: Head and neck cancer: etiology and prevention, 17th UICC International Cancer Congress,

Rio de Janeiro, Brazil (August 23, 1998).

28. "New approaches in the molecular epidemiology of HPV infection and cervical cancer." Session: Cervix:

epidemiology and etiology, 17th UICC International Cancer Congress, Rio de Janeiro, Brazil (August 26,

1998).

29. “Epidemiology and Natural History of HPV-Induced Disease.” Plenary lecture, 17th International

Papillomavirus Conference, Charleston, USA (January 12, 1999).

30. Co-chairperson: Session “Epidemiology II”, 17th International Papillomavirus Conference, Charleston, USA

(January 12, 1999).

31. Chairperson: Workshop VII “P53 polymorphism and HPV-mediated cancers”, 17th International

Papillomavirus Conference, Charleston, USA (January 14, 1999).

32. Chairperson: Scientific Session "Cancer epidemiology IV." Annual Meeting of the Canadian Society for

Epidemiology and Biostatistics, Vancouver, Canada (May 7, 1999).

33. "Risk factors for oral cancer in Brazil: Basis for primary prevention and screening", 4th

Brazilian Congress of

Oral Cancer, São Paulo, Brazil (May 28, 1999).

34. "Risk factors other than tobacco and alcohol", 4th

Brazilian Congress of Oral Cancer, São Paulo, Brazil (May

29, 1999).

35. Chairperson: Roundtable Session "Role of epidemiology in discovering necessary or sufficient causes." 32nd

Annual Meeting of the Society for Epidemiologic Research, Baltimore, USA (June 11, 1999).

36. Chairperson: Scientific Session "Statistical issues for childhood cancer researchers." Joint Meeting of

International Society for Pediatric Oncology and American Society of Pediatric Hematology, Montreal,

Canada (September 14, 1999).

37. Discussant: Roundtable Session "Study Design Issues." Meeting on Spiral CT screening for lung cancer,

Division of Cancer Prevention, National Cancer Institute, Gaithersburg, Maryland, USA (October 26, 1999).

38. Chairperson: Symposium on “Epidemiology of HPV infection”, 10th World Congress of Cervical Pathology

& Colposcopy, Buenos Aires, Argentina (November 8, 1999).

39. "Costs associated with cervical cancer screening in Canada", HPV Infections and Cervical Cancer 2000:

Conference on the Current & Emerging Issues in the Management of HPV Infections and Cervical Cancer;

Cervical Health Society and Women's Health Bureau and HIV/AIDS/STD Division, Health Canada, Toronto,

Canada (February 24, 2000).

40. Chairperson and presenter: Session ME4 “Meet the experts: How to design a clinical research project”,

EUROGIN 2000, 4th

International Congress on Lower Genital Tract Infections and Neoplasia, Paris, France

(April 6, 2000).

41. Chairperson: Plenary Session PS2 "Epidemiology and natural history", EUROGIN 2000, 4th

International

Congress on Lower Genital Tract Infections and Neoplasia, Paris, France (April 7, 2000).

42. "Determinants of persistent HPV infection" EUROGIN 2000, 4th

International Congress on Lower Genital

Tract Infections and Neoplasia, Paris, France (April 7, 2000).

43. Co-chairperson: Session FC3 “Award in memory of Prof. J. Walboomers,” EUROGIN 2000, 4th

International


44. Discussant: Scientific Session SS1 “Unresolved issues in cervical cancer causation” EUROGIN 2000, 4th

International Congress on Lower Genital Tract Infections and Neoplasia, Paris, France (April 8, 2000).

45. Chairperson: Scientific Session SS23 "Screening and epidemiology", EUROGIN 2000, 4th

International



53

46. “Epidemiologic evidence for screening efficacy” EUROGIN 2000, 4th

International Congress on Lower

Genital Tract Infections and Neoplasia, Paris, France (April 9, 2000).

47. “Epidemiology of HPV infection and cervical neoplasia”, Title X Region V Family Planning Workshop,

Chicago, USA (April 28, 2000).

48. “Epidemiology of HPV infection: implications for the prevention of cervical cancer” Opening lecture in main

plenary session, 5th

Workshop of Lower Genital Tract Pathology, Viareggio, Italy (June 15, 2000).

49. “Epidemiological principles of screening: worldwide results and the way forward”, 5th

Workshop of Lower

Genital Tract Pathology, Viareggio, Italy (June 15, 2000).

50. Co-chairperson: Session “Epidemiology I”, 18th International Papillomavirus Conference, Barcelona, Spain

(July 24, 2000).

51. “HPV versus Pap testing in the screening of cervical cancer precursors in Newfoundland, Canada.” 18th

International Papillomavirus Conference, Barcelona, Spain (July 24, 2000).

52. Discussant: Special Workshop “Screening in Developing Countries.” 18th International Papillomavirus

Conference, Barcelona, Spain (July 26, 2000).

53. “Epidemiologia e história natural das infecçôes por HPV” and “Associação de métodos” (2 lectures).

Seminário para elaboração de normas técnicas sobre infecção pelo HPV, Brazilian Ministry of Health,

Brasília, Brazil (October 9-10, 2000).

54. Chairperson: Session on “Preneoplastic Manifestations” 5th

International Symposium on Predictive Oncology,

International Society for Predictive Oncology, Geneva, Switzerland (October 28-31, 2000).

55. “Viruses in oncogenesis: the role of HPV” Plenary lecture, 5th

International Symposium on Predictive

Oncology, International Society for Predictive Oncology, Geneva, Switzerland (October 28-31, 2000).

56. “HPV testing as a screening approach for cervical cancer precursor lesions” Session on “Estrategias de

prevención de cáncer cervical para el siglo XXI”, Congreso Nacional de Salud Pública, Mexico City, Mexico

(March 5, 2001).

57. Session Leader and Speaker: "Methodological issues in the evaluation of HPV tests in screening programs"

and "HPV tests as secondary to cytology." Module 3, HPV testing as primary screening for cervical cancer.

World Health Organization's Consultation on Cervical Cancer Screening, Geneva, Switzerland (March 27-30,

2001).

58. Chairperson: Session 2 on “Etiopathogenesis and infection”, 2nd

International Symposium on HPV and

Cancer, Lisbon, Portugal (May 24, 2001).

59. “Molecular epidemiology of cervical cancer: recent advances” Special lecture, 2nd

International Symposium

on HPV and Cancer, Lisbon, Portugal (May 24, 2001).

60. “Epidemiologic evidence for screening efficacy in cervical cancer” Special lecture, 2nd

International

Symposium on HPV and Cancer, Lisbon, Portugal (May 24, 2001).

61. “HPV and upper aero-digestive tract cancer” Special lecture, 2nd

International Symposium on HPV and

Cancer, Lisbon, Portugal (May 25, 2001).

62. “HPV vaccine: Recent developments” Lecture, 5th

Scientific Meeting on Prevention and Early Diagnosis of

Gynecological Cancer, Thessaloniki, Greece (May 27, 2001).

63. “HPV versus Pap testing in cervical cancer screening: the worldwide perspective” Lecture, 5th

Scientific

Meeting on Prevention and Early Diagnosis of Gynecological Cancer, Thessaloniki, Greece (May 27, 2001).

64. "Evidence of benefit for cancer screening methods: cervix versus other sites." Lecture, 19th

International

Papillomavirus Conference, Florianopolis, Brazil (September 2, 2001).

65. "The role of evidence-based medicine in screening and prevention of cervical cancer" Opening lecture,

International Leaders' Meeting on Global Challenges and Opportunities in Cervical Cancer Prevention,

European Research Organization on Genital Infection and Neoplasia (EUROGIN), Nice, France (October 12,

2001).

66. Chairperson: Session "Prevention of HPV associated lesions: Perspectives for HPV vaccines", International

Leaders' Meeting on Global Challenges and Opportunities in Cervical Cancer Prevention, European Research

Organization on Genital Infection and Neoplasia (EUROGIN), Nice, France (October 13, 2001).

67. "Evidence-based policy recommendations in screening and prevention of cervical cancer" Grand-Rounds

Lecture at the 2nd

International Cervical Cancer Conference, The University of Texas MD Anderson Cancer

Center, Houston, USA (April 12, 2002).

68. "Epidemiology of HPV infections" Lecture at the 2nd

International Cervical Cancer Conference, The

University of Texas MD Anderson Cancer Center, Houston, USA (April 13, 2002).


54

69. Chairperson and speaker: Session on "The Contribution of Epidemiology to our Understanding of Cervical

Cancer Etiology and Prevention", 35th Annual Meeting, Society for Epidemiologic Research, Palm Desert,

California, USA (June 20, 2002).

70. "Cervical cancer." Lecture in Symposium "Application of Epidemiology to Cancer Prevention," 16th

World

Congress of Epidemiology, International Epidemiological Association, Montreal, Canada (August 21, 2002)

71. "Cancer epidemiology at a crossroads: Time for reappraisal" Conference, Cancer 2002, an International

Symposium, King Faisal Hospital and Research Centre, Riyadh, Saudi Arabia (October 15, 2002).

72. "HPV infection and cervical cancer." Lecture to the Forum on Emerging Infectious Diseases, Board on Global

Health, Institute of Medicine, National Academy of Sciences, Washington, USA (October 21, 2002).

73. "Infection-related cancer risk." Lecture to the 1st International Symposium on Cancer Prevention, Lucie and

Andre Chagnon Foundation, Montreal, Canada (November 4, 2002).

74. "Epidemiological evidence and rationale for HPV testing." Lecture in session "HPV in clinical practice",

EUROGIN 2003, 5th

International Congress on Lower Genital Tract Infections and Neoplasia, Paris, France

(April 13, 2003).

75. "Cervical cancer control: Priorities and new directions for epidemiology." Plenary lecture, EUROGIN 2003,

5th


76. Chairperson: Symposium "HPV vaccines: Future trends in HPV disease prevention." EUROGIN 2003, 5th


77. Chairperson and speaker: Session on "Redefining the focus on HPV Epidemiology." EUROGIN 2003, 5th


78. Speaker and discussant: “Persistent HPV infection.” Technical consultation on HPV vaccine efficacy

outcomes. Meeting convened by the World Health Organization, Geneva, Switzerland (May 1, 2003).

79. Keynote speaker: "Epidemiology of cervical cancer." 25th

Annual Meeting of the International Association of

Cancer Registries, Honolulu, Hawaii, USA (June 17, 2003).

80. "Molecular epidemiology of human papillomavirus infection and cancer." Lecture in Symposium "Infectious

Agent-Cancer Relationships: Molecular Epidemiology and Prospects for Prevention." 94th Annual Meeting of

the American Association for Cancer Research, Washington, USA (July 13, 2003).

81. Chairperson, Plenary sessions 1 and 2: "HPV Vaccines: Potential Impact on STD Control Programs" and "

Herpes Virus Vaccines – When and How?" 15th Biennial Congress of the International Society for Sexually

Transmitted Diseases Research (ISSTDR), Ottawa, Canada (July 28, 2003).

82. Chairperson and speaker: Symposium on "Human Papillomaviruses and cancer: Perspectives for prevention."

15th Biennial Congress of the International Society for Sexually Transmitted Diseases Research (ISSTDR),

Ottawa, Canada (July 28, 2003).

83. Keynote speaker: "The role of HPV testing and implications for cervical cancer prevention and screening."

Workshop on Cervical Cancer Screening, Ontario Cervical Screening Program, Cancer Care Ontario, Toronto,

Canada (October 8, 2003).

84. "Epidemiologic Criteria in Establishing Causal Associations between Infectious Agents and Cancer." Lecture

in Workshop on Validation of a Causal Relationship: Criteria to Establish Etiology. National Institutes of

Health, National Cancer Institute, Washington, USA (December 11, 2003).

85. "Infecção pelo HPV: Bases Epidemiológicas e Perspectivas de Prevenção." Opening lecture, Simpósio sobre

Doenças Sexualmente Transmissíveis, Secretaria da Saúde do Estado de São Paulo, São Paulo, Brazil

(January 29, 2004).

86. Chairperson, Session on Viral Infections, 7th International Symposium on Predictive Oncology, International

Society for Predictive Oncology, Nice, France (February 7, 2004).

87. "HPV and other cofactors in cervical cancer." Plenary lecture, 7th International Symposium on Predictive

Oncology, International Society for Predictive Oncology, Nice, France (February 8, 2004).

88. Chairperson and Speaker, Session on Screening and Detection II, 7th International Symposium on Predictive


89. "Cancer epidemiology at a crossroads." Closing address, 7th International Symposium on Predictive


90. "Issues in the design and interpretation of studies of HPV testing in cervical cancer screening." Plenary

lecture, 21st International Papillomavirus Conference, Mexico City, Mexico (February 20, 2004).

91. "Outlook for the role of epidemiology in the era of primary prevention of HPV infection." Plenary lecture,

21st International Papillomavirus Conference, Mexico City, Mexico (February 20, 2004).

92. "Cervical cancer and HPV infection in Latin America." Plenary lecture, 21st International Papillomavirus

Conference, Mexico City, Mexico (February 23, 2004).


55

93. Chairperson, Session 8 on Screening, 21st International Papillomavirus Conference, Mexico City, Mexico

(February 24, 2004).

94. Chairperson, GSK-sponsored Special Symposium on HPV Vaccines, 21st International Papillomavirus

Conference, Mexico City, Mexico (February 25, 2004).

95. "HPV testing in cervical cancer screening: Toward evidence-based prevention." Conference, XV International

Congress of Cytology, Santiago, Chile (April 12, 2004).

96. Discussant and author, Expert Group for the drafting of the IARC Handbook of Cancer Prevention, Vol. 10.

Cervix Cancer Screening, International Agency for Research on Cancer, Lyon, France (April 20-27, 2004).

97. "Epidemiologia Molecular." Plenary lecture in session "Epidemiologia e seus adjetivos: clássica, social,

clínica e molecular", Brazilian Congress of Epidemiology, Recife, Brazil (June 21, 2004).

98. Chairperson, Session on Clinical and Public Health Research, Centennial Symposium on New Oral Health

Knowledge for the 21st Century, a joint conference by McGill University and Université de Montréal,

Montreal, Canada (September 18, 2004).

99. “Vaccinating against human papillomavirus infection: A new paradigm in cervical cancer control.” Plenary

lecture, 4th World Congress on Vaccines and Immunization, Tokyo, Japan (October 3, 2004).

100. “Overview of HPV Biology, Epidemiology, and Public Health” Lecture, III Simpósio Internacional HPV e

Cancro, Lisbon, Portugal (October 13, 2004).

101. "Epidemiologia do HPV: Actualização." Lecture, III Simpósio Internacional HPV e Cancro, Lisbon, Portugal

(October 14, 2004).

102. "A Persistência da Infecção por HPV é um Factor de Risco para a Neoplasia?" Lecture, III Simpósio

Internacional HPV e Cancro, Lisbon, Portugal (October 14, 2004).

103. “HPV testing in screening of cervical cancer precursors” Lecture, III Simpósio Internacional HPV e Cancro,

Lisbon, Portugal (October 14, 2004).

104. “A Paradigm Shift in Cervical Cancer Prevention: From an Oncological to an STD Perspective” Symposium

lecture, Frontiers in Cancer Prevention Research Conference, American Association for Cancer Research,

Seattle, USA (October 18, 2004).

105. Discussant, Plenary session "Putting Science into Practice", International Leaders' Meeting on HPV Infection

and Cervical Cancer Prevention, European Research Organization on Genital Infection and Neoplasia

(EUROGIN), Nice, France (October 21, 2004).

106. "Interpreting efficacy in HPV screening studies." Plenary lecture, International Leaders' Meeting on HPV

Infection and Cervical Cancer Prevention, European Research Organization on Genital Infection and

Neoplasia (EUROGIN), Nice, France (October 21, 2004).

107. "Positions of Health Technology Assessment Agencies concerning Cervical Cancer Screening." Plenary

lecture, International Leaders' Meeting on HPV Infection and Cervical Cancer Prevention, European Research

Organization on Genital Infection and Neoplasia (EUROGIN), Nice, France (October 22, 2004).

108. “What are the current barriers to reducing cervical cancer incidence in developed countries?” Lecture in

Symposium: The potential of HPV Vaccines in the Global Control of Cervical Cancer. International Leaders'

Meeting on HPV Infection and Cervical Cancer Prevention, European Research Organization on Genital

Infection and Neoplasia (EUROGIN), Nice, France (October 22, 2004).

109. Discussant and Speaker, Session “Prevenção do cancro ginecológico e mamário no século XXI: Objectivos a

atingir e desafios”, Simpósio sobre Controvérsias em Ginecologia Oncológica, Porto, Portugal (December 2,

2004).

110. “New perspectives in cervical cancer epidemiology” Plenary lecture, Simpósio sobre Controvérsias em

Ginecologia Oncológica, Porto, Portugal (December 2, 2004).

111. “Epidemiologic Research Opportunities in Childhood Cancer: Exploring the International Variation in

Environmental Exposures and in Health Care Settings” Lecture in the Symposium Epidemiology of

Childhood Cancer: A Global Perspective, Childhood Oncology Group, Los Angeles, USA (March 31, 2005).

112. “Epidemiology of HPV and CIN” Plenary lecture, 22nd International Papillomavirus Conference and Clinical

Workshop, Vancouver, Canada (April 30, 2005).

113. “The global impact of human papillomavirus infection: epidemiology and economic burden of HPV and

HPV-associated diseases” Plenary lecture, Symposium: Is Prevention of Cervical Cancer and Other HPV-

Related Diseases Possible with a Vaccine? 22nd International Papillomavirus Conference and Clinical

Workshop, Vancouver, Canada (April 30, 2005).

114. Co-Chair, Session “Clinical Science Abstracts” 22nd International Papillomavirus Conference and Clinical

Workshop, Vancouver, Canada (May 3, 2005).


56

115. "Assessing the efficacy of HPV-based technologies: The tyranny of evidence-based public health" Plenary

lecture to the HPV 2005 Conference, Hannover, Germany (June 4, 2005).

116. “Epidemiologia do cancro ginecológico e da mama: Desafios e previsões” Lecture to the Congresso Nacional

de Ginecologia, Lisbon, Portugal (June 8, 2005).

117. “Medicina baseada em evidência e a prática clínica” Lecture to the Congresso Nacional de Ginecologia,

Lisbon, Portugal (June 12, 2005).

118. Chairperson and Speaker, Symposium “When epidemiology delays progress in public health policy: The case

of cervical cancer prevention” Joint Meeting of the Society for Epidemiologic Research and the Canadian

Society for Epidemiology & Biostatistics, Toronto, Canada (June 29, 2005).

119. Chairperson, Roundtable “Should Epidemiologists be assuming a Larger Political Role in Developing

Countries? Joint Meeting of the Society for Epidemiologic Research and the Canadian Society for

Epidemiology & Biostatistics, Toronto, Canada (June 29, 2005).

120. Chairperson, Session I, XVI Reunion Internacional de Cancer Cervicouterino y las Lesiones Precursoras,

Oaxaca, Mexico (August 4, 2005).

121. “Cervical Cancer Prevention: Current World Status” Plenary lecture, XVI Reunion Internacional de Cancer

Cervicouterino y las Lesiones Precursoras, Oaxaca, Mexico (August 4, 2005).

122. “Epidemiology of Cervical Cancer” Plenary lecture, XVI Reunion Internacional de Cancer Cervicouterino y

las Lesiones Precursoras, Oaxaca, Mexico (August 4, 2005).

123. “HPV Testing: Current Trends” Plenary lecture, XVI Reunion Internacional de Cancer Cervicouterino y las

Lesiones Precursoras, Oaxaca, Mexico (August 4, 2005).

124. “HPV Primary Screening: Canadian, USA and European Experience” Plenary lecture, XVI Reunion

Internacional de Cancer Cervicouterino y las Lesiones Precursoras, Oaxaca, Mexico (August 4, 2005).

125. “Evidence-Based Cervical Cancer Prevention” Plenary lecture, XVI Reunion Internacional de Cancer

Cervicouterino y las Lesiones Precursoras, Oaxaca, Mexico (August 6, 2005).

126. “Cancer Epidemiology: Triumphs, Pitfalls, and Growing Pains” Plenary lecture, IV Sao Paulo Cancer

Congress, Sao Paulo, Brazil (November 10, 2005).

127. “Prevenção do Câncer de Colo Uterino: Epidemiologia e Controle da Doença” Symposium Lecture for the

51st Congresso Brasileiro de Ginecologia e Obstetrícia, Rio de Janeiro, Brazil (November 23, 2005).

128. "HPV vaccination: A new promising strategy for cervical cancer prevention" Plenary lecture, 30th Annual

Meeting of the American Society of Preventive Oncology, Bethesda, USA (February 28, 2006).

129. “Epidemiology and natural history of high-risk and low-risk HPV infections”, Plenary lecture, 6th

International Multidisciplinary Congress, EUROGIN 2006, Paris, France (April 23, 2006).

130. Chairperson and Speaker, Symposium “HPV testing in cervical cancer screening”, 6th International

Multidisciplinary Congress, EUROGIN 2006, Paris, France (April 23, 2006).

131. Chairperson, Symposium “Public Health Issues”, 6th International Multidisciplinary Congress, EUROGIN

2006, Paris, France (April 23, 2006).

132. Chairperson, Symposium “The essential library on HPV and cervical cancer” 6th International

Multidisciplinary Congress, EUROGIN 2006, Paris, France (April 23, 2006).

133. Chairperson, Oral Communications session SS-13, 6th International Multidisciplinary Congress, EUROGIN

2006, Paris, France (April 23, 2006).

134. “Assessing the Efficacy of Prophylactic HPV Vaccines”, Plenary lecture, 6th Annual Continuing Professional

Development Meeting, Society of Gynecologic Oncologists of Canada, Montreal, Canada (April 28, 2006).

135. Chairperson and Speaker, “Molecular epidemiology of HPV infection and cervical cancer”, Plenary session,

XVIII Reunion Internacional de Cancer Cervicouterino y Lesiones Precursoras, Veracruz, Mexico (May 25,

2006).

136. “Is HPV infection a sexually-transmitted disease?”, Plenary lecture, XVIII Reunion Internacional de Cancer

Cervicouterino y Lesiones Precursoras, Veracruz, Mexico (May 25, 2006).

137. “HPV testing in cervical cancer screening: North american and European experience”, Plenary lecture, XVIII

Reunion Internacional de Cancer Cervicouterino y Lesiones Precursoras, Veracruz, Mexico (May 25, 2006).

138. “Preventing cervical cancer by HPV vaccination: the new frontier in cancer prevention”, Plenary lecture,

XVIII Reunion Internacional de Cancer Cervicouterino y Lesiones Precursoras, Veracruz, Mexico (May 26,

2006).

139. “Should cervical cancer screening change in the era of HPV vaccination?”, Plenary lecture, XVIII Reunion

Internacional de Cancer Cervicouterino y Lesiones Precursoras, Veracruz, Mexico (May 26, 2006).

140. “Concluding remarks”, Plenary lecture, XVIII Reunion Internacional de Cancer Cervicouterino y Lesiones

Precursoras, Veracruz, Mexico (May 27, 2006).


57

141. “Inovação na Prevenção do Câncer Cervical” Plenary lecture and panel discussion, 6th Congresso Brasileiro

de Citologia Clinica, Curitiba, Brazil (June 5, 2006).

142. “O uso do teste HPV no rastreamento do câncer de colo uterino: Promessas e obstáculos”, Plenary lecture, 6th

Congresso Brasileiro de Citologia Clinica, Curitiba, Brazil (June 6, 2006).

143. “História Natural do HPV e do Câncer do Colo Uterino: O que resta a descobrir?” Plenary lecture, 6th

Congresso Brasileiro de Citologia Clinica, Curitiba, Brazil (June 7, 2006).

144. Chair, Plenary session “Recognizing and Solving Public Health Problems with Epidemiology: The Example

of Cervical Cancer Control”, lecture: “A timeline for public health research in cervical cancer etiology and

prevention” Congress of Epidemiology 2006 (sponsored by 18 societies), Seattle, USA (June 22, 2006).

145. Chair, Contributed paper session “Innovation in Cancer Screening and Prevention” Congress of Epidemiology

2006 (sponsored by 18 societies), Seattle, USA (June 22, 2006).

146. Nominator’s Introduction during Awards Ceremony to introduce Dr. Nubia Muñoz as Outstanding

Epidemiologist of 2006. Congress of Epidemiology 2006 (sponsored by 18 societies), Seattle, USA (June 23,

2006).

147. “Impacto das vacinas contra o HPV no rastreio do cancro cervico-uterino” Plenary lecture, Symposium “O

Vírus HPV, as Vacinas e o Cancro”, Instituto Português de Oncologia do Porto, Porto, Portugal (June 27,

2006).

148. “Infeccões como agentes etiologicos no cancro: o papel das vacinas” Plenary lecture, Symposium “O Vírus

HPV, as Vacinas e o Cancro”, Instituto Português de Oncologia do Porto, Porto, Portugal (June 27, 2006).

149. “Vacinação Contra a Infecção pelo HPV: O novo Paradigma da Prevenção do Cancro do Colo do Útero”

Plenary lecture, Symposium “O Vírus HPV, as Vacinas e o Cancro”, Instituto Nacional de Saúde, Lisbon,

Portugal (June 29, 2006).

150. “O Impacto da Vacinação Contra o HPV no Rastreio do Cancro de Colo do Útero” Plenary lecture,

Symposium “O Vírus HPV, as Vacinas e o Cancro”, Instituto Nacional de Saúde, Lisbon, Portugal (June 29,

2006).

151. Chair and Speaker, “Human Papillomavirus Infection and Cervical Cancer: Promises and Perils in Prevention

Research” Symposium: “Infection and Cancer: Prospects for Prevention”, UICC World Cancer Congress,

Washington, USA (July 9, 2006).

152. Chair and Speaker, “Global burden of cervical cancer and HPV-associated diseases”, Symposium “Advances

with Vaccines for the Prevention of Cervical Cancer and Other HPV-Related Diseases", UICC World Cancer

Congress, Washington, USA (July 10, 2006).

153. “New approaches in cervical cancer screening” Lecture in Session: “Cervical Cancer Screening: Strategies for

Developing Countries”, UICC World Cancer Congress, Washington, USA (July 10, 2006).

154. “HPV vaccination as a promising new strategy for cervical cancer prevention”, 37th Annual Conference, New

Zealand Society of Cytology, Napier, New Zealand (August 24, 2006).

155. “Efficacy of HPV testing in cervical cancer screening”, 37th Annual Conference, New Zealand Society of

Cytology, Napier, New Zealand (August 24, 2006).

156. “The impact of HPV vaccination on cervical cancer screening”, 37th Annual Conference, New Zealand

Society of Cytology, Napier, New Zealand (August 24, 2006).

157. “Assessing new cancer screening technologies: The tyranny of evidence-based medicine”, 37th Annual

Conference, New Zealand Society of Cytology, Napier, New Zealand (August 25, 2006).

158. “Epidemiology of HPV and CIN” Plenary lecture, 23rd International Papillomavirus Conference and Clinical

Workshop, Prague, Czech Republic (September 1, 2006).

159. Chairperson, Clinical Workshop Session 1, 23rd International Papillomavirus Conference and Clinical

Workshop, Prague, Czech Republic (September 1, 2006).

160. Speaker, Session “Handling HPV vaccines and screening”, 23rd International Papillomavirus Conference and

Clinical Workshop, Prague, Czech Republic (September 3, 2006).

161. Co-Chair, Session PS10 “Preventive vaccines: models”, 23rd International Papillomavirus Conference and

Clinical Workshop, Prague, Czech Republic (September 4, 2006).

162. Speaker, Meet the Experts Session: Putting Science into Practice, 23rd International Papillomavirus

Conference and Clinical Workshop, Prague, Czech Republic (September 5, 2006).

163. “O Valor da Vacinação contra o HPV na Prevenção do Câncer de Colo do Útero” Opening keynote lecture,

Congresso Internacional de Experts: Patologia do Trato Genital Inferior e Colposcopia, Porto Alegre, Brazil

(October 4, 2006).


58

164. “Controle do Câncer de Colo do Útero na Prática Diária: O impacto da Vacinação contra o HPV” Plenary

lecture, Congresso Internacional de Experts: Patologia do Trato Genital Inferior e Colposcopia, Porto Alegre,

Brazil (October 5, 2006).

165. “Grau de Evidência no Diagnóstico de Lesões Cervicais” Roundtable presentation, Congresso Internacional

de Experts: Patologia do Trato Genital Inferior e Colposcopia, Porto Alegre, Brazil (October 6, 2006).

166. Chair and Speaker “L’impact attendu de la vaccination contre le virus du papillome humain sur les pratiques

de dépistage du cancer du col utérin” in the Symposium “Dépistage du cancer du col utérin: une approche en

pleine mutation”, 10es Journées annuelles de santé publique, Montréal, Canada (October 27, 2006).

167. “Historia natural de las infecciones por virus del papiloma humano”, Plenary lecture, 1st Congress of the

Sociedad Mexicana del Virus del Papiloma, Mexico City, Mexico (November 3, 2006).

168. “Tendencias actuales para detección de VPH”, Plenary lecture, 1st Congress of the Sociedad Mexicana del

Virus del Papiloma, Mexico City, Mexico (November 3, 2006).

169. Chair and Speaker, Session on Vaccines, “La eficacia de vacunas bivalentes”, 1st Congress of the Sociedad

Mexicana del Virus del Papiloma, Mexico City, Mexico (November 4, 2006).

170. “Concluding Remarks: The Road Ahead”, Closing Plenary Lecture, 1st Congress of the Sociedad Mexicana

del Virus del Papiloma, Mexico City, Mexico (November 4, 2006).

171. Chair and Speaker, “Prevention of cervical cancer: New paradigms”, Lecture in Workshop “Human Papilloma

Virus Vaccination - A New Cervical Cancer Control Strategy”, 6th World Congress on Vaccines and

Immunization, Montreal, Canada (November 8, 2006).

172. “Planning Cervical Cancer Screening in the Era of HPV Vaccines”, Symposium lecture, Frontiers in Cancer

Prevention Research Conference, American Association for Cancer Research, Boston, USA (November 15,

2006).

173. “Human Papillomavirus: Truth or Fiction”, Plenary lecture, Continuing Medical Education Conference

“Eradicating Cervical Cancer”, Cancer Care Manitoba, Winnipeg, Canada (November 17, 2006).

174. “Marrying HPV vaccines to screening”, Plenary lecture, Continuing Medical Education Conference

“Eradicating Cervical Cancer”, Cancer Care Manitoba, Winnipeg, Canada (November 17, 2006).

175. “Epidemiologia da Infecção por HPV”, Plenary lecture, Conferencia sobre Patologia Cervical 2006,

Sociedade Portuguesa de Ginecologia, Aveiro, Portugal (November, 24, 2006).

176. “Rastreio do Cancro do Colo do Útero na Era Pós-Vacina”, Plenary lecture, Conferencia sobre Patologia

Cervical 2006, Sociedade Portuguesa de Ginecologia, Aveiro, Portugal (November, 24, 2006).

177. “Questões relacionadas com a implementação da vacina: O que sabemos?”, Plenary lecture, Conferencia

sobre Patologia Cervical 2006, Sociedade Portuguesa de Ginecologia, Aveiro, Portugal (November, 24, 2006).

178. “Impact of HPV vaccination on screening practices” Lecture, HPV and Cervical Cancer Prevention Summit:

New Opportunities for Partnerships and Prevention, Montreal, Canada (November 28, 2006).

179. “Molecular epidemiology of HPV infection: new approaches” Roundtable presentation, 1st International

Symposium on Cancer Research: Integrating Basic Science, Clinical Practice, and Epidemiology. São Paulo,

Brazil (November 30, 2006).

180. Co-Chair and Discussant, Session “Childhood cancer – HPV and retinoblastoma: is there a relationship?”, 1st

International Symposium on Cancer Research: Integrating Basic Science, Clinical Practice, and

Epidemiology. São Paulo, Brazil (December 1, 2006).

181. “Distal and proximal causal agents in cancer: Reconciling social and molecular epidemiology” Lecture, 1st

International Symposium on Cancer Research: Integrating Basic Science, Clinical Practice, and

Epidemiology. São Paulo, Brazil (December 1, 2006).

182. “Vacuna VPH 16 & 18: una estrategia viable para la prevención del Ca. Cu.” Plenary lecture, Congreso

Internacional de Colposcopia en la Practica Medica, Mexico City, Mexico (March 30, 2007).

183. “Impacto esperado de la vacunacion sobre los programas de deteccion” Plenary lecture, Congreso


184. “La vacuna candidata de GSK VPH 16 & 18 contra Ca. Cu. Preguntas y respuestas” Plenary lecture, Congreso


185. Co-Chair and Speaker, “Impact of Vaccination on Screening Programs: An Opportunity” Lecture in Session

“Implementation of the HPV Vaccine: Gaps in Knowledge and Opportunities”, 7th Annual Continuing

Professional Development Meeting, Society of Gynecologic Oncologists of Canada, Toronto, Canada (April

27, 2007).

186. “New directions in epidemiologic research on HPV and cancer” Symposium lecture, 3rd

Puerto Rican

Conference of Public Health, San Juan, Puerto Rico, USA (May 9, 2007).


59

187. “Epidemiology of Genital HPV Infection and Cancer of the Cervix”, Lecture, 2nd

Annual Gynaecologic

Cancer Update Day: “Emerging Trends in Cervical Cancer”, Stratford, Canada (May 11, 2007).

188. “Issues in planning screening in the era of HPV vaccination” Lecture, 2nd

Annual Gynaecologic Cancer

Update Day: “Emerging Trends in Cervical Cancer”, Stratford, Canada (May 11, 2007).

189. “The implications of a new paradigm in cervical cancer prevention” Plenary lecture, XXXII Réunion des

Registres des pays de Langue Latine, Montreal, Canada (May 17, 2007).

190. “Bivalent HPV prophylactic vaccine: Efficacy for the prevention of cervical cancer” Plenary Lecture,

International HPV Clinical Training and Scientific Workshop, Medellin, Colombia (May 24, 2007).

191. “Gaps in knowledge and research priorities for the prevention of cervical cancer in Latin American countries”

Plenary Lecture, International HPV Clinical Training and Scientific Workshop, Medellin, Colombia (May 25,

2007).

192. “Impact of HPV vaccination in cervical cancer screening programs” Plenary Lecture, International HPV

Clinical Training and Scientific Workshop, Medellin, Colombia (May 26, 2007).

193. “HPV vaccination and screening: The need for synergy in cervical cancer prevention strategies” Plenary

lecture, Congress “Prevenzione HPV: dalla ricerca traslazionale al vaccini: Nuove strategie e nuovi paradigmi

di prevenzione sul territorio regionale”, Rome, Italy (May 31, 2007).

194. “New paradigms in primary and secondary cervical cancer prevention” Keynote plenary lecture, 63rd

Annual

Clinical Meeting, Society of Obstetricians and Gynaecologists of Canada, Ottawa, Canada (June 22, 2007).

195. “Cervical cancer screening in the era of HPV vaccination” Keynote plenary lecture, 63rd

Annual Clinical

Meeting, Society of Obstetricians and Gynaecologists of Canada, Ottawa, Canada (June 22, 2007).

196. “Presente, futuro y recomendaciones de la aplicación de la vacuna 16-18 para VPH” Plenary Lecture, VI

International and XI National Conference of the Mexican Association of Colposcopy and Pathology,

Acapulco, Mexico (July 20, 2007).

197. “Las vacunas y los cambios en las politicas de salud: Sinergismo en las estrategias preventivas” Plenary

Lecture, VI International and XI National Conference of the Mexican Association of Colposcopy and

Pathology, Acapulco, Mexico (July 20, 2007).

198. “La vacuna VPH 16/18: de la investigación a la realidad” Keynote plenary lecture, 3rd

Regional Congress of

the Pediatric College of Puebla, Puebla, Mexico (July 20, 2007).

199. “Avances en vacunas en la prevención del HPV” Symposium lecture, Congreso Internacional, Hospital

Aleman, Buenos Aires, Argentina (August 9, 2007).

200. “Rastreamento. Uma nova geracao livre do cancer? Symposium lecture, XII Congresso Paulista de Obstetrícia

e Ginecologia, São Paulo, Brazil (August 17, 2007).

201. “Diagnóstico: Citologia e métodos moleculares” Symposium lecture, XII Congresso Paulista de Obstetrícia e

Ginecologia, São Paulo, Brazil (August 18, 2007).

202. Co-Moderator and Speaker “Impact of Mandatory and/or Universal Immunization for HPV on the

Epidemiology of Cervical Cancer” Policy Workshop, Annual Meeting of the American College of

Epidemiology, Fort Lauderdale, USA (September 17, 2007).

203. “The burden of HPV-related diseases” Plenary lecture, EUROGIN 2007 Conference on New Strategies of

Cervical Cancer Prevention: The Reality of HPV Vaccines, Monte-Carlo, Monaco (October 4, 2007).

204. “What new proofs are needed to foster universal implementation of HPV vaccines?” Plenary lecture,

EUROGIN 2007 Conference on New Strategies of Cervical Cancer Prevention: The Reality of HPV

Vaccines, Monte-Carlo, Monaco (October 5, 2007).

205. “HPV testing as a more logical screening approach following vaccination” Plenary lecture, EUROGIN 2007

Conference on New Strategies of Cervical Cancer Prevention: The Reality of HPV Vaccines, Monte-Carlo,

Monaco (October 6, 2007).

206. Rapporteur “Screening approach for vaccinated population” Plenary session, EUROGIN 2007 Conference on

New Strategies of Cervical Cancer Prevention: The Reality of HPV Vaccines, Monte-Carlo, Monaco (October

6, 2007).

207. Chair, Scientific Session 12: Epidemiology. EUROGIN 2007 Conference on New Strategies of Cervical

Cancer Prevention: The Reality of HPV Vaccines, Monte-Carlo, Monaco (October 6, 2007).

208. “The value of HPV testing in cervical cancer screening” Plenary session, Symposium on HPV and Cervical

Cancer, Hong Kong, China (November 1, 2007).

209. “Epidemiology of HPV infection” Lecture, Fogarty Symposium, 24th

International Papillomavirus Conference

and Clinical Workshop, Beijing, China (November 5, 2007).

210. Co-Chair, Scientific Session: Epidemiology I, 24th

International Papillomavirus Conference and Clinical

Workshop, Beijing, China (November 6, 2007).


60

211. “Impacto de la vacuna VPH en el cribado del cancer de cervix” Keynote lecture, XIX Congreso Annual,

Asociación Española de Patología Cervical y Colposcopia, Oviedo, Spain (November 17, 2007).

212. “Cancer Epidemiology at a Crossroads: Time for Reappraisal” Keynote lecture, 7th

Scientific Meeting of the

International Epidemiological Association, Eastern Mediterranean Region, Riyadh, Saudi Arabia (November

28, 2007).

213. “Perspectivas en tamización de cáncer de cuello uterino” Keynote lecture, Programa Evento Socialización y

Recomendaciones Tamización de Cancer de Cuello Uterino, Ministerio de la Protección Social, Instituto

Nacional de Cancerología, Bogota, Colombia (December 17, 2007: via teleconference; travel cancelled due to

snow storm).

214. “HPV DNA testing: a more logical cervical cancer screening strategy for the era of HPV vaccination?”

Plenary lecture, 1st Scientific Meeting of the Hellenic HPV Society, Thessaloniki, Greece (January 26, 2008).

215. “Confidence in implementing universal HPV vaccination: What additional proofs are needed?” Plenary

lecture, 1st Scientific Meeting of the Hellenic HPV Society, Thessaloniki, Greece (January 26, 2008).

216. “Cervical Cancer Prevention in Latin America: Gaps in Knowledge and Research Priorities” Plenary lecture,

Congreso Internacional de Colposcopia en la Practica Medica, Mexico City, Mexico (April 4, 2008).

217. “Scientific Merit of Arguments Against HPV Vaccination: An Epidemiologic Perspective” Plenary lecture,

Congreso Internacional de Colposcopia en la Practica Medica, Mexico City, Mexico (April 4, 2008).

218. “Human papillomaviruses and neoplasia: New prevention strategies” Session lecture, American Association

for Cancer Research Annual Meeting 2008, San Diego, USA (April 12, 2008).

219. “The scientific basis for the arguments for and against HPV vaccination” Plenary lecture, 64th

Annual Clinical

Meeting, Society of Obstetricians and Gynaecologists of Canada, Calgary, Canada (June 27, 2008).

220. “HPV Vaccine Introduction and Screening Tests: Determinants of Decision Making for National Cervical

Cancer Prevention Programmes” Lecture at Symposium “WHO Cervical Cancer prevention strategies:

challenges and opportunities in developing countries”, UICC 2008 World Cancer Congress, Geneva,

Switzerland (August 30, 2008).

221. “Projected impact of HPV vaccination on cervical cancer screening practices” Lecture, Society of

Gynecologic Oncologists Forum on Future Strategies of Cervical Cancer Prevention, Chicago, USA


222. Moderator, Session on “The role of journals”, North American Workshop, 18th

World Congress of

Epidemiology, International Epidemiological Association, Porto Alegre, Brazil (September 21, 2008).

223. Coordinator, Session on “Searching for causes of disease in an ageing world”, 18th

World Congress of

Epidemiology, International Epidemiological Association, Porto Alegre, Brazil (September 22, 2008).

224. Chair, Oral Communication Session on “HPV diseases”, 18th

World Congress of Epidemiology, International

Epidemiological Association, Porto Alegre, Brazil (September 23, 2008).

225. “Expected impact of HPV vaccination on cervical cancer screening practices: The need for synergy between

prevention strategies”, Lecture in Symposium on cancer screening, 18th

World Congress of Epidemiology,

International Epidemiological Association, Porto Alegre, Brazil (September 23, 2008).

226. “Vacíos en el conocimiento y prioridades en ivestigación para la prevención del cáncer de cuello uterino en

América Latina”, Plenary lecture, International Multidisciplinary HPV Symposium, Argentine Association of

Microbiology, Buenos Aires, Argentina (September 30, 2008).

227. “Impacto de la vacunacion en el tamizaje poblacional”, Plenary lecture, International Multidisciplinary HPV

Symposium, Argentine Association of Microbiology, Buenos Aires, Argentina (September 30, 2008).

228. “Presentación de la Monografía ‘HPV en Latinoamérica’”, Plenary lecture, International Multidisciplinary

HPV Symposium, Argentine Association of Microbiology, Buenos Aires, Argentina (October 1, 2008).

229. “Buenos y malos argumentos respecto de la vacunación contra HPV”, Plenary lecture, International

Multidisciplinary HPV Symposium, Argentine Association of Microbiology, Buenos Aires, Argentina

(October 1, 2008).

230. “Epidemiology of HPV infection and cervical cancer”, Keynote Address, Cervical Pathology and Colposcopy

Congress, Turkish Society of Cervical Pathology, Antalya, Turkey (October 8, 2008).

231. “Challenges in Research on the Epidemiology of HPV infection”, Lecture, Cervical Pathology and

Colposcopy Congress, Turkish Society of Cervical Pathology, Antalya, Turkey (October 9, 2008).

232. “Value of HPV testing in clinical practice”, Plenary Lecture, Cervical Pathology and Colposcopy Congress,

Turkish Society of Cervical Pathology, Antalya, Turkey (October 9, 2008).

233. “Scientific validity of the arguments for and against HPV vaccination”, Plenary Lecture, Cervical Pathology

and Colposcopy Congress, Turkish Society of Cervical Pathology, Antalya, Turkey (October 9, 2008).


61

234. “Expected impact of HPV vaccination on cervical cancer screening practices”, Plenary Lecture, Cervical

Pathology and Colposcopy Congress, Turkish Society of Cervical Pathology, Antalya, Turkey (October 9,

2008).

235. “New paradigms in cervical cancer screening”, Plenary Lecture, Updates in Gynecology & Women’s Health,

King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia (October 15, 2008).

236. “HPV associated disease and vaccination”, Plenary Lecture, Updates in Gynecology & Women’s Health,

King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia (October 15, 2008).

237. “Integrating HPV vaccination into cervical cancer control: Need for synergy between prevention strategies”,

Plenary Lecture, Gairdner Awards Symposium, Toronto, Canada (October 22, 2008).

238. “The burden of HPV associated diseases”, Plenary lecture, EUROGIN 2008 Congress ‘Joining Forces for

Cervical Cancer Prevention’, Nice, France (November 12, 2008).

239. Co-Chair, Scientific Session “Current and emergent technologies for secondary cervical cancer prevention -

towards knowledge-based practice”, EUROGIN 2008 Congress ‘Joining Forces for Cervical Cancer

Prevention’, Nice, France (November 14, 2008).

240. “Expected impact of vaccination on screening and diagnostic practices”, Plenary lecture, EUROGIN 2008

Congress ‘Joining Forces for Cervical Cancer Prevention’, Nice, France (November 14, 2008).

241. “Arguments for and against vaccination: separating sensible from silly”, Plenary lecture, EUROGIN 2008

Congress ‘Joining Forces for Cervical Cancer Prevention’, Nice, France (November 15, 2008).

242. Co-Chair, Scientific Session “Epidemiology”, EUROGIN 2008 Congress ‘Joining Forces for Cervical Cancer

Prevention’, Nice, France (November 15, 2008).

243. “Looking to the Future: How to Address HPV Vaccination and Testing”, Plenary Lecture, Fourth Annual

HPV and Cervical Cancer Summit: Across the Globe and the Lifespan, Women In Government, Washington,

USA (November 22, 2008).

244. Chair, Session 5 “Natural History”, XIX Reunion Internacional de Cancer Cervico-Uterino y Lesiones

Precursoras, Sociedad Mexicana del Virus del Papiloma; Federacion Mexicana de Sociedades de Colposcopia,

Mexico City, Mexico (December 5, 2008).

245. “Natural history of cervical neoplasia”, Plenary lecture, XIX Reunion Internacional de Cancer Cervico-

Uterino y Lesiones Precursoras, Sociedad Mexicana del Virus del Papiloma; Federacion Mexicana de

Sociedades de Colposcopia, Mexico City, Mexico (December 5, 2008).

246. “Future of HPV testing in cervical cancer screening”, Plenary lecture, XIX Reunion Internacional de Cancer

Cervico-Uterino y Lesiones Precursoras, Sociedad Mexicana del Virus del Papiloma; Federacion Mexicana de


247. Discussant, Session 6 “HPV in other sites”, XIX Reunion Internacional de Cancer Cervico-Uterino y Lesiones

Precursoras, Sociedad Mexicana del Virus del Papiloma; Federacion Mexicana de Sociedades de Colposcopia,

Mexico City, Mexico (December 5, 2008).

248. “Expected impact of HPV vaccination on the efficacy of cervical cancer screening”, Plenary lecture, XIX

Reunion Internacional de Cancer Cervico-Uterino y Lesiones Precursoras, Sociedad Mexicana del Virus del

Papiloma; Federacion Mexicana de Sociedades de Colposcopia, Mexico City, Mexico (December 6, 2008).

249. Discussant, Session 8 “HPV vaccination”, Plenary lecture, XIX Reunion Internacional de Cancer Cervico-



250. “The Tyranny of Evidence-Based Medicine in Cancer Prevention", Keynote Lecture, 2nd

Residents’ Research

Day, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia (January 21, 2009).

251. “Communicating Clinical and Epidemiological Research findings in a Scientific Article”, Lecture, 2nd

Residents’ Research Day, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia (January

21, 2009).

252. “Arguments for and against HPV vaccination: A plea for scientific cogency”, Lecture, Symposium on Future

prospects for vaccination and screening to prevent HPV-induced cancer, New York Academy of Sciences,

New York, USA (March 2, 2009).

253. “New cervical cancer screening models in the HPV vaccination era”, Plenary Lecture, PCC2009 Conference

on Preventing Cervical Cancer, Victorian Cytology Service and National Centre for Immunisation Research

and Surveillance, Melbourne, Australia (March 19, 2009).

254. Discussant, Session “Planning for the future”, PCC2009 Conference on Preventing Cervical Cancer, Victorian

Cytology Service and National Centre for Immunisation Research and Surveillance, Melbourne, Australia

(March 20, 2009).


62

255. “O vírus HPV, as Vacinas e Questões não resolvidas”, Lecture, Symposium SPPV 2009, Portuguese

Papillomavirus Society, Lisbon, Portugal (April 24, 2009).

256. “Professor Zur Hausen’s Nobel 2008: Recognition to a scientist’s brave pursuit of an etiological association”,

Lecture, Symposium SPPV 2009, Portuguese Papillomavirus Society, Lisbon, Portugal (April 24, 2009).

257. “Cervical cancer screening; the principles and evaluation parameters of the programme”, Lecture, Clinical

Workshop, 25th International Papillomavirus Conference, Malmo, Sweden (May 9, 2009).

258. “Knowledge Gaps and Research Priorities for Cervical Cancer in Latin America”, Lecture, BD Latin America

Symposium, 25th International Papillomavirus Conference, Malmo, Sweden (May 9, 2009).

259. Co-Chair, Plenary session “Epidemiology of HPV infection”, 25th International Papillomavirus Conference,

Malmo, Sweden (May 11, 2009).

260. “Whither epidemiologic research?”, Plenary lecture, session “The future of papillomavirus research”, 25th

International Papillomavirus Conference, Malmo, Sweden (May 11, 2009).

261. “Making ends meet: Integrating screening and post-vaccination monitoring”, Lecture, CDC Symposium

“HPV Vaccine Monitoring: Biologic Outcomes”, 25th International Papillomavirus Conference, Malmo,

Sweden (May 12, 2009).

262. Chair, Symposium “HPV vaccination for cervical cancer prevention: Facts for evidence-based policy”, Joint

Conference of the Canadian Society for Epidemiology & Biostatistics and Association of Public Health

Epidemiologists of Ontario, Ottawa, Canada (May 27, 2009).

263. “Biases and pitfalls in interpreting the efficacy of cancer screening technologies: The epidemiologists'

perspective”, Lecture, Symposium “Evaluation of Medical Screening and Diagnostic Tests”, 2009 Annual

Meeting of the Statistical Society of Canada, Vancouver, Canada (June 1, 2009).

264. Chair, Plenary Session “How to screen for cervical cancer in the 21st Century”, 35

th European Congress of

Cytology, Lisbon, Portugal (September 28, 2009).

265. “The scientific validity of the arguments against HPV vaccination: Myths and misconceptions”, Plenary

lecture, HPV Vaccination Forum, Norwegian Gynecology Society and Institute Sanofi-Pasteur, Oslo, Norway

(October 23, 2009).

266. “Tirania da Medicina Baseada em Evidências no Controle do Câncer”, Magna lecture, XVIII Congresso

Brasileiro de Cancerologia, Curitiba, Brazil (October 29, 2009).

267. “Desafios, mitos, controvérsias e realidade do rastreamento do câncer do colo do útero”, Symposium lecture,

XVIII Congresso Brasileiro de Cancerologia, Curitiba, Brazil (October 29, 2009).

268. “Epidemiologia da infecção pelo HPV e seu papel na gênese do câncer de colo uterino”, Symposium lecture,

XVIII Congresso Brasileiro de Cancerologia, Curitiba, Brazil (October 29, 2009).

269. “Prevenção do câncer do colo uterino com vacina”, Symposium lecture, XVIII Congresso Brasileiro de

Cancerologia, Curitiba, Brazil (October 30, 2009).

270. “HPV testing in primary screening for cervical cancer: Evidence from controlled clinical trials and

epidemiologic studies”, Lecture, Qiagen HPV Forum, Beijing, China (November 5, 2009).

271. “Does screening have any impact on cancer outcomes?”, Plenary Lecture, 3rd

International Cancer Control

Congress, Como, Italy (November 10, 2009).

272. “HPV vaccines and integration into cervical cancer prevention programs”, Workshop lecture, 3rd

International

Cancer Control Congress, Como, Italy (November 10, 2009).

273. “Tamizaje de Cáncer de Cuello Uterino: últimos avances”, Lecture, Symposium “Nuevas perspectivas en

Prevención de Cáncer de Cuello Uterino”, Universidad del Rosario, Canadian Embassy, and Gairdner

Foundation, Bogota, Colombia (November 17, 2009).

274. “HPV vaccination: myths and misconceptions”, Lecture, Regional Symposium on New Vaccines, convened

by the Pan American Health Organization, Sabin Institute, and Centers for Disease Control and Prevention,

Lima, Peru (December 1, 2009).

275. “Should cervical cancer screening incorporate HPV testing”, Lecture, XXX Sunshine Seminar on Recent

Advances in ObGyn, Puerto Rico Section of the American College of Obstetrics and Gynecology, Dorado,

Puerto Rico, USA (February 13, 2010).

276. “Knowledge gaps and research needs on HPV and cervical cancer prevention”, Lecture, XXX Sunshine

Seminar on Recent Advances in ObGyn, Puerto Rico Section of the American College of Obstetrics and

Gynecology, Dorado, Puerto Rico, USA (February 13, 2010).

277. Co-Chair, Plenary Session TC4, EUROGIN 2010 Congress ‘20 Years of Progress and a Path to the Future’,

Monte-Carlo, Monaco (February 17, 2010).

278. “Impact on screening, diagnosis and treatment”, Plenary lecture, EUROGIN 2010 Congress ‘20 Years of

Progress and a Path to the Future’, Monte-Carlo, Monaco (February 17, 2010).


63

279. Honourary President’s Opening Address, EUROGIN 2010 Congress ‘20 Years of Progress and a Path to the

Future’, Monte-Carlo, Monaco (February 17, 2010).

280. “Is type replacement something to worry about: yes or no?” Lecture and Debate, EUROGIN 2010 Congress

‘20 Years of Progress and a Path to the Future’, Monte-Carlo, Monaco (February 18, 2010).

281. “Overview of trials of HPV testing in primary screening”, Plenary Lecture, EUROGIN 2010 Congress ‘20

Years of Progress and a Path to the Future’, Monte-Carlo, Monaco (February 19, 2010).

282. Co-Chair, Plenary Session “Gaps in knowledge and needed research directions”, EUROGIN 2010 Congress

‘20 Years of Progress and a Path to the Future’, Monte-Carlo, Monaco (February 20, 2010).

283. Chair, Plenary Session “HPV and Cervical Cancer”, National Infectious Agents Symposium, Canadian

Partnership Against Cancer, Toronto, Canada (March 11, 2010).

284. “HPV-based clinical and public health interventions”, Plenary lecture, National Infectious Agents

Symposium, Canadian Partnership Against Cancer, Toronto, Canada (March 12, 2010).

285. “The Burden of HPV-Associated Disease”, Plenary lecture, Biennial Meeting of the American Society for

Colposcopy and Cervical Pathology, Las Vegas, USA (March 24, 2010).

286. “HPV Testing and Typing: Update on Clinical Trials” Symposium lecture, Biennial Meeting of the American

Society for Colposcopy and Cervical Pathology, Las Vegas, USA (March 24, 2010).

287. Debate Panel Member, Session “Panel of Leaders: Cervical Cancer: Past, Present & Future”, Biennial

Meeting of the American Society for Colposcopy and Cervical Pathology, Las Vegas, USA (March 25, 2010).

288. “HPV testing for cervical cancer screening: A compelling evidence base”, Symposium lecture, 5th

General

Assembly of the Asian Pacific Organization for Cancer Prevention, Istanbul, Turkey (April 5, 2010).

289. “HPV and Cervical Carcinogenesis”, Symposium lecture, 5th

General Assembly of the Asian Pacific

Organization for Cancer Prevention, Istanbul, Turkey (April 5, 2010).

290. "Epidemiology of HPV infection: Many sites and diseases”, Keynote address, National HPV Institute

Workshop, Sao Roque, Brazil (April 25, 2010).

291. "HPV DNA testing in primary cervical cancer screening and its potential in the post-vaccination era"

Symposium lecture, National HPV Institute Workshop, Sao Roque, Brazil (April 27, 2010).

292. “El valor de la vacuna tetravalente contra el VPH”, Plenary lecture, Congreso Actualizaciones y Controversias

en Colposcopia, Mexican Gynecology Society, Mexico City, Mexico (May 7, 2010).

293. “Cambio de paradigma en programas de prevencion oportuna de cancer cervical en la era de vacunas contra

VPH”, Plenary lecture, Congreso Actualizaciones y Controversias en Colposcopia, Mexican Gynecology

Society, Mexico City, Mexico (May 7, 2010).

294. “Ventajas y limitaciones de las vacunas bivalente y tetravalente” Roundtable, Congreso Actualizaciones y

Controversias en Colposcopia, Mexican Gynecology Society, Mexico City, Mexico (May 7, 2010).

295. “Evidencia científica sobre nuevas tecnologías para el cribado del cáncer cervicouterino”, Plenary lecture,

Latin America Sub-regional Meeting on Cervical Cancer Prevention: “New technologies for cervical cancer

prevention: from scientific evidence to program planning”, Panama City, Panama (June 2, 2010).

296. Chair, Symposium “Dispelling the myth that all high-risk HPV genotypes are the same”, 26th International

Papillomavirus Conference, Montreal, Canada (July 5, 2010).

297. “How to succeed in an academic career” Workshop lecture, 26th International Papillomavirus Conference,

Montreal, Canada (July 6, 2010).

298. Chair, Symposium “Outstanding Scientific & Public Health Issues in the HPV Field”, 26th International

Papillomavirus Conference, Montreal, Canada (July 6, 2010).

299. “Clinical correlates of protection: what we know, what we don’t know, what should we know?” Lecture,

Canadian HPV Network Workshop, 26th International Papillomavirus Conference, Montreal, Canada (July 6,

2010).

300. Chair and moderator, Qiagen HPV World Leaders Summit, 26th International Papillomavirus Conference,

Montreal, Canada (July 6, 2010).

301. Chair, Symposium “Because Cervical Cancer Prevention Matters”, 26th International Papillomavirus

Conference, Montreal, Canada (July 6, 2010).

302. “Epidemiology of genital HPV infection and cervical cancer”, Lecture, 2nd Annual Workshop on Dynamic

Modelling for Health Policy: Chronic & Infectious Disease Interactions, Public Health Agency of Canada and

University of Saskatchewan, Saskatoon, Canada (July 20, 2010).

303. Chair, Session “Primary prevention of HPV/Cervical cancer”, 10th World Cancer Congress, International

Union Against Cancer, Shenzhen, China (August 19, 2010).

304. “HPV vaccination and the integration of vaccination in screening/surveillance”, Lecture, 10th World Cancer

Congress, International Union Against Cancer, Shenzhen, China (August 19, 2010).


64

305. Chair, Session “Secondary prevention of HPV/Cervical cancer: traditional and new technologies”, 10th World

Cancer Congress, International Union Against Cancer, Shenzhen, China (August 19, 2010).

306. “Current Evidence for Population-Based Screening”, Lecture, 10th World Cancer Congress, International

Union Against Cancer, Shenzhen, China (August 21, 2010).

307. “Bases cientificas para um rastreamento mais eficiente do Câncer de colo uterino no Brasil”, Lecture, XV

Congresso Paulista de Obstetrícia e Ginecologia (SOGESP), Sao Paulo, Brazil (September 3, 2010).

308. “Tirania da medicina baseada em evidencias no controle do cancro”, Keynote lecture, Symposium, Liga

Portuguesa Contra o Cancro, Porto, Portugal (October 11, 2010).

309. “Avancos recentes na prevencao do cancro do colo de utero”, Lecture, Symposium, Liga Portuguesa Contra o

Cancro, Porto, Portugal (October 11, 2010).

310. “Vacinas contra o HPV e o principio do fim do Cancro Cervical: Questões não resolvidas”, Lecture,

International Symposium on Cervical Cancer , Instituto Portugues de Oncologia, Porto, Portugal (October 12,

2010).

311. Session Chair and Plenary Speaker, “Epidemiology of HPV infection”, XX Reunion Internacional de Cancer

Cervico-Uterino y Lesiones Precursoras, Sociedad Mexicana del Virus del Papiloma; Federacion Mexicana de

Sociedades de Colposcopia, Mexico City, Mexico (November 4, 2010).

312. “Burden of disease caused by HPV infection”, Plenary lecture, XX Reunion Internacional de Cancer Cervico-


Sociedades de Colposcopia, Mexico City, Mexico (November 4, 2010).

313. “HPV vaccination and cervical cancer screening: Need for an integrated approach”, Plenary lecture, XX


Papiloma; Federacion Mexicana de Sociedades de Colposcopia, Mexico City, Mexico (November 4, 2010).

314. “HPV DNA testing in cervical cancer screening: The evidence from clinical studies”, Plenary lecture, XX


Papiloma; Federacion Mexicana de Sociedades de Colposcopia, Mexico City, Mexico (November 5, 2010).

315. “Research on cervical cancer etiology and prevention: A unique timeline”, Keynote Lecture, Alberta Cancer

Foundation Research Meeting, Banff, Canada (November 8, 2010).

316. “The scientific validity of arguments against HPV vaccines”, Plenary lecture, Turkish HPV Meeting,

Federation of Turkish Pathology Societies, Izmir, Turkey (November 26, 2010).

317. “Expected impact of HPV on cervical cancer screening practices”, Plenary lecture, Turkish HPV Meeting,

Federation of Turkish Pathology Societies, Izmir, Turkey (November 27, 2010).

318. “DNA testing in cervical cancer screening”, Plenary lecture, Turkish HPV Meeting, Federation of Turkish

Pathology Societies, Izmir, Turkey (November 27, 2010).

319. “HPV 16/18 genotyping in cervical cancer screening programs”, Plenary lecture, 2nd

Latin American Forum

on In Vitro Diagnosis, Sao Paulo, Brazil, (December 3, 2010).

320. “Screening strategies in an HPV vaccinated population”, Lecture, Consensus Conference of the Federación

Mexicana de Colegios de Obstetricia y Ginecologia, Puerto Vallarta, Mexico (February 26, 2011).

321. “Cuáles son los mitos y las realidades en la prevención del cáncer cervical a nivel mundial”, Lecture, 14th

Congreso Nacional de Investigación en Salud Pública, Cuernavaca, Mexico (March 2, 2011).

322. “Evidencia cientifica para um melhor rastreio do cancro de colo uterino: O teste do HPV e genotipagem no

estudo ATHENA”, Lecture, 19th Portuguese Congress of Obstetrics and Gynecology, Porto, Portugal (March

18, 2011).

323. “Epidemiology of HPV infection and cervical cancer” Lecture, 1st Symposium on HPV and cancer,

Universidade Federal do Maranhão, São Luis, Brazil (April 7, 2011).

324. “Cervical cancer screening: Glory for some, failure for many” Lecture, 1st Symposium on HPV and cancer,

Universidade Federal do Maranhão, São Luis, Brazil (April 7, 2011).

325. “Cervical cancer screening as a post-vaccination surveillance activity”, Plenary lecture, EUROGIN 2011

Congress, Lisbon, Portugal (May 9, 2011).

326. “Epidemiologic, genetic, behavioural factors and the male partner influence: are they important?”, Plenary

Chairperson and Lecture, PS3, EUROGIN 2011 Congress, Lisbon, Portugal (May 10, 2011).

327. “Age-specific HPV incidence and prevalence: potential perspective for screening and vaccination”, Lecture,

SS11, EUROGIN 2011 Congress, Lisbon, Portugal (May 10, 2011).

328. “Unresolved questions concerning HPV infection and transmission”, Chairperson and Lecture, SS16,

EUROGIN 2011 Congress, Lisbon, Portugal (May 11, 2011).

329. “Verification bias: does it matter? Yes”, Lecture, CS2, EUROGIN 2011 Congress, Lisbon, Portugal (May 11,

2011).


65

330. “Closing Remarks-Day 1”, Plenary Lecture, Student Conference, Canadian Society for Epidemiology and

Biostatistics, Montreal, Canada (June 19, 2011).

331. Chairperson, Spotlight Session “HPV and cervical cancer”, North American Congress of Epidemiology,

Montreal, Canada (June 23, 2011).

332. “Current evidence of clinical utility for HPV-DNA tests”, Lecture, 14th

Congress of the International

Federation of Cervical Pathology and Colposcopy, Rio de Janeiro, Brazil (July 4, 2011).

333. “Arguments against HPV vaccination: myths and facts” , Lecture, 14th


Federation of Cervical Pathology and Colposcopy, Rio de Janeiro, Brazil (July 6, 2011).

334. Chairperson and Lecturer: “HPV testing for cervical cancer screening: evaluating the benefit of identifying

individual HPV16/18 infection to improve the prediction of risk for high-grade cervical disease: the ATHENA

study”, Symposium lecture, 14th

Congress of the International Federation of Cervical Pathology and

Colposcopy, Rio de Janeiro, Brazil (July 7, 2011).

335. “Combining vaccination and screening for efficient cervical cancer control”, Lecture, 14th

Congress of the

International Federation of Cervical Pathology and Colposcopy, Rio de Janeiro, Brazil (July 7, 2011).

336. “Screening for cervical cancer in the era of HPV vaccination”, Lecture, 19th


Society for STD Research, Quebec City, Canada (July 13, 2011).

337. “Tyranny of evidence-based medicine and public health”, Lecture, Pre-Congress Workshop, XIX World

Congress of Epidemiology, International Epidemiological Association, Edinburgh, Scotland (August 7, 2011).

338. “Burden of Disease, Health Indicators, and Challenges for Epidemiology in North America”, Symposium

lecture, XIX World Congress of Epidemiology, International Epidemiological Association, Edinburgh,

Scotland (August 10, 2011).

339. “Knowledge gaps and research priorities for cervical cancer control in Latin America: An update”, Plenary

lecture, Conference on Methodological Issues in Cancer Research, University of Puerto Rico and MD

Anderson Cancer Center, San Juan, Puerto Rico (August 26, 2011).

340. Discussant, Symposium on Alternate vaccine dosing schedules, 27th

International Papillomavirus Conference,

Berlin, Germany (September 19, 2011).

341. Chair and Speaker, Symposium “HPV vaccines: The post-launch era”, 27th

International Papillomavirus

Conference, Berlin, Germany (September 19, 2011).

342. Chair and Speaker, Session 4: Prevention, 27th

International Papillomavirus Conference, Berlin, Germany


343. “Bases cientificas para um melhor rastreamento do câncer do colo de útero no Brasil”, Plenary lecture,

Cervicolp 2011, XXII Congresso da Sociedade Brasileira de Patologia do Trato Genital Inferior, São Paulo,

Brasil (September 30, 2011).

344. “Prevenção primaria via vacinação: A validade científica dos argumentos contra e a favor”, Plenary lecture,

Cervicolp 2011, XXII Congresso da Sociedade Brasileira de Patologia do Trato Genital Inferior, São Paulo,

Brasil (September 30, 2011).


66

APPENDIX 3

LECTURES AND SEMINARS AT

ACADEMIC, RESEARCH AND CLINICAL

DEPARTMENTS

1995-2011


67

LECTURES AND SEMINARS AT ACADEMIC, RESEARCH, AND CLINICAL

DEPARTMENTS (by invitation, no abstracts)

1. “The impact of a needle exchange program on the seroepidemiology of HIV-1 in Montreal” (co-presented

with Julie Bruneau). Research Seminar in the AIDS/HIV Program, Centers for Disease Control and

Prevention, Atlanta, USA (March 8, 1995).

2. “Cancer Epidemiology and Prevention.” Department of Oncology Lecture Series, McGill University,

Montreal, Canada (March 15, 22, 29, 1995).

3. “The molecular epidemiology of HPV infection and cervical cancer.” Lecture in the Division of Clinical

Epidemiology, Royal Victoria Hospital, Montreal, Canada (September 21, 1995).

4. “Participation in needle exchange programs and risk of HIV seroconversion: Paradoxical results from a cohort

study in Montreal.” Lecture in the Department of Epidemiology and Biostatistics, McGill University,

Montreal, Canada (February 15, 1996).

5. “The epidemiology of HPV infection and cervical cancer.” Seminar at Boehringer Ingelheim Research Inc.,

Laval, Canada (October 2, 1996).

6. “Human papillomavirus and cancer: the merging of molecular biology and epidemiologic approaches.”

Seminar to the Montreal Cancer Research Group, Biochem Pharma Inc. and McGill University, Montreal,

Canada (October 24, 1996).

7. “The molecular epidemiology of HPV infection and cervical cancer.” Lecture in the Department of

Epidemiology and Biostatistics, McGill University, Montreal, Canada (November 21, 1996).

8. “Risk factors and survival determinants in oral cancer.” Seminar to the Faculty of Dentistry, McGill

University, Montreal, Canada (January 8, 1997).

9. “The epidemiology of HPV infection and cervical cancer.” Grand rounds at the Department of Oncology,

McGill University, Montreal, Canada (May 14, 1997)

10. “Case-control study of upper aero-digestive tract cancers in Brazil.” Seminar to the Unit of Field Intervention

Studies, International Agency for Research on Cancer, Lyon, France (June 27, 1997).

11. “New epidemiology of HPV infection and cervical cancer.” Seminar to research staff, Roche Molecular

Systems, Alameda, California, USA (December 1, 1997).

12. “New epidemiology of HPV infection and cervical cancer.” Seminar to the Department of Molecular Genetics

and Microbiology, University of New Mexico, Albuquerque, USA (December 2, 1997).

13. "The natural history of human papillomavirus infection and cervical neoplasia: An ongoing cohort study in a

high risk area." Seminar to the Minority Cancer Prevention and Control Program, Arizona Cancer Center,

University of Arizona, Tucson, USA (March 11, 1998).

14. "The emerging epidemiology of HPV infection and cervical neoplasia." Seminar to research staff,

MedImmune, Inc., Gaithersburg, MD, USA (March 19, 1998).

15. “Human papillomavirus infections in high risk populations.” Gender Health Lecture Series, McGill

University, Montreal, Canada (October 7, 1998).

16. "Recent advances in the molecular epidemiology of cervical neoplasia." Lecture in the Department of

Epidemiology and Biostatistics, McGill University, Montreal, Canada (October 15, 1998).

17. “Human papillomavirus infection: Testing and screening recommendations.” Conference to the Minister’s

Advisory Group on Sexually-Transmitted Diseases. Ministère de la Santé et des Services sociaux du Québec,

RRSSS de Montréal-Centre, Montreal, Canada (October 16, 1998).

18. “A cohort study of the natural history of human papillomavirus infection and cervical neoplasia.” Seminar to

the Department of Epidemiology, Johns Hopkins University, Baltimore, USA (November 20, 1998).

19. "The role of human papillomavirus in the pathogenesis of cervical neoplasia." Lecture in the Department of

Pathology, McGill University, Montreal, Canada (March 29, 1999).

20. “Looking beyond tobacco and alcohol consumption: The search for other risk factors for upper aero-digestive

tract cancers.” Seminar to the Department of Epidemiology, Emory University, Atlanta, USA (May 21, 1999).

21. “Cancer epidemiology at a crossroads.” Conference at the AC Camargo Cancer Hospital (in Portuguese), Sao

Paulo, Brazil (May 31, 1999).

22. “Epidemiology and natural history of HPV induced disease.” Conference at the Foothills Medical Centre,

University of Calgary, Canada (June 17, 1999).

23. “Can traditional epidemiologic approaches distinguish between necessary and non-necessary causes of

cancer.” Seminar at the Alberta Cancer Board, Calgary, Canada (June 18, 1999).


68

24. “Natural history of Human Papillomavirus infection and cervical cancer precursors: A molecular

epidemiology study in a high risk area.” Seminar to the Department of Epidemiology, Emory University,

Atlanta, USA (July 29, 1999).

25. "Human papillomavirus testing for primary screening of cervical cancer precursors." Lecture in the Cancer

Control Seminar Series, Cancer Bureau, Laboratory Centre for Disease Control, Ottawa, Canada (October 19,

1999).

26. "Molecular epidemiology of HPV infection and cervical cancer." Seminar to the Adolescent Vaccine

Division, SmithKline Beecham Pharmaceuticals, Rixensart, Belgium (November 29, 1999).

27. "HPV testing in primary screening of cervical cancer precursors: The Newfoundland study." Lecture in the

Division of Clinical Epidemiology, Royal Victoria Hospital, Montreal, Canada (April 13, 2000).

28. “HPV and cervical cancer.” Seminar at the Grand Rounds of the Division of Radiation Oncology, Montreal

General Hospital, Montreal, Canada (April 17, 2000).

29. “Molecular epidemiology of HPV infection and cervical neoplasia.” Seminar to the Centre de recherche en

cancérologie de l’Université Laval, Laval, Canada (May 5, 2000).

30. “Natural history of Human Papillomavirus infection and cervical cancer.” Lecture in the Department of

Medical Epidemiology, Karolinska Institute, Stockholm, Sweden (August 29, 2000).

31. “HPV testing in primary screening of cervical cancer precursors: The Newfoundland study." Lecture in the

Microbiology & Tumor Biology Center, Karolinska Institute, Stockholm, Sweden (August 31, 2000).

32. "Perspectivas do uso do teste de HPV no rastreio de lesoes precursoras do carcinoma do colo uterino."

Seminar to the Instituto Português de Oncologia "Francisco Gentil", Lisbon, Portugal (May 23, 2001).

33. "Epidemiologia do carcinoma do colo uterino: de onde viemos e para onde devemos ir." Seminar to the

Faculty of Medicine, University of Lisbon, Portugal (May 23, 2001).

34. "Molecular epidemiology of HPV infection and cervical cancer." Seminar to the McMaster University

Regional Grand Rounds, Hamilton, Canada (March 6, 2002).

35. "Evidence-based policy recommendations for screening and prevention of cervical cancer." Seminar to the

Department of Obstetrics & Gynaecology, McMaster University, Hamilton, Canada (March 6, 2002).

36. “Evidence-based policy guidelines in cancer screening and prevention.” Seminar to the Grand Rounds of the

Department of Radiation Oncology, McGill University Health Centre, Montreal, Canada (May 27, 2002).

37. "Cancer epidemiology at a crossroads: Time for reappraisal." Lecture in the Department of Epidemiology and

Biostatistics, McGill University, Montreal, Canada (September 30, 2002).

38. "Human papillomavirus and cervical cancer as a prevention paradigm in oncology." Lecture to the André

Aisenstadt Memorial Clinical Day, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Canada

(October 23, 2002).

39. “Should we change one of the oldest medical tests? The Pap test versus new technologies for cervical cancer

screening.” Seminar to the Centre for Clinical Epidemiology & Community Studies, Sir Mortimer B. Davis

Jewish General Hospital, Montreal, Canada (November 27, 2002).

40. "Whither epidemiologic research in an era of heightened expectations for cervical cancer prevention

initiatives?" Seminar to the Fred Hutchinson Cancer Research Center, Seattle, USA (August 25, 2003).

41. "Papel da epidemiologia no controle do câncer: Fim do caminho ou inicio de uma nova era?" Conference to

the Instituto Nacional de Câncer, Brazilian Ministry of Health, Rio de Janeiro, Brazil (October 24, 2003).

42. "Molecular epidemiology of HPV infection and cervical neoplasia". Lecture to the Centro de Investigación y

de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico (February 24, 2004).

43. "Molecular epidemiology and prevention of HPV infection." Two conferences to the Colposcopy Working

Group of the Alberta Cervical Cancer Screening Program, Edmonton and Calgary, Alberta, Canada (March 10

and 11, 2004, respectively).

44. "HPV infection and cervical cancer: Whither epidemiologic research?" Seminar to the Department of

Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, USA (March 26, 2004).

45. “Primary HPV Screening in Canada: Are We Ready Yet ?“ Lecture, Journée annuelle de la recherche du

Département d’obstétrique-gynécologie de l’Université de Montréal, Montreal, Canada (April 30, 2004).

46. “Epidemiology of HPV infection and cervical dysplasia” Seminar to the 3M Pharmaceuticals Division, St-

Paul, Minnesota, USA (June 4, 2004).

47. "Persistent HPV infection as the key precursor in the natural history of cervical neoplasia: Epidemiologic

evidence" Seminar to the HPV Vaccine Division, Glaxo SmithKline Pharmaceuticals, Rixensart, Belgium

(June 8, 2004).

48. “The future of cervical cancer prevention” Sir Mortimer B. Davis Jewish General Hospital’s Grand Rounds,

Montreal, Canada (November 12, 2004).


69

49. “Cervical cancer: Fast track to prevention.” Seminar to the Grand Rounds of the Department of Radiation

Oncology, McGill University Health Centre, Montreal, Canada (November 15, 2004).

50. "Cancer epidemiology at a crossroads: Is it time for a reappraisal?" Seminar to the Division of Cancer

Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA

(December 9, 2004).

51. “Overview of HPV infection and cervical cancer” Lecture to Cervarix staff of Glaxo Smithkline Canada,

Mississauga, Ontario, Canada (December 13, 2004).

52. “HPVs: Biology, epidemiology, natural history, and immunity” Lecture to the HPV Vaccine Planning

Committee, Canadian Association for Immunization Research and Evaluation, Vancouver, Canada (January

28, 2005).

53. “Overview of HPV infection and cervical cancer” Lecture to Medical and R&D staff of Glaxo Smithkline

Canada, Mississauga, Ontario, Canada (February 24, 2005).

54. "Cancer epidemiology at a crossroads: Time for a reappraisal" Seminar to the Comprehensive Cancer Center,

University of California at San Francisco, San Francisco, USA (March 11, 2005).

55. "Promises and perils of new paradigms in cervical cancer prevention" Lecture in the Symposium to honour

Dean Abraham Fuks, Faculty of Medicine, McGill University, Montreal, Canada (May 12, 2005).

56. “HPV testing vs. Pap cytology: Preliminary results from the Canadian Cervical Cancer Screening Trial

(CCCaST)" Seminar to the Division of Cancer Prevention and Control, Centers for Disease Control and

Prevention, Atlanta, USA (September 26, 2005).

57. "The road to cancer prevention: A tale promising a happy ending" Lecture to the New Brunswick Chapter of

the Canadian Cancer Society, Dalhousie, New Brunswick, Canada (October 23, 2005).

58. “Epidemiology of Cervical Cancer: Implications for Prevention” Lecture in the CME Grand Rounds in

Gynecologic Oncology, Montreal General Hospital, Montreal, Canada (November 15, 2005).

59. "Cancer Prevention: The Tyranny of Evidence-Based Medicine" Seminar to the Faculty of Dentistry, McGill

University, Montreal, Canada (December 1, 2005).

60. “Epidemiology of Cervical Cancer: The Road Ahead” Seminar to the Department of Community and Family

Medicine. Duke University, Durham, USA (March 24, 2006).

61. “Promises and Perils of New Approaches in Cervical Cancer Prevention” Grand Rounds Lecture to the

Department of Obstetrics & Gynaecology, University of Western Ontario, London, ON, Canada (April 12,

2006).

62. “Principles of Clinical Research in Oncology: Grand Rounds Lecture to the Oncology Training Program,

McGill University Health Centre, Montreal General Hospital, Montreal, Canada (September 29, 2006).

63. “HPV Vaccination: A New Paradigm in Cervical Cancer Prevention” Seminar to the Department of

Epidemiology & Biostatistics, McGill University, Montreal, Canada (October 16, 2006).

64. “Expected impact of HPV vaccination on cervical cancer screening practices” Seminar to the Merck-Frosst

HPV Club, Montreal Museum of Fine Arts, Montreal, Canada (October 25, 2006).

65. "Molecular epidemiology of HPV infection and cervical cancer" Lecture at the Sainte-Justine Hospital,

Montreal, Canada (November 10, 2006).

66. “The expected impact of HPV vaccination on cervical cancer screening practices” Lecture to the Cervical

Cancer Screening Management Staff, Cancer Care Ontario, Toronto, Canada (December 14, 2006).

67. “HPV Vaccination in Cervical Cancer Prevention: Evidence and Implications” Lecture at the Division of

Preventive Oncology, Cancer Care Ontario, Toronto, Canada (December 14, 2006).

68. “Changing Landscapes in HPV and Cervical Cancer Prevention and Screening” Lecture at the CityWide

Grand Rounds, Women's Hospital, University of Toronto, Toronto, Canada (December 15, 2006).

69. "HPV Vaccination in cervical cancer prevention: promises & perils" Lecture given in the Symposium

Challenges in Obstetrics & Gynecology, Gelber Conference Centre, Montreal, Canada (March 16, 2007).

70. “Promises and perils in the changing landscape of cervical cancer prevention” Lecture given to the

Department of Obstetrics and Gynecology, School of Medicine, Universidad de Puerto Rico, San Juan, USA

(May 8, 2007).

71. “Changing Landscapes in HPV and Cervical Cancer Prevention and Screening” Lecture given to the Institut

du Cancer de Montreal, Centre de Recherche du CHUM-Hôpital Notre-Dame, Montreal, Canada (May 16,

2007).

72. “Epidemiology of Cervical Cancer in Latin American Countries” Lecture at the Latin American HPV Master

Class and Clinical Workshop, São Paulo, Brazil (August 16, 2007).

73. “Expected impact of HPV vaccination on Screening for cervical cancer” Lecture at the Latin American HPV

Master Class and Clinical Workshop, São Paulo, Brazil (August 16, 2007).


70

74. “Expected impact of HPV vaccination on current screening practice” Lecture at the Middle East and North

Africa HPV Master Class and Clinical Workshop, Cairo, Egypt (September 6, 2007).

75. “Expected impact of vaccination on screening practices: Theoretical concerns and research opportunities”

Lecture at the HPV Master Class of the Canadian Association for Immunization Research and Evaluation,

Ottawa, Canada (September 22, 2007).

76. “HPV testing in cervical cancer screening” Grand Rounds Seminar at McMaster University, Hamilton,

Canada (September 28, 2007).

77. “New Primary and Secondary Prevention Strategies for Cervical Cancer Prevention” Lecture to the Alberta

Cancer Board Provincial/Regional Medical Laboratory Meeting, Banff, Canada (October 17, 2007).

78. “What’s the fuss about infectious diseases? Infections and cancer” Café Scientifique, Canadian Institutes of

Health Research, Montreal, Canada (January 22, 2008).

79. “Arguments for and against HPV vaccination: Separating sensible from silly” Seminar to the Merck HPV

Club, Toronto, Canada (February 4, 2008).

80. “Epidemiologic issues in implementing HPV vaccination” Lecture at the Sub-Saharan Africa HPV Master

Class and Clinical Workshop, Johannesburg, South Africa (February 26, 2008).

81. “Research at McGill’s Division of Cancer Epidemiology” Seminar at the Faculty Retreat of the Department of

Oncology, McGill University, Montreal, Canada (March 13, 2008).

82. “Molecular epidemiology of HPV infection and cervical cancer”, Seminar at the Division of Epidemiology,

School of Public Health, University of California, Berkeley, USA (April 15, 2008).

83. “The tyranny of evidence-based medicine in cancer prevention”, Grand Rounds Seminar at McMaster

University, Hamilton, Canada, (October 23, 2008).

84. “Distal and proximal causal factors in cancer: Reconciling social and molecular epidemiology”, Seminar to

the Department of Epidemiology & Biostatistics, McGill University, Montreal, Canada (November 3, 2008).

85. “HPV screening in the era of vaccination” Seminar at the Département de Microbiologie Médicale et

Infectiologie, Hôpital Notre-Dame, Centre Hospitalier de l’Université de Montréal, Montreal, Canada

(December 8, 2008).

86. “HPV testing in primary cervical cancer screening: updated results from Canadian study and review of

European studies” Lecture at the Centers for Disease Control and Prevention, Atlanta, USA (January 12,

2009).

87. “Epidemiologic Research Opportunities in Childhood Cancer: Exploring the International Variation in

Environmental Exposures and in Health Care Settings" Lecture to the Department of Pediatric Hematology

and Oncology, King Faisal National Children Cancer Center, Riyadh, Saudi Arabia (January 20, 2009).

88. “The Role of Observational Studies in the Era of Evidence-Based Medicine” Lecture to the Department of

Family Medicine, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia (January 20,

2009).

89. “As Vacinas na Prevenção do Cancro do Colo do Utero” Keynote lecture, Workshop: Prevenção do Cancro e

a Vacinação em Discussão, Instituto Português de Oncologia, Porto, Portugal (January 23, 2009).

90. “HPV testing in primary screening: Recent findings from European and Canadian RCTs and methodological

issues” Lecture, Qiagen Experts Forum: HPV testing in Cervical Cancer Screening in Canada, Quebec City,

Canada (February 10, 2009).

91. “New strategies for cervical cancer control: HPV vaccination and HPV testing in screening” Meet-the-

Researcher Lecture to the Staff of the Canadian Cancer Society, Toronto, Canada (via teleconference from

Montreal) (February 13, 2009).

92. “Principles of clinical research and publishing in medical journals”, Lecture, Multidisciplinary Oncology

Residency Education, Montreal General Hospital, Montreal, Canada (April 3, 2009).

93. “HPV transmission and natural history: Insights from epidemiological studies in Canada and Brazil” Seminar,

HPV Transmission Workshop, Cambridge University, Cambridge, UK (September 11, 2009).

94. "New frontiers in cervical cancer prevention: HPV vaccination and screening strategies", Lecture, Continuing

Medical Education Series, Faculty of Medicine, McGill University, Montreal, Canada (January 28, 2010).

95. “Cervical cancer screening: Glory for some, failure for many”, Seminar, BD Diagnostics, Research Triangle

Park, North Carolina, USA (September 13, 2010).

96. “Replacing the Oldest Cancer Test: Epidemiologic Evidence For A New Strategy In Cervical Cancer

Screening”, Seminar, Division of Clinical Epidemiology, McGill University Health Centre, Royal Victoria

Hospital, Montreal, Canada (February 3, 2011).


71

97. “New Frontiers in Cervical Cancer Prevention: HPV Vaccination and Screening Strategies”, Seminar,

Queen’s Cancer Research Institute and Department of Community Health and Epidemiology, Queen’s

University, Kingston, Canada (April 15, 2011).

98. “Overview of HPV infection and Cervical Cancer Prevention via Vaccination”, Seminar, CME session for

gynecologists, Café Ferreira, Montreal, Canada (June 16, 2011).

99. “Bases cientificas para um rastreio mais eficiente do cancer de colo uterino no Brasil”, Lecture, CME session

for gynecologists, Hotel Bourbon Ibirapuera, Sao Paulo, Brazil (July 1, 2011).

100. “The tyranny of evidence-based medicine in cancer prevention and control”, Seminar, Department of Clinical

Epidemiology & Biostatistics, McMaster University, Hamilton, Canada (September 8, 2011).

101. “New Technologies in Cervical Cancer Screening: A Paradigm Change in Cancer Control”, Grand Rounds

Lecture, Juravinski Cancer Centre, Hamilton, Canada (September 8, 2011).

102. “Distinguishing sensible from silly: The scientific validity of arguments against Human papillomavirus

vaccination”, Seminar, Population Health Research Institute, Hamilton, Canada (September 8, 2011).

103. “The expected impact of HPV vaccination on cervical cancer screening”, Seminar, Public Health &

Preventive Medicine Residency Program, McMaster University, Hamilton, Canada (September 9, 2011).

104. “Emerging role of new technologies in cervical cancer screening and the future role of the Pap smear”,

Seminar, Expert Input Forum on the Integration of Screening and Vaccination, Merck, Vaccines Division,

Berlin, Germany (September 23, 2011).


72

APPENDIX 4

ABSTRACTS AND SHORT

COMMUNICATIONS

(ORAL AND POSTER, OFFERED)

1995-2011


73

ABSTRACTS AND SHORT COMMUNICATIONS (oral and poster, offered)

1. Franco E, Villa LL, Ruiz A, Ribeiro M, Rohan T. Determinants of persistent cervical human papillomavirus

infection. 86th Annual Meeting of the American Association for Cancer Research, Toronto, Canada, March

1995.

2. Bruneau J(§), Lamothe F, Franco E, Lachance N, Vincelette J, Soto J. Needle exchange program attendance

and HIV-1 infection in Montreal: Report of a paradoxical association. Sixth International Conference on the

Reduction of Drug Related Harm, Florence, Italy, April 1995.

3. Ferenczy A, Franco E, Robitaille J, Wright T, Richart R. Combined liquid-based cytology and HPV DNA

testing in screening for cervical neoplasia. 64th Annual Meeting of the Royal College of Physicians and

Surgeons of Canada, Montreal, Canada, September 1995.

4. Robitaille J, Ferenczy A, Franco E, Arseneau J, Richart R, Wright T. A paired comparison of conventional

Pap smears and Thin-prep (TM) smears obtained by Accelon (TM) cervical biosampler. 64th Annual Meeting

of the Royal College of Physicians and Surgeons of Canada, Montreal, Canada, September 1995.

5. Bruneau J(§), Lamothe F, Franco E, Lachance N, Vincelette J, Soto J. A paradoxical association between

needle exchange program attendance and seroconversion to HIV-1 in Montreal. 5th Annual Canadian

Conference on HIV/AIDS Research, Winnipeg, Canada, 1995.

6. Van Caloen B, Lamothe F, Bruneau J, Franco E, Vincelette J, Soto J. Recherche qualitative et épidémiologie:

un design de recherche. 5th Annual Canadian Conference on HIV/AIDS Research, Winnipeg, Canada, 1995.

7. Bruneau J(§), Lamothe F, Franco E, Lachance N, Vincelette J, Soto J. A paradoxical association between

needle exchange program attendance and seroconversion to HIV-1 in Montreal. 37th International Congress on

Alcohol and Drug Dependence, San Diego, USA, August 1995.

8. Pintos J(§), Bergeron J, Richardson H, Franco E, Arella M, Black M, Shenouda G, Rochon L. Association of

HPV DNA detection with markers of disease severity in patients with cancers of the upper aero-digestive tract.

Workshop on Recurrent Respiratory Papillomatosis - Head and Neck Diseases Associated With

Papillomaviruses, Quebec City, Canada, July 1995.

9. Villa L, Franco E, Rahal P, Ruiz A, Caballero OL, Rohan TE. Cohort study of persistence of cervical HPV

infection defined by molecular variant analysis. 14th International Papillomavirus Conference, Quebec City,

Canada, July 1995.

10. Villa L, Caballero O, Simpson A, Franco E. Types associated with high viral copy frequencies in

asymptomatic women with cervical HPV infection. 14th International Papillomavirus Conference, Quebec

City, Canada, July 1995.

11. Caballero O(§), Villa L, Simpson A, Franco E. Determinants of viral load in cervical carcinomas harbouring

HPV. 14th International Papillomavirus Conference, Quebec City, Canada, July 1995.

12. Nonnenmacher B(§), Schiller J, Franco E, Villa L, Kirnbauer R, Hubbert N, et al. Correlates of serological

response to HPV capsids in asymptomatic women screened for cervical cancer in southern Brazil. 14th

International Papillomavirus Conference, Quebec City, Canada, July 1995.

13. Ferenczy A, Franco E, Robitaille J, Arseneau J, Wright T. Richart R. HPV DNA testing using liquid-based

thin-Prep smear technology. 14th International Papillomavirus Conference, Quebec City, Canada, July 1995.

14. Richardson H(§), Bergeron J, Pintos J, Franco E, Tellier P, Arella M. Risk factors for cervical HPV infection

in female university students in Montreal. 14th International Papillomavirus Conference, Quebec City, Canada,

July 1995.

15. Pintos J(§), Bergeron J, Richardson H, Franco E, Arella M, Black M, Shenouda G, Rochon L. Association of

HPV DNA detection with markers of disease severity in patients with cancers of the upper aero-digestive tract.

14th International Papillomavirus Conference, Quebec City, Canada, July 1995.

16. Foulkes WD, Brunet JS, Kowalski LP, Narod SA, Franco EL. Family history of cancer is a risk factor for

squamous cell carcinoma of the head and neck: a case-control study from Brazil. 45th Annual Meeting of the

American Society of Human Genetics, Minneapolis, U.S.A, October 1995.

17. Bruneau J(§), Lamothe F, Franco E, Lachance N, Desy M, Soto J, Vincelette J. Participation in a needle

exchange program: an unexpected association with HIV acquisition. 7th International Conference on the

Reduction of Drug Related Harm, Hobart, Australia, March 1996.

18. Velly AM(§), Franco E, Kowalski L. Dental health characteristics and risk of cancer of the mouth in Brazil.

74th Annual Meeting of the International Association of Dental Research, San Francisco, USA, March 1996.


74

19. Pintos J(§), Franco E, Bergeron J, Richardson H, Arella M, Black M, Shenouda G. Détection de l’ADN de

papillomavirus et la gravité de la maladie chez des patients atteints de cancer des voies aérodigestives

supérieures. Colloque de l’ACFAS sur la recherche thématique en santé bucco-dentaire, Montreal, Canada,

May 1996.

20. Lamothe F, Bruneau J, Franco E, Lachance N, Desy M, Vincelette J, Soto J. Risk factors for HIV

seroconversion among injection drug users in the Saint-Luc cohort, Montreal 1988-1995. 11th International

Conference on AIDS, Vancouver, Canada, July 1996.

21. Bruneau J(§), Franco E, Lamothe F, Lachance N, Desy M, Soto J, Vincelette J. Increased HIV seroprevalence

and seroincidence associated with participation in a needle exchange program: Unexpected findings from the

Saint-Luc Cohort study in Montreal. 11th International Conference on AIDS, Vancouver, Canada, July 1996.

22. Lachance N, Lamothe F, Bruneau J, Franco E, Vincelette J, Soto J. Injecting and sharing iv equipment in

different cities: a potential risk for HIV dissemination. 11th International Conference on AIDS, Vancouver,

Canada, July 1996.

23. Pintos J(§), Franco E, Oliveira B, Curado M, Fava A, Kowalski L. Use of wood stove and risk of cancers of

the upper aero-digestive tract in Southern Brazil. 4th International Conference on Head and Neck Cancer,

Toronto, Canada, July 1996.

24. Rahal P(§), Termini L, Sobrinho JSP, Franco EL, Villa LL. A follow-up study of persistence of cervical HPV

infection. VIII Encontro Nacional de Virologia, Sociedade Brasileira de Virologia, São Lourenço, Brazil,

November 1996.

25. Candeias JMG(§), Franco EL, Schiller JT, Villa LL. Detection of antibodies against human papillomavirus

(HPV) type 16 by an ELISA using recombinant HPV-16 L1 capsids in sera of women with cervical cancer. VIII

Encontro Nacional de Virologia, Sociedade Brasileira de Virologia, São Lourenço, Brazil, November 1996.

26. Franco EL, Villa LL, Rahal P, Rohan TE. Incidence of cervical HPV infection in a cohort of women from a

high risk area for cervical cancer. 15th International Papillomavirus Conference, Gold Coast, Australia,

December 1996.

27. Franco EL, Villa LL, Rahal P, Ferenczy A, Rohan TE. Risk of cervical intraepithelial neoplasia following

transient and persistent HPV infection. 15th International Papillomavirus Conference, Gold Coast, Australia,

December 1996.

28. Villa LL, Franco EL, Caballero O, Rahal P, Ferenczy A, Rohan TE. Viral load, persistent cervical HPV

infection, and cumulative risk of cervical intraepithelial neoplasia in a high risk area. 15th International

Papillomavirus Conference, Gold Coast, Australia, December 1996.

29. Franco EL, Villa LL, Rahal P, Rousseau MC, Rohan TE. Risk factors for incident and persistent cervical HPV

infection in a cohort of asymptomatic women. 15th International Papillomavirus Conference, Gold Coast,

Australia, December 1996.

30. Candeias JM(§), Franco EL, Schiller JT, Villa LL. Antibodies against human papillomavirus (HPV) type 16

capsids in cervical cancer patients. 15th International Papillomavirus Conference, Gold Coast, Australia,

December 1996.

31. Franco EL, Villa LL, Rahal P, Caballero O, Rohan TE, Ferenczy A. Epidemiology of incident and persistent

human papillomavirus infection and risk of cervical intraepithelial neoplasia. 3rd International Congress on

Lower Genital Tract Infections and Neoplasia, Paris, France, March 1997.

32. Caballero O(§), Villa LL, Franco EL, Rahal P, Ferenczy A, Rohan TE. Viral load as a predictor of HPV-

associated cervical intraepithelial neoplasia. 3rd International Congress on Lower Genital Tract Infections and

Neoplasia, Paris, France, March 1997.

33. Franco EL, Villa LL, Rahal P, Ferenczy A, Rohan TE. Incident cervical intraepithelial neoplasia following

transient and persistent human papillomavirus infection. 88th Annual Meeting of the American Association for

Cancer Research, San Diego, USA, April 1997.

34. Lamothe F, Vincelette J, Bruneau J, Tepper M, Gully PR, Lachance N, Franco E. Prevalence, seroconversion

rates and risk factors for hepatitis B core, Hepatitis C and HIV antibodies among intravenous drug users of the

Saint-Luc cohort. 6th Annual Canadian Conference on AIDS Research, Ottawa, Canada, May 1997.

35. Caballero OL(§), Villa LL, Franco EL, Rahal P, Ferenczy A, Rohan TE. Viral load as predictor of HPV-

associated cervical intraepithelial neoplasia. XXVI Reunião Anual, Sociedade Brasileira de Bioquímica e

Biologia Molecular, Caxambu, Brazil, May 1997.

36. Rahal P(§), Villa LL, Franco EL, Ferenczy A, Rohan TE. Risk of intraepithelial neoplasia following transient

and persistent HPV infection. XXVI Reunião Anual, Sociedade Brasileira de Bioquímica e Biologia Molecular,

Caxambu, Brazil, May 1997.


75

37. Rahal P(§), Franco EL, Villa LL. Molecular variant analysis as a tool in natural history studies of human

papillomavirus infection and cervical neoplasia. 43rd Congresso Nacional de Genética, Goiânia, Brazil, August

1997.

38. Caballero O(§), Villa LL, Franco EL, Rahal P, Ferenczy A, Rohan TE. Viral load as a predictor of HPV-

associated cervical intraepithelial neoplasia. 43rd Congresso Nacional de Genética, Goiânia, Brazil, August

1997.

39. Allison PJ(§), Franco E, Locker D, Feine JS. The role of delays and anatomical site in determining disease

stage among oral and pharyngeal cancer patients. 5th International Congress on Oral Cancer, London, UK,

September 1997.

40. Bruneau J(§), Franco E, Lamothe F, Lachance N. Quand la mesure étalon est inaccessible: peut-on utiliser les

études de cohorte pour mesurer l’impact des interventions? Réunion Scientifique de l’Association des

Epidémiologistes de Langue Française; Epidémiologie et évaluation en toxicomanie. Lausanne, Switzerland,

September 1997.

41. Franco E, Kulaga S, Negassa A, Villa L, Ferenczy A, Rohan T. Longitudinal analysis of the association

between HPV and cervical intraepithelial neoplasia in a high risk area for cervical cancer. 16th International

Papillomavirus Conference, Siena, Italy, September 1997.

42. Rousseau MC(§), Franco E, Villa L, Rohan T. Determinants of incident cervical HPV infection with

oncogenic and non-oncogenic types. 16th International Papillomavirus Conference, Siena, Italy, September

1997.

43. Candeias J(§), Franco E, Villa L, Schiller J, Ferenczy A, Rohan T. Serological reactivity to HPV 16 capsid

antigens is predictive of persistent HPV infection and cervical intraepithelial neoplasia. 16th International

Papillomavirus Conference, Siena, Italy, September 1997.

44. Rahal P(§), Villa LL, Franco EL. Molecular variant analysis of HPV-16 and -18 isolates in a cohort of women

from a high risk area for cervical cancer. 16th International Papillomavirus Conference, Siena, Italy,

September 1997.

45. Camargo B(§), Franco EL. Prenephrectomy chemotherapy on Wilms tumor: Epidemiological, clinical and

surgical features. 29th Annual Meeting of the International Society of Paediatric Oncology, Istanbul, Turkey,

September 1997.

46. Candeias JMG(§), Thomann P, Franco EL, Villa LL, Schiller JT, Ferenczy A, Rohan TE. Serology to HPV 16

capsid antigens is predictive of persistent HPV infection and cervical intraepithelial neoplasia. VI Virológica 97,

Sociedade Brasileira de Virologia, Fortaleza, Brazil, November 1997.

47. Bernier L, Lamothe F, Bruneau J, Franco E, Cohen E. Genetic analysis of HIV infection among IDUs from

the Montreal Saint-Luc Cohort. 7th

Annual Canadian Conference on HIV/AIDS Research, Quebec City,

Canada, April/May 1998.

48. Lamothe F, Bruneau J, Franco E, Lachance N, Vincelette J. Needle exchange program attendance and places

of encounter for new sharing partners among injection drug users from the Saint-Luc Cohort. 7th

Annual

Canadian Conference on HIV/AIDS Research, Quebec City, Canada, April/May 1998.

49. Bruneau J(§), Lachance N, Franco E, Lamothe F, Desy M, Vincelette J, Soto J. Type of drugs associated with

HIV seroconversion among injection drug users in Montreal. The saint-Luc Cohort 1992-97. 7th

Annual


50. Bruneau J(§), Lachance N, Franco E, Lamothe F, Desy M, Vincelette J, Soto J. Injection behaviours associated

with HIV seroconversion among injection drug users in Montreal. The saint-Luc Cohort 1992-97. 7th

Annual


51. Franco EL, Negassa A, Kulaga S, Villa LL, Ferenczy A, Rohan TE. Human papillomavirus infection and

cervical intraepithelial neoplasia: a cohort study in a high risk area for cervical cancer. 31st Annual Meeting of

the Society for Epidemiologic Research, Chicago, USA, June 1998.

52. Lamothe F, Bruneau J, Franco E, Lachance N, Vincelette J. Places of encounter for new sharing partners

among needle exchange attenders. 12th

World AIDS Conference, Geneva, Switzerland, June/July 1998.

53. Bruneau J(§), Lachance N, Franco E, Lamothe F, Desy M, Vincelette J, Soto J. Injection behaviours in HIV

seroconversion among IV drug users in Montreal. 12th

World AIDS Conference, Geneva, Switzerland,

June/July 1998.

54. Rousseau MC(§), Franco EL, Villa LL, Rohan TE. Determinants of incident and cumulative genital HPV

infection. First International Conference on Human Papillomavirus Infection and Cervical Cancer, Montreal,

Canada, July 1998.


76

55. Richardson H(§), Pintos J, Coutlée F, Tellier P, Gravitt P, Franco E. Risk factors for persistent cervical human

papillomavirus infection in Montreal university students. First International Conference on Human

Papillomavirus Infection and Cervical Cancer, Montreal, Canada, July 1998.

56. Klam S(§), Arseneau J, Mansour M, Franco E, Ferenczy A. Endocervical canal evaluation using curettage

versus brush histology: a randomized clinical trial in women with cervical neoplasia. First International

Conference on Human Papillomavirus Infection and Cervical Cancer, Montreal, Canada, July 1998.

57. Latorre MR(§), Franco EL, Lopes A. Fatores prognósticos de pacientes com câncer de pênis. 4th Brazilian

Congress of Epidemiology, Rio de Janeiro, Brazil, August 1998.

58. Maciag P, Villa LL, Franco EL, Petzl-Erler ML. Association between HLA class II alleles and risk of

squamous cell carcinoma of the cervix and HPV infection in Brazilian women. 10th

International Congress of

Immunology, New Delhi, India, November 1998.

59. Coutlée F, Gravitt P, Franco E, Hankins C, Lapointe N, Voyer H. Non-isotopic detection of human

papillomavirus DNA in genital samples by the line blot assay. 66th Conjoint Meeting on Infectious Diseases,

Toronto, Canada, November 1998.

60. Candeias JMG(§), Thomann P, Pintos J, Franco EL, Ferenczy A, Villa LL. Serology to human papillomavirus

type 16 predicts risk of infection with HPV-16 and the development of cervical lesions. 9th National Meeting

of Virology, Brazilian Society of Virology, Sao Lourenco, Brazil, November 1998.

61. Trevisan A, Caballero OL, Franco EL, Villa LL. HPV viral load in paraffin-embedded tissues from genital

tumors. 9th National Meeting of Virology, Brazilian Society of Virology, Sao Lourenco, Brazil, November

1998.

62. Makni H(§), Kaiano J, Villa L, Lebrecque S, Dudley R, Storey A, Matlashewski G, Franco E. P53

polymorphism in codon 72 and risk of HPV-induced cervical neoplasia: Effect of inter-laboratory variation.

17th International Papillomavirus Conference, Charleston, USA, January 1999.

63. Richardson H(§), Pintos J, Coutlée F, Ferenczy A, Tellier P, Franco E. Risk factors for persistent cervical HPV

infection in Montreal university students. 17th International Papillomavirus Conference, Charleston, USA,

January 1999.

64. Rousseau MC(§), Franco EL, Villa LL, Prado JC, Rohan TE. Cumulative incidence case-control analysis of

risk factors for cervical HPV infections: A new approach to study the natural history of individual HPV types.

17th International Papillomavirus Conference, Charleston, USA, January 1999.

65. Caballero OL(§), Trevisan L, Villa LL, Ferenczy A, Franco EL. High viral load is associated with persistent

HPV infection and risk of cervical dysplasia. 17th International Papillomavirus Conference, Charleston, USA,

January 1999.

66. Sichero L, Rahal P, Villa LL, Ferenczy A, Franco EL. Molecular variants of HPV-16 and -18 associated with

high-grade cervical lesions. 17th International Papillomavirus Conference, Charleston, USA, January 1999.

67. Candeias JMG(§), Thomann P, Villa LL, Pintos J, Ferenczy A, Franco EL. Serology to HPV 16 capsid

antigens is predictive of persistent HPV infection and cervical intraepithelial neoplasia. 17th International

Papillomavirus Conference, Charleston, USA, January 1999.

68. Nonnenmacher B(§), Prolla JC, Nucci L, Schwartzmann G, Franco EL, Schiller J, Lowy D, Bozzetti MC.

Epidemiologic correlates of positive human papillomavirus serology among non-symptomatic women. 17th

International Papillomavirus Conference, Charleston, USA, January 1999.

69. Nonnenmacher B(§), Prolla JC, Nucci L, Schwartzmann G, Franco EL, Villa L, Lorincz A, Bozzetti MC.

Epidemiologic correlates of genital human papillomavirus infection among non-symptomatic women. 17th

International Papillomavirus Conference, Charleston, USA, January 1999.

70. Ratnam S, Ghatage P, Franco E, Ferenczy A. Utility of HPV testing in combination with Papanicolaou smear

in primary cervical cancer screening. 17th International Papillomavirus Conference, Charleston, USA, January

1999.

71. Schlecht NF(§) (for the MARSH International Collaborative Group). Meta-analysis of the repeatability of

sexual history and HPV infection: preliminary results from the MARSH study. 17th International

Papillomavirus Conference, Charleston, USA, January 1999.

72. McIntosh R, Ratnam S, Ghatage P, Franco E, Ferenczy A. Correlation of cytopathological diagnoses of

cervical smears with human papillomavirus testing. Annual Meeting of the US and Canadian Academy of

Pathology, San Francisco, USA, March 1999.

73. Villa LL, Caballero OL, Trevisan L, Ferenczy A, Franco EL. High viral load is associated with persistent

human papillomavirus infection and risk of cervical dysplasia. Keystone Symposia on Molecular and Cellular

Biology: Molecular Approaches to Human Vaccines, Snowbird, Utah, USA, April 1999.


77

74. Caballero OL(§), Trevisan L, Villa LL, Ferenczy A, Franco EL. High viral load is associated with persistent

HPV infection and risk of cervical dysplasia. XXVIII Reunião Anual, Sociedade Brasileira de Bioquímica e

Biologia Molecular, Caxambu, Brazil, May 1999.

75. Sichero L, Rahal P, Ferenczy A, Franco EL, Villa LL. Molecular variants of HPV-16 and -18 associated with

high-grade cervical lesions. XXVIII Reunião Anual, Sociedade Brasileira de Bioquímica e Biologia Molecular,

Caxambu, Brazil, May 1999.

76. Candeias JMG(§), Thomann P, Villa LL, Pintos J, Ferenczy A, Franco EL. Persistent HPV infection and

cervical intraepithelial neoplasia can be predicted by serology to HPV 16 capsid antigens. XXVIII Reunião

Anual, Sociedade Brasileira de Bioquímica e Biologia Molecular, Caxambu, Brazil, May 1999.

77. Makni H(§), Kaiano J, Villa L, Lebrecque S, Dudley R, Storey A, Matlashewski G, Franco E. P53

polymorphism in codon 72 and risk of HPV-induced cervical neoplasia: Effect of inter-laboratory variation.

XXVIII Reunião Anual, Sociedade Brasileira de Bioquímica e Biologia Molecular, Caxambu, Brazil, May 1999.

78. Trevisan L, Caballero OL, Franco EL, Villa LL. HPV viral load in paraffin-embedded tissues from genital

tumors. XXVIII Reunião Anual, Sociedade Brasileira de Bioquímica e Biologia Molecular, Caxambu, Brazil,

May 1999.

79. Ratnam S, Ghatage P, Franco E, Ferenczy A. HPV testing in combination with cervical cytology (HPV/Pap)

in primary cervical cancer screening. 7th

Biennial Meeting of the International Gynecologic Cancer Society,

Rome, Italy, September 1999.

80. Latorre MR(§), Braga PE, Rodrigues AL, Franco EL. Comparison between two statistical methods in survival

analysis. 15th

International Scientific Meeting of the International Epidemiological Association, Florence, Italy,

September 1999.

81. Trevisan A, Caballero OL, Franco EL, Villa LL. HPV viral load in paraffin-embedded tissues from genital

tumors. 45th National Congress of Genetics, Gramado, Brazil, October 1999.

82. Schlecht NF(§), Franco EL, Negassa A, Villa LL, Ferenczy A, Rohan TE. Longitudinal data analysis of the

association between HPV and cervical intraepithelial neoplasia in Southern Brazil. EUROGIN 2000, 4th

International Congress on Lower Genital Tract Infections and Neoplasia, Paris, France, April 2000.

83. Franco E, Ratnam S, Ferenczy A, Walter S, Macaskill P. HPV testing for primary screening of cervical cancer

precursors in Newfoundland. EUROGIN 2000, 4th International Congress on Lower Genital Tract Infections

and Neoplasia, Paris, France, April 2000.

84. Kornegay J, Shepard A, Coutlée F, Hankins C, Lapointe N, Franco E, Richardson H. Detection of genital

HPV from cervical specimens using a generic probe in a 96-well format. EUROGIN 2000, 4th International

Congress on Lower Genital Tract Infections and Neoplasia, Paris, France, April 2000.

85. Brogly S(§), Franco E, Lamothe F, Bruneau J. Behaviour changes following an HIV positive test result among

Montreal injection drug users. CAHR 2000, 9th Annual Conference on HIV/AIDS Research, Montreal, April

2000.

86. Tran-thanh D, Provencher D, Drouin P, Dubuc-Lissoir J, Gauthier P, Franco E, Kessous-Elbaz A, Allaire G,

Vauclair R, Coutlée F. Rôle du virus Herpes simplex type 2 dans les lésions pré- néoplasiques et néoplasiques

du col utérin. Congrès de l’Association Canadienne Française d’Avancement de la Science, Montreal, May

2000.

87. Schlecht NF(§), Franco E, Villa L, Ferenczy A. Longitudinal data analysis of the association between HPV

and cervical intraepithelial neoplasia in southern Brazil. 18th International Papillomavirus Conference,

Barcelona, Spain, July 2000.

88. Sichero L, Villa L, Rahal P, Caballero O, Ferenczy A, Rohan T, Franco E. Molecular variants of human

papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. 18th International

Papillomavirus Conference, Barcelona, Spain, July 2000.

89. Rousseau MC(§), Franco E, Villa L. Natural history of cervical infections with multiple HPV types. 18th

International Papillomavirus Conference, Barcelona, Spain, July 2000.

90. Schlecht NF(§), Franco E, Villa L, Ferenczy A, Greenberg M. HPV persistence and viral load as correlates of

cervical abnormalities detected by cervicography and cytology. 18th International Papillomavirus Conference,

Barcelona, Spain, July 2000.

91. Thomann P, Maciag P, Franco E, Villa L. IgM-seroreactivity to HPV-16 capsids is associated with low

oncogenic risk HPV infections. 18th International Papillomavirus Conference, Barcelona, Spain, July 2000.

92. Maciag P(§), Schlecht N, Souza P, Franco E, Petzl-Erler M, Villa L. Major histocompatibility complex class ii

polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women. 18th

International Papillomavirus Conference, Barcelona, Spain, July 2000.


78

93. Richardson H(§), Franco E, Coutlée F, Tellier P. Risk factors for incident cervical human papillomavirus

infection in Montreal university students. 18th International Papillomavirus Conference, Barcelona, Spain, July

2000.

94. Tran-Thanh D, Provencher D, Franco E, Kessous A, Dipaolo J A, Drouin P, Dubuc-Lissoir J, Gauthier P,

Vauclair R, Allaire G, Gravitt P, Kornegay J, Coutlée F. Herpes simplex virus type II is not a cofactor to

human papillomavirus in high-grade lesions of the uterine cervix. 40th Interscience Conference on

Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 2000.

95. Villa L, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, Franco E. Molecular variants of human

papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. Molecular Biology and New

Therapeutic Strategies: 5th

Joint Conference of the American Association for Cancer Research and the

Japanese Cancer Association, Maui, Hawaii, USA, February 2001.

96. Brogly SB(§), Palepu A, Franco E, Bruneau J. The Injection Drug User Quality of Life Scale (IDUQOL). 1st

Canadian Network for Vaccines and Immunotherapeutics (CANVAC) Annual Scientific Meeting, Lake

Louise, Canada, April 2001.

97. Carvalho AL(§), Pintos J, Schlecht N, Oliveira BV, Fava AS, Curado MP, Kowalski LP, Franco EL. Factors

influencing patient and professional delay in oral cancer diagnosis. 7th International Congress on Oral Cancer,

The Hague, Netherlands, April 2001.

98. Carvalho AL(§), Pintos J, Schlecht N, Oliveira BV, Fava AS, Curado MP, Kowalski LP, Franco EL. Incidence

of second primary tumors in a cohort of head and neck cancer patients in Brazil. 7th International Congress on

Oral Cancer, The Hague, Netherlands, April 2001.

99. Carvalho AL(§), Pintos J, Schlecht N, Oliveira BV, Fava AS, Curado MP, Kowalski LP, Franco EL.

Predictive factors for diagnosis of an advanced stage upper aerodigestive tract cancer. Annual Meeting of the

American Head and Neck Cancer Society, Pal Desert, USA, May 2001.

100. Lambrinos A(§), Steinberg S, Richardson H, Franco E. Attachment, abuse, and psychopathology indicators –

Human papillomavirus infection. Annual Meeting of the American Psychiatric Association, New Orleans,

USA, May 2001.

101. Brogly SB(§), Palepu A, Franco E, Bruneau J. Development of an instrument to measure the quality of life of

injection drug users: the Injection Drug User Quality of Life Scale (IDUQOL). 10th Annual Canadian

Conference on HIV/AIDS Research, Toronto, Canada, May-June 2001.

102. Richardson H(§), Franco EL, Rousseau MC, Coutlée F, Tellier P. Determinants of acquisition and persistence

of cervical human papillomavirus infections in Montreal university students. 2001 Congress of Epidemiology,

Society for Epidemiologic Research, Toronto, Canada, June 2001.

103. Rousseau MC(§), Franco EL, Villa LL, Rohan TE. Is co-infection with human papillomavirus (HPV) a

predictor for acquisition of other HPV types? 2001 Congress of Epidemiology, Society for Epidemiologic

Research, Toronto, Canada, June 2001.

104. Schlecht NF(§), Franco EL, Villa LL, Ferenczy A, Rohan TE. Longitudinal data analysis of the association

between human papillomavirus and squamous intraepithelial lesions in southern Brazil. 2001 Congress of

Epidemiology, Society for Epidemiologic Research, Toronto, Canada, June 2001.

105. Nishimoto IN(§), Pintos J, Schlecht NF, Torloni H, Carvalho AL, Kowalski LP, Franco EL. Assessment of

selection bias in a hospital-based case-control study of upper aero-digestive tract cancers in Southern Brazil.

2001 Congress of Epidemiology, Society for Epidemiologic Research, Toronto, Canada, June 2001.

106. Trevisan A, Schlecht N, Rousseau MC, Sobrinho J, Prado J, Rohan T, Franco E, Villa L. Correlates of viral

load among HPV-infected women enrolled in a cohort study in Brazil. 19th International Papillomavirus

Conference, Florianopolis, Brazil, September 2001.

107. Pintos J(§), Ratnam S, MacIntosh R, Francis P, Goldsworthy J, Coutlée F, Franco E. HPV DNA testing as an

ancillary tool for the evaluation of cervical cancer screening by Pap cytology. 19th International

Papillomavirus Conference, Florianopolis, Brazil, September 2001.

108. Schlecht N(§), Robitaille J, Ferreira S, Miyamura R, Duarte-Franco E, Rohan T, Ferenczy A, Villa L, Franco

E. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. 19th

International Papillomavirus Conference, Florianopolis, Brazil, September 2001.

109. Duarte-Franco E, Robitaille J, Santos M, Miyamura R, Rohan T, Ferenczy A, Villa L, Franco E. HPV

infection as a predictor of the cervical lesion outcome among women with benign cellular changes on Pap

cytology. 19th International Papillomavirus Conference, Florianopolis, Brazil, September 2001.

110. Thomann P(§), Candeias JMG, Trevisan A, Rohan T, Villa LL, Franco EL. Serological reactivity to capsid

antigens of HPV 16 and the occurrence of HPV infection of low and high viral load in the Ludwig-McGill

Cohort Study. 19th International Papillomavirus Conference, Florianopolis, Brazil, September 2001.


79

111. Rousseau MC(§), Ferreira S, Myamura R, Villa LL, Rohan TE, Franco EL. Can co-infection with multiple

HPV types predict acquisition of other types and persistence of existing HPV infections? 19th International


112. Rousseau MC(§), Trevisan A, Villa LL, Rohan TE, Franco EL. Viral load as a predictor of HPV infection

persistence among women in the Ludwig-McGill cohort study in Sao Paulo, Brazil. 19th International


113. Schlecht N(§), Trevisan A, Rohan T, Ferenczy A, Villa L, Franco E. Viral load as a predictor of lesion grade

severity in cervical intraepithelial neoplasia. 19th International Papillomavirus Conference, Florianopolis,

Brazil, September 2001.

114. Sangwa-Lugoma G(§), Herrero R, Muñoz N, Sankaranarayanan R, Brogly S, Schlecht N, Robitaille J, Coutlée

F, Franco E. Epidemiology of human papillomavirus and cervical neoplasia in Congo: The results of a pilot

study. 19th International Papillomavirus Conference, Florianopolis, Brazil, September 2001.

115. Sichero L, Junes K, Souza PSA, Maciag PC, Franco EL, Villa LL. Diverse distribution of human

papillomavirus type 16 E6 variants in cervical carcinomas and normal cervical specimens from Brazilian

women. 19th International Papillomavirus Conference, Florianopolis, Brazil, September 2001.

116. Maciag PC(§), Souza PSA. Schlecht NF, Rabachini T, Rohan T, Franco EL, Villa LL.Valine at position 86 of

the HLA-DR chain is associated with a lower risk for HPV positivity and persistence. 19th International


117. Koushik A(§), Coutlée F, Provencher D, Kessous A, DiPaolo J, Drouin P, Franco E. HPV and infectious

cofactors in cervical neoplasia: a cross-sectional study. 19th International Papillomavirus Conference,

Florianopolis, Brazil, September 2001.

118. Richardson H(§), Rousseau MC, Tellier P, Coutlée F, Franco E. The role of modifiable risk factors in the

dynamics of incident and persistent cervical HPV infections. 19th International Papillomavirus Conference,


119. Rousseau MC(§), Ghosh A, Morse R, Sichero L, Matlashewski G, Villa LL, Rohan TE, Ferenczy A, Franco

EL. p53 codon 72 polymorphism and early events in cervical carcinogenesis among Brazilian women. 19th

International Papillomavirus Conference, Florianopolis, Brazil, September 2001.

120. Maciag PC(§), Schlecht NF, Souza PSA, Rabachini T, Rohan T, Franco EL, Villa LL. Polymorphism of the

human leukocyte antigen drb1 and dqb1 genes plays a role in the natural history of human papillomavirus

infection. 19th International Papillomavirus Conference, Florianopolis, Brazil, September 2001.

121. Giuliano AR, Siegel EM, Roe D, Ferreira S, Prado JC, Duarte-Franco E, Villa LL, Rohan TE, Franco EL.

Dietary carotenoid intake and risk of persistent type-specific HPV infection among women in the Ludwig-

McGill Natural History Cohort. 19th International Papillomavirus Conference, Florianopolis, Brazil,

September 2001.

122. Souza PSA, Maciag PC, Franco EL, Petzl-Erler ML, Villa LL. Interaction between polymorphism of the

human leukocyte antigen and HPV-16 variants on the risk of invasive cervical cancer. 19th International


123. Barbosa ACC, Soares F, Franco EL, Ferenczy A, Villa LL. Genomic imbalances in microdissected cells from

Pap smears detected by comparative genomic hybridization. 19th International Papillomavirus Conference,


124. Trevisan A, Sobrinho JSP, Mann JC, Rohan T, Franco EL, Villa LL. Correlates of viral load among HPV

infected women enrolled in a cohort study in Brazil. XII Encontro Nacional de Virologia e 4th Encontro de

Virologia do Mercosul, Caldas Novas, Brazil, November 2001.

125. Siegel EM, Roe D, Papenfuss M, Marshall JR, Craft N, Villa LL, Franco EL, Giuliano AR. Characterization

of serum retinoids from multiple measures in the Ludwig-McGill HPV Natural History Cohort. 93rd Annual

Meeting of the American Association for Cancer Research, San Francisco, USA, April 2002.

126. Koushik A(§), Coutlée F, Provencher D, Kessous A, DiPaolo J, Drouin P, Franco E. A case-control analysis of

sexually-transmitted infections and cervical neoplasia. 16th

World Congress of Epidemiology of the

International Epidemiological Association, Montreal, Canada, August 2002.

127. Schlecht N(§), Trevisan A, Rohan T, Ferenczy A, Villa L, Franco E. Viral burden as a predictor of lesion

incidence in cervical intraepithelial neoplasia. 16th

World Congress of Epidemiology of the International

Epidemiological Association, Montreal, Canada, August 2002.

128. Trevisan A, Schlecht N, Rohan T, Ferenczy A, Franco E, Villa L. Physical state of HPV-16 DNA and viral

load in cervical smears from the Ludwig-McGill cohort. 20th International Papillomavirus Conference, Paris,

France, October 2002.


80

129. Rabachini T, Koushik A, Ghosh A, Morse R, Matlashewski G, Ferenczy A, Rohan T, Franco E, Villa L. P53

Codon 72 polymorphism and HPV persistence in cervical neoplasia. 20th International Papillomavirus

Conference, Paris, France, October 2002.

130. Rabachini T, Koushik A, Ghosh A, Morse R, Matlashewski G, Ferenczy A, Rohan T, Franco E, Villa L. The

effect of inter-methodology variation in P53 codon 72 polymorphism assessment. 20th International

Papillomavirus Conference, Paris, France, October 2002.

131. Goldie S, Grima D, Kohli M, Wright T, Weinstein M, Franco E. The potential impact of a human

papillomavirus 16/18 vaccine. 20th International Papillomavirus Conference, Paris, France, October 2002.

132. Goldie S, Grima D, Kohli M, Wright T, Weinstein M, Franco E. A comprehensive natural history model of

human papillomavirus (HPV) Infection and cervical cancer: Potential impact of an HPV 16/18 vaccine. 24th

Annual Meeting of the Society for Medical Decision Making, Baltimore, USA, October 2002.

133. Goldie S, Grima D, Kohli M, Wright T, Weinstein M, Franco E. A comprehensive natural history model of

human papillomavirus (HPV) Infection and cervical cancer: Potential impact of an HPV 16/18 vaccine. 5th

Annual Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR),

Rotterdam, The Netherlands, November 2002.

134. Koushik A(§), Rabachini T, Rousseau MC, Ghosh A, Matlashewski G, Villa L, Franco E. P53 codon 72

polymorphism and persistence of cervical infection by human papillomavirus. 11th Annual Meeting of the

International Genetic Epidemiology Society, New Orleans, USA, November 2002.

135. Brogly S(§), Bruneau J, Palepu A, Franco E. Quality of life and public health program use of Montreal cocaine

and heroin injection drug users. 12th Annual Canadian Conference on HIV/AIDS Research, Halifax, Canada,

April 2003.

136. Rouleau D, Trépanier JM, Vézina S, Ghattas G, Coté P, Coté B, Poliquin M, MacLeod JD, Aho J, Allaire G,

Kornegay J, Franco E, Coutlée F. A wide spectrum of genital HPV types cause anal infection and disease in

HIV-seropositive men. 12th Annual Canadian Conference on HIV/AIDS Research, Halifax, Canada, April

2003.

137. Ratnam S, Franco E. HPV testing in primary cervical cancer screening: A Canadian experience. EUROGIN

2003, 5th

International Congress on Lower Genital Tract Infections and Neoplasia, Paris, France, April 2003.

138. Haben M(§), Kost K, Desy M, Gesser R, Timm C, Franco E. Videostrobolaryngoscopy in a residency training

program. 106th Annual Meeting/COSM of The American Laryngological, Rhinological and Otological

Society, Nashville, TN, USA, May 2003.

139. Trevisan A, Schlecht N, Rohan T, Ferenczy A, Franco E, Villa LL. Physical state of HPV-16 DANN and viral

load in cervical smears. XXXII Reunião Anual da Sociedade Brasileira de Bioquimica e Biologia Molecular –

SBBq, Caxambu, Brazil, May 2003.

140. Rousseau MC(§), Abrahamowicz M, Villa LL, Costa MC, Rohan TE, Franco EL. Predictors of cervical

infection with multiple human papillomavirus types in a cohort of Brazilian women. Biennial Meeting of the

Canadian Society of Epidemiology and Biostatistics, Halifax, NS, Canada, June 2003.

141. Koushik A(§), Platt RW, Franco EL. Cervical neoplasia and the p53 codon 72 polymorphism: A systematic

review. Biennial Meeting of the Canadian Society of Epidemiology and Biostatistics, Halifax, NS, Canada,

June 2003.

142. Mayrand M-H(§), Duarte-Franco E, Coutlée F, Ratnam S, Rodrigues I, Walter SD, Franco EL. HPV testing

versus Pap cytology in screening cervical cancer precursors: The Cervical Cancer Screening Trial. Biennial

Meeting of the Canadian Society of Epidemiology and Biostatistics, Halifax, NS, Canada, June 2003.

143. Richardson H(§), Abrahamowicz M, Tellier P, Kelsall G, Berger R, Ferenczy A, Coutlée F, Franco EL.

Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections.

Biennial Meeting of the Canadian Society of Epidemiology and Biostatistics, Halifax, NS, Canada, June 2003.

144. Spence A(§), Duarte-Franco E, Coutlée F, Drouin P, Ferenczy A, Band P, Deschamps M, Ghadirian P, Franco

E. Pap Cytology Screening Failure: Influences of the Patient, Physician and Laboratory. Biennial Meeting of

the Canadian Society of Epidemiology and Biostatistics, Halifax, NS, Canada, June 2003.

145. Pintos J(§), Black MJ, Sadeghi N, Viscidi RP, Ghadirian P, Coutlée F, Franco EL. Human papillomavirus

infection and oral cancer: a case-control study. Biennial Meeting of the Canadian Society of Epidemiology and

Biostatistics, Halifax, NS, Canada, June 2003.

146. Lau S(§), Pintos J, Villa L, Ferenczy A, Franco E. HPV DNA detection as a predictor of lesion progression

among women with ASCUS cytological diagnoses. 13th

Annual Meeting, Society of Obstetricians and

Gynecologists of Canada, Prince Edward Island, Canada, June 2003.

147. Goldie S, Kohli M, Grima D, Weinstein M, Wright T, Bosch FX, Franco E. Projected clinical benefits and

cost-effectiveness of an HPV 16/18 vaccine. 15th Biennial Congress of the International Society for Sexually


81

Transmitted Diseases Research, Ottawa, Canada, July 2003.

148. Duarte-Franco E, Mayrand MH, Rodrigues A, Coutlée F, Ratnam S, Rajan R, Rodrigues I, Walter SD, Franco

EL, for the CCaST Study Group. The cervical cancer screening trial: HPV testing versus Pap cytology in

screening cervical cancer precursors. 15th Biennial Congress of the International Society for Sexually

Transmitted Diseases Research, Ottawa, Canada, July 2003.

149. Haben M(§), Kost K, Desy M, Gesser R, Timm C, Franco E. Stroboscopic Variations in the Clinical Voice

Practice. Annual meeting of the American Academy of Otolaryngology-Head and Neck Surgery, Orlando,

USA, September 2003.

150. Healey S(§), Aronson KJ, Mao Y, Franco EL. Human papillomavirus and cervical dysplasia in Nunavut:

Prelude to a screening strategy. 12th International Congress of Circumpolar Health, Nuuk, Greenland,

September 2003.

151. Trevisan A, Schlecht N, Rohan T, Ferenczy A, Franco EL, Villa LL. Viral load and physical state of HPV-16

DNA in cervical smears. XIV Encontro Nacional de Virologia, Florianópolis, Brazil, September 2003.

152. Siegel EM, Craft N, Roe DJ, Ferreira S, Duarte-Franco E , Villa LL, Franco EL, Giuliano AR. Factors

Associated with Circulating Endogenous Retinoic Acid Among Women: Ludwig-McGill HPV Natural History

Cohort . 2nd American Association for Cancer Research's International Frontiers in Cancer Prevention

Research Conference, Phoenix, Arizona, USA, October 2003.

153. Rodrigues I, Mayrand MH(§),Duarte E, Coutlée F, Ratnam S, Walter SD, Franco EL. HPV testing versus Pap

cytology for screening cervical cancer precursors: the Canadian Cervical Cancer Screening Trial (CCCaST).

Annual Meeting of the North American Primary Care Research Group, Banff, Canada, October 2003.

154. Brassard P, Proulx M, Coutlée F, Roger M, Franco E. Prevalence of human papillomavirus infection in

aboriginal women of Nunavik, Northern Québec. 2003 Conjoint Meeting of the Canadian Association for

Clinical Microbiology And Infectious Diseases, Montreal, Canada, November 2003.

155. Goldie S, Kohli M, Grima D, Wright T, Weinstein M, Bosch FX, Franco E. Projected clinical benefits and

cost-effectiveness of an HPV 16/18 vaccine. 6th Annual European Congress of the International Society for

Pharmacoeconomics and Outcomes Research (ISPOR), Barcelona, Spain, November 2003.

156. Mahmud SM(§), Franco EL, Aprikian AG. Prostate cancer and use of non-steroidal anti-inflammatory drugs:

systematic review and meta-analysis. Congrès de l'Association des urologues du Québec, Quebec City,

November 2003.

157. Carvalho A(§), Pintos J, Schlecht N, Oliveira B, Fava A, Curado MP, Kowalski LP, Franco EL. Age and

alcohol consumption influence prognosis of head and neck cancer patients. 9th

International Congress on Oral

Cancer, Melbourne, Australia, November 2003.

158. Mahmud SM(§), Franco EL, Aprikian AG. Prostate cancer and use of non-steroidal anti-inflammatory drugs:

systematic review and meta-analysis. 7th International Symposium on Predictive Oncology, International

Society for Predictive Oncology, Nice, France, February, 2004.

159. Richardson H(§), Coutlée F, Abrahamowicz M, Tellier P, Kelsall G, Voyer H, Ferenczy A, Franco EL.

Infection with HPV 16 or HPV 18 variants and risk of low-grade squamous intraepithelial lesions in young

women. 7th International Symposium on Predictive Oncology, International Society for Predictive Oncology,

Nice, France, February 2004.

160. Duarte-Franco E, Mayrand MH, Coutlée F, Ratnam S, I Rodrigues, Walter SD, Ferenczy A, Franco EL.

Preliminary results from the Canadian Cervical Cancer Screening Trial (CCCaST Study). 7th International

Symposium on Predictive Oncology, International Society for Predictive Oncology, Nice, France, February,

2004.

161. Fontaine J, Palefsky J, Rouleau D, Costa M, Holly E, Efird J, Darragh T, Trépanier JM, Ghattas G, Allaire G,

Franco E, Coutlée F. High viral loads of HPV-16 E6 and HPV-16 integrated forms are associated with anal

intraepithelial lesions in HIV-seropositive men. 21st International Papillomavirus Conference, Mexico City,

Mexico, February 2004.

162. Duarte-Franco E, Mahmud S, Robitaille J, Santos M, Rohan T, Ferenczy A, Villa L, Franco E. Cervical

inflammation as predictors of incident HPV infection in a long-term cohort study of women of screening age.

21st International Papillomavirus Conference, Mexico City, Mexico, February 2004.

163. Goldie S, Kohli M, Grima D, Wright T, Weinstein M, Bosch FX, Franco E. The potential impact of waning of

vaccine-induced immunity against human papillomavirus 16/18. 21st International Papillomavirus Conference,

Mexico City, Mexico, February 2004.

164. Sichero L, Franco EL, Villa LL. Different p105 promoter activity among naturally occurring variants of

human papillomavirus type 18. 21st International Papillomavirus Conference, Mexico City, Mexico, February

2004.


82

165. Mayrand MH(§), Duarte-Franco E, Coutlée F, Ratnam S, Rodrigues I, Walter SD, Franco EL, for the cccast

Study Group. HPV testing versus Pap cytology in screening cervical cancer precursors: Design and baseline

patient characteristics of The Canadian Cervical Cancer Screening Trial (cccast). 21st International

Papillomavirus Conference, Mexico City, Mexico, February 2004.

166. Prado JCM, Junes KS, Franco EL, Villa LL. HPV-58 variants in women from the Ludwig-McGill cohort

study. 21st International Papillomavirus Conference, Mexico City, Mexico, February 2004.

167. Robinson K(§), Mahmud S, Richardson H, Roger M, Coutlée F, Franco E. HLA associations with acquisition

and persistence of cervical HPV infection in a cohort of female university students in Montreal. 21st

International Papillomavirus Conference, Mexico City, Mexico, February 2004.

168. Mahmud S(§), Franco E. Effects of study design and test sensitivity and specificity on the accuracy of

estimating infection clearance time in longitudinal studies of HPV natural history. 21st International

Papillomavirus Conference, Mexico City, Mexico, February 2004.

169. Siegel EM, Giuliano AR, Craft N, Ferreira S, Duarte-Franco E, Villa LL, Franco EL. Circulating antioxidant

nutrients and clearance of HPV infection among women in the Ludwig-McGill natural history cohort. 21st

International Papillomavirus Conference, Mexico City, Mexico, February 2004.

170. Siegel EM, Craft N, Ferreira S, Duarte-Franco E, Villa LL, Franco EL, Giuliano AR. Effect of endogenous

retinoic acid on type-specific HPV clearance in women participating in the Ludwig-McGill HPV natural

history cohort. 21st International Papillomavirus Conference, Mexico City, Mexico, February 2004.

171. Thomann P(§), Mahmud SM, Pastrana DV, Schiller JT, Trevisan A,Villa LL, Franco EL. Pseudovirus

neutralizing serum antibodies and vlp ELISA igg seroreactivity to HPV16: Do they indicate a protective

immune response? 21st International Papillomavirus Conference, Mexico City, Mexico, February 2004.

172. Trevisan A(§), Schlecht NF, Mahmud SM, Ferenczy A, Villa LL, Franco EL. Role of integration of HPV16-

dna in the natural history of cervical neoplasia. 21st International Papillomavirus Conference, Mexico City,

Mexico, February 2004.

173. Trevisan A(§), Schlecht NF, Ferreira S, Sichero L, Franco EL, Villa LL. Correlates of viral load variability by

real-time and low-stringency pcr testing of cervical smears. 21st International Papillomavirus Conference,

Mexico City, Mexico, February 2004.

174. Nicolau B(§), Allison P, Archer J, Kowalski LP, Hier M, Black M, Franco E. The life course approach to

studying the etiology of head and neck cancer. 58th Annual Meeting of the Canadian Society of

Otolaryngology, Quebec City, Canada, May 2004.

175. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E. Understanding the impact of

waning of vaccine-induced immunity against human papillomavirus. 1st Annual Meeting of the Canadian

Association for Health Services and Policy Research, Montreal, Canada, May 2004.

176. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E. Potential impact of waning of

vaccine-induced immunity against human papillomavirus 16/18. 9th Annual International Meeting of the

International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Arlington, USA, May 2004.

177. Vilela L(§), Allison P, Franco E, Nicolau B, Edgar L, Hier M, Black M. Coping with head and neck cancer:

Results of a feasibility study. 58th Annual Meeting of the Canadian Society of Otolaryngology-Head & Neck

Surgery, Quebec City, Canada, May 2004.

178. Goffin F, Mayrand MH, Gauthier P, Alobaid A, Provencher D, Drouin P, Lussier C, Franco E, Coutlée F.

Association between history of VIN and vulvar and/or cervical HPV infection. Annual Clinical Meeting of the

Society of Obstetrics & Gynecology of Canada, Edmonton, Canada, June 2004.

179. Lau S(§), Pintos J, Villa L, Ferenczy A, Franco E. HPV DNA detection as a predictor of lesion progression

among women with ASCUS cytological diagnoses. Annual Clinical Meeting of the Society of Obstetrics &

Gynecology of Canada, Edmonton, Canada, June 2004.

180. Nicolau BF(§), Allison PJ, Archer J, Kowalski LP, Hier M, Black M, Franco E. The life course approach to

studying the etiology of head and neck cancer. 6th International Conference on Head and Neck Cancer of the

American Head and Neck Society, Washington, USA, August 2004.

181. Allison PJ, Nicolau B, Archer J, Hier M, Black M, Franco E. The life course approach to studying the etiology

of head and neck cancer. Annual Congress of the Association d’otolrhinolaryngologie et de chirurgie cervico-

faciale du Quebec, Canada, September 2004.

182. Duarte-Franco E, Mayrand MH, Coutlée F, Ratnam S, I Rodrigues, Walter SD, Franco EL. The Canadian

Cervical Cancer Screening Trial (CCCaST) of HPV testing versus Pap cytology. EUROGIN 2004:

International Experts’ Meeting on HPV Infection and Cervical Cancer Prevention, Nice, France, October 2004.

183. Nicolau B, Allison PJ, Franco E. The life-course approach to studying the aetiology of oral cancer. 34th

Annual Meeting of the International Association for Dental Research, Baltimore, USA, March 2005.


83

184. Rouleau D, Mahmud S, Trépanier JM, Ghattas G, Vézina S, Coté P, Coté B, Poliquin M, MacLeod J, Allaire

G, Kornegay J, Franco E, Coutlée F. Determinants of anal intraepithelial neoplasia (AIN) in HIV-seropositive

men vary with antiretroviral therapy. AMMI Canada Meeting. Ottawa, Canada, April 2005.

185. Rousseau MC, Mahmud S, Ferreira S, Villa LL, Franco EL. Independent effect of age on human

papillomavirus infection occurrence in a cohort of Brazilian women. 22nd International Papillomavirus

Conference, Vancouver, Canada, May 2005.

186. Mayrand MH(§), Duarte E, Rodrigues I, Walter SD, Ratnam S, Coutlée F, Franco EL. HPV vs Pap testing for

screening cervical cancer and its high grade precursors: Preliminary efficacy data from the Canadian Cervical

Cancer Screening Trial (CCCaST). 22nd International Papillomavirus Conference, Vancouver, Canada, May

2005.

187. Mahmud S(§), Koushik A, Duarte E, Costa J, Fontes G, Bicho M, Coutlée F, Franco E. Haptoglobin

phenotype and risk of cervical neoplasia and HPV infection: a case-control study. 22nd International

Papillomavirus Conference, Vancouver, Canada, May 2005.

188. Mahmud S(§), Trevisan A, Baggio M, Galan L, Rohan T, Villa L, Franco EL. Effect of menstrual cycle on

HPV detection and viral load. 22nd International Papillomavirus Conference, Vancouver, Canada, May 2005.

189. Rouleau D, Mahmud S, Trepanier JM, Ghattas G, Allaire G, Kornegay J, MacLeod J, Franco EL, Coutlée F.

Anal intraepithelial neoplasia and HPV infection in HIV-seropositive men in the era of HAART. 22nd

International Papillomavirus Conference, Vancouver, Canada, May 2005.

190. Coutlée F, Franco E, Schlag P, Boyle S, Kornegay J, Hankins C, Rouleau D, Forest P. Detection and typing of

37 HPV types in anogenital samples using the linear array HPV test. 22nd International Papillomavirus


191. Jenkins D, Lindsay L, Wieting S, Zahaf T, Dubin G, Franco EL. Natural history of incident and persistent

HPV infection and pre-invasive cervical lesions in 15-25 year old women from North America and Brazil.

22nd International Papillomavirus Conference, Vancouver, Canada, May 2005.

192. Spence A(§), Trottier H, Duarte E, Mahmud S, Rohan T, Ferenczy A, Villa L, Franco E. Cigarette smoking,

HPV status, and cervical lesions: a cumulative case-control analysis using repeated measurements of smoking

and viral and lesion status. 22nd International Papillomavirus Conference, Vancouver, Canada, May 2005.

193. Kim J, Kuntz K, Goldhaber-Fiebert J, Mahmud S, Villa L, Franco E, Goldie S. Calibration of a natural history

model of cervical cancer using longitudinal primary data. 22nd International Papillomavirus Conference,

Vancouver, Canada, May 2005.

194. Burchell AN(§), Richardson H, Mahmud S, Trottier H, Kelsall G, Tellier PP, Coutlée F, Franco EL. High

probability of human papillomavirus transmission per act of intercourse: stochastic computer simulation of

observed incidence among female university students in Montreal, Canada. 22nd International Papillomavirus


195. Sangwa-Lugoma G(§), Mahmud S, Nasr S, Ferenczy A, Lorincz A, Liaras J, Kayembe PK, Tozin RR, Franco

EL. Visual inspection, cytology, and HPV testing as cervical cancer screening strategies in a primary health

care setting in Africa. 22nd International Papillomavirus Conference, Vancouver, Canada, May 2005.

196. Khouadri S, Gagnon S, Koushik A, Richardson H, Ferreira S, Simao J, Matlashewski G, Villa LL, Franco E,

Coutlée F. HPV-33 polymorphism is associated with high-grade cervical lesions of the uterine cervix. 22nd


197. Brassard P, Steensma C, Coutlée F, Roger M, Kornegay J, Franco EL. Epidemiology of human

papillomavirus infection in aboriginal women of Nunavik, Quebec. 22nd International Papillomavirus


198. Kines R(§), Odunsi K, Trottier H, Koh S, Lele S, Franco E, Thanavala Y. An analysis of the influence of the

immune response on viral clearance and disease regression. 22nd International Papillomavirus Conference,

Vancouver, Canada, May 2005.

199. Trottier H(§), Kines R, Lele S, Odunsi K, Franco E, Thanavala Y. Human papillomavirus and time to

regression of cytological abnormalities. 22nd International Papillomavirus Conference, Vancouver, Canada,

May 2005.

200. Bernard LM, Lindsay L, Kohli M, Bosch X, Franco E. Potential impact of a human papillomavirus 16/18

vaccine on cervical cancer incidence and mortality in Poland: a population-based model. 22nd International


201. Brassard P, Steensma C, Roger M, Coutlée F, Kornegay J, Franco EL. HLA status and its association with

persistent and high risk human papillomavirus infection in Aboriginal women of Nunavik, Quebec. 22nd


202. Stuart G, Taylor G, Bancej CM, Beaulac J, Colgan T, Franco EL, Kropp RY, Lotocki R, Mai V, McLachlin


84

CM, Onysko J, Martin RE Stanimir G, Romanowski B, Phelan J, Payne P, Hutchison T. The 2003 Pan-

Canadian forum on cervical cancer prevention and control consensus recommendations. 22nd International


203. Ferko N, Kohli M, Bosch FX, Franco EL. Clustering countries according to sociodemographic and

behavioural indicators of human papillomavirus infection and cervical cancer risk. 22nd International


204. Mahmud SM(§), Franco EL, Aprikian AG. Non-Steroidal Anti-Inflammatory Drug (NSAID) use and Prostate

Cancer in a High-Risk Population. American Urological Association 2005 Annual Meeting, San Antonio,

Texas, USA, May 2005.

205. Mahmud SM(§), Franco EL, Aprikian AG. Non-Steroidal Anti-Inflammatory Drug (NSAID) use and Prostate

Cancer in a High-Risk Population. The Canadian Urological Association’s 60th Annual Meeting, Ottawa,

Canada, June 2005.

206. Mayrand MH(§), Rodrigues I, Duarte E, Walter SD, Ratnam S, Coutlée F, Franco EL. HPV DNA detection

with Hybrid capture is more sensitive than Pap testing for screening cervical cancer and its high grade

precursors: Preliminary results from the Canadian Cervical Cancer Screening Trial (CCCaST). Annual

Meeting of the North American Primary Care Research Group, Quebec City, Canada, October 2005.

207. Siegel EM, Craft N, Duarte-Franco EF, Villa LL, Franco EL, Giuliano AR. Associations between serum

carotenoids and tocopherols and type-specific HPV persistence within the Ludwig-McGill Cohort Study. 4th

Annual AACR Frontiers in Cancer Prevention Research, Baltimore, USA, October 2005.

208. Kines R(§), Odunsi K, Trottier H, Koh S, Kornegay J, Lele S, Franco E, Thanavala Y. The cellular immune

response to human papillomavirus E7: A possible predictor of viral persistence and delayed cervical disease

regression. Upstate New York Immunology Conference, Bolton Landing, New York, USA, October 2005.

209. Sichero L, Franco EL, Villa LL. Different p105 Promoter Activities Among Natural Variants of Human

Papillomavirus type p18. IV São Paulo Research Conference Cancer Today: From Molecular Biology to

Treatment. São Paulo, Brazil, November 2005.

210. Brogly SB, Watts H, Ylitalo N, Franco E, Seage G, Oleske J, Eagle M, Van Dyke R. Reproductive health of

perinatally HIV-infected adolescent girls. 11th Annual Maternal and Child Health Epidemiology Conference,

Miami, USA, December 2005.

211. Mayrand MH(§), Duarte-Franco E, Rodrigues I, Walter SD, Ratnam S, Coutlée F, Franco EL. Cross-sectional

efficacy estimates of Pap vs hpv testing from the Canadian cervical cancer screening trial. 6th

International

Multidisciplinary Congress EUROGIN 2006, Paris, France, April 2006.

212. Trottier H(§), Mahmud S, Lindsay L, Jenkins D, Wieting S, Franco EL. Natural history of hpv infection and

cervical lesions in women from the placebo arm of an as04 adjuvanted hpv-16/18 L1 vaccine trial. 6th

International Multidisciplinary Congress EUROGIN 2006, Paris, France, April 2006.

213. Bernard L, Lindsay L, Rogoza R, Kohli MA, Franco EL. Use of Evidence-Based Models to Demonstrate the

Long-term Clinical Benefits of HPV Vaccination. 11th Annual International Meeting, International Society for

Pharmacoeconomics and Outcomes Research (ISPOR), Philadelphia, USA, May 2006.

214. Brassard P, Steensma C, Coutlée F, Roger M, Kornegay JR, Franco EL. Epidemiologie du virus du papillome

humain au Nunavik. Congrés de l’Association francophone pour le savoir (ACFAS), Montreal, Canada, May

2006.

215. de Pokomandy A(§), Rouleau D, Ghattas G, Vézina S, Coté P, Macleod J, Allaire G, Franco EF, Coutlée F.

HPV-16, 18, 31, 45 viral loads in anal intra-epithelial lesions in HIV-seropositive men. 15th Annual Canadian

Conference on HIV/AIDS research, Ottawa, Canada, June 2006.

216. Gagnon S, Hankins C, Pourreaux K, Franco E, The Canadian Women’s HIV Study Group, Coutlée F.

Polymorphism of the capsid L1 gene is not a determinant of persistence of HPV-52 infection in HIV-

seropositive women. 15th Annual Canadian Conference on HIV/AIDS research, Ottawa, Canada, June 2006.

217. Mayrand MH(§), Mahmud SM, Franco EL, Hanley J. Design, ethical and statistical challenges when studying

the performance of new screening tests for cervical cancer. 23rd International Biometric Conference, Montreal,

Canada, July 2006.

218. Burchell AN(§), Hanley J, Richardson H, Mahmud SM, Trottier H, Tellier PP, Coutlée F, Franco EL. Use of

stochastic computer simulation and maximum likelihood methods to estimate sexual transmissibility of human

papillomavirus infection. 23rd International Biometric Conference, Montreal, Canada, July 2006.

219. Trottier H(§), Schaffer A, Koushik A, Duarte-Franco E, Coutlée F, Pollak M, Franco EL. Insulin-like growth

factor-I and risk of high-grade cervical intraepithelial neoplasia. 23rd International Papillomavirus Conference,

Prague, Czech Republic, September 2006.


85

220. Trottier H(§), Mahmud S, Prado J, Rohan TE, Villa LL, Franco EL. Duration of type-specific HPV infection:

Results from the Ludwig-McGill cohort study. 23rd International Papillomavirus Conference, Prague, Czech

Republic, September 2006.

221. Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M.

Estimating the long-term impact of a prophylactic human papillomavirus (HPV) 16/18 vaccine on the burden

of cervical disease in the UK. 23rd International Papillomavirus Conference, Prague, Czech Republic,

September 2006.

222. Trevisan A, Schlecht NF, Ferreira S, Sichero L, Ferenczy A, Duarte-Franco E, Franco EL, Villa LL.

Correlation between viral load measured by real-time and low-stringency PCR testing of cervical specimens.

23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006.

223. Sichero L, Ferreira S, Trottier H, Ferenczy A, Franco EL, Villa LL. High grade cervical lesions are caused

preferentially by non-European variants of HPVs 16 and 18. 23rd International Papillomavirus Conference,

Prague, Czech Republic, September 2006.

224. Sénécal M, Maunsell E, Ferenczy A, Franco EL, Ratnam S, Coutlée F, Palefsky JM, Foucart S, Brisson M,

Mansi JA. Psychosocial impact of cervical screening and condyloma: an epidemiological study (pisces). 23rd

International Papillomavirus Conference, Prague, Czech Republic, September 2006.

225. Mayrand MH(§), Duarte-Franco E, Rodrigues I, Walter SD, Coutlée F , Ratnam S, Franco EL. Comparison of

Pap and hpv testing strategies for screening high-grade cervical cancer precursors: Results from the Canadian

Cervical Cancer Screening Trial (CCCaST). 23rd International Papillomavirus Conference, Prague, Czech

Republic, September 2006.

226. De Pokomandy A(§), Rouleau D, Ghattas G, Vézina S, Côté P, MacLeod J, Allaire G, Fontaine J, Trépanier

JM, Franco EL, Coutlée F. Human Papillomavirus 16, 18, 31, 45 viral loads and grade of anal intraepithelial

neoplasia in HIV-infected men. 23rd International Papillomavirus Conference, Prague, Czech Republic,

September 2006.

227. Tomita LY(§), Carneiro LC, Villa LL, Franco EL, Cardoso MA. Serum micronutrients in relation to human

papillomavirus infection in Brazilian women: Preliminary results. 1st World Congress of Public Health

Nutrition, Barcelona, Spain, September 2006.

228. Tomita LY(§), Carneiro LC, Franco EL, Villa LL, Cardoso MA. Fatores dietéticos e infecção por HPV em

mulheres de baixa renda, cidade de São Paulo. 14th

Congresso Latino-Americano de Nutrição, Florianópolis,

Brazil, November 2006.

229. Tomita LY(§), D´Almeida V, Longatto-Filho A, Villa LL, Franco EL, Cardoso MA. Higher homocysteine and

lower serum levels of alpha-tocopherol are risk factors for cervical dysplasia in women living in São Paulo,

Brazil. Frontiers in Cancer Prevention Research Conference, American Association for Cancer Research,

Boston, USA, November, 2006.

230. Gall SA, Teixeira J, Wheeler CM, Naud P, Harper DM, Franco EL, Quint W, Zahaf T, Schuind A, Jenkins D,

Dubin G. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women

vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. American Association for Cancer Research

Annual Meeting: Proceedings; 2007 Apr 14-18; Los Angeles, CA. Philadelphia (PA): AACR; 2007. Abstract

nr 4900

231. Mahmud S, Turner D, Franco E, Aprikian A. Meta-analysis of the effects of aspirin, NSAID and

acetaminophen use on prostate cancer risk. Poster presentation. Canadian Society of Epidemiology and

Biostatistics. Calgary, Canada, May 2007.

232. Salemi JL, Siegel EM, Lu B, Franco EL, Villa L, Giuliano AR. Dietary Carotenoid Intake and Risk of

Squamous Intraepithelial Lesions of the Cervix: The Ludwig-McGill Human Papillomavirus Natural History

Study. 40th

Annual Meeting of the Society for Epidemiologic Research, Boston, USA, June 2007.

233. Burchell AN(§), Hanley J, Tellier P, Coutlée F, Franco EL. Agreement in women’s and men’s reporting of

vaginal sex encounters in the HITCH cohort study. 17th

Congress of the International Society for Sexually

Transmitted Diseases Research, Seattle, USA, July 2007.

234. Mahmud S, Turner D, Franco E, Aprikian A. Meta-analysis of the effects of aspirin, NSAID and

acetaminophen use on prostate cancer risk. Oral presentation. 23rd International Conference on

Pharmacoepidemiology. Quebec City, Canada, August 2007.

235. Burchell AN(§), Hanley J, Tellier P, Coutlée F, Franco EL. HPV concordance among couples who recently

initiated a sexual relationship: Results from the HITCH cohort study. EUROGIN 2007: New Strategies of

Cervical Cancer Prevention, Monte Carlo, Monaco, October 2007.


86

236. Trottier H, Mahmud S, Prado JM, Sobrinho JS, Costa MC, Rohan TE, Villa LL, Franco EL. Duration of type-

specific HPV infection: Implications for HPV screening and vaccination. EUROGIN 2007: New Strategies of

Cervical Cancer Prevention, Monte Carlo, Monaco, October 2007.

237. Mayrand MH(§), Trottier H, Duarte-Franco E, Rodrigues I, Walter SD, Coutlée F, Ratnam S, Franco EL.

Modelling the sensitivity and specificIty of Pap and HPv DNA testing in screening for cervical cancer

precursors: Results from the CCCaST study. EUROGIN 2007: New Strategies of Cervical Cancer Prevention,

Monte Carlo, Monaco, October 2007.

238. Sauthier P, Davies P, Mayrand MH, Provencher D, Petignat P, Drouin P, Gauthier P, Dupuis MJ, Michon B,

Ouellet S, Lussier C, Franco EL, Coutlée F(*). Comparison of hybrid capture 2 (hc2) and amplicor hpv (mwp

hpv) tests for the triage to colposcopy of women with ascus. EUROGIN 2007: New Strategies of Cervical

Cancer Prevention, Monte Carlo, Monaco, October 2007.

239. Van Niekerk D, Ogilvie G, Krajden M, Martin R, Ehlen T, Stuart G, Peacock S, Smith L, Franco E, Coldman

A. A randomised controlled trial of hpv testing for cervical cancer screening. Hpv Focal Sudy. EUROGIN

2007: New Strategies of Cervical Cancer Prevention, Monte Carlo, Monaco, October 2007.

240. Krawczyk A, Rosberger Z, Knauper B, Koestner R, Rosen N, DiDio P, Franco E. Asking the right questions

about sexual behaviour following the introduction of the Human Papillomavirus vaccine to prevent cervical

cancer and genital warts. 33rd

Annual Meeting of the Canadian Sex Research Forum, Banff, Canada, October

2007.

241. Rosen N, Knauper B, DiDio P, Morrison E, Tabing R, Mayrand MH, Franco E, Rosberger Z. Informing

women about HPV testing to prevent cervical cancer:The impact of matching information to women’s

intolerance of uncertainty. 33rd

Annual Meeting of the Canadian Sex Research Forum, Banff, Canada, October

2007.

242. Spence A(§), Trottier H, Villa LL, Franco EL. Cigarette smoking and the natural history of cervical human

papillomavirus infection. Making Connections: A Canadian Cancer Research Conference Celebrating NCIC’s

60th Anniversary, Toronto, Canada, November 2007.

243. Spence A(§), Goggin P, Franco EL. Process of care failures in invasive cervical cancer: Systematic review and

meta-analysis. Making Connections: A Canadian Cancer Research Conference Celebrating NCIC’s 60th

Anniversary, Toronto, Canada, November 2007.

244. Burchell AN(§), Hanley J, Tellier P, Coutlée F, Franco EL. Evidence of hpv transmission among couples who

recently initiated a sexual relationship: Results from the hitch cohort study. 24th


Conference, Beijing, China, November 2007.

245. Trottier H(§), Duarte-Franco E, Prado JM, Sobrinho JS, Costa MC, Rohan TE, Ferenczy A, Villa LL, Franco

EL. HPV infection, cervical neoplasia and contraceptive methods. 24th


Conference, Beijing, China, November 2007.

246. Trottier H(§), Mahmud S, Lindsay L, Wieting S, Jenkins D, Franco EL. Risk of cervical lesions following

incident human papillomavirus infection in young women without evidence of prior exposure. 24th

International Papillomavirus Conference, Beijing, China, November 2007.

247. Siegel EM, Lu B, Craft NE, Trevisan A, Villa LL, Duarte-Franco E, Franco EL, Giuliano A. Circulating

antioxidant nutrients predictors of HPV viral load over time. 24th


Beijing, China, November 2007.

248. Trevisan A, Schlecht NF, Franco EL, Villa LL. Validation of a new protocol to detect viral HPV-16 DNA

integration. 24th

International Papillomavirus Conference, Beijing, China, November 2007.

249. Hamlin-Douglas L, Franco EL, Coutlée F, Brassard P. Prevalence and determinants of HPV infection in

aboriginal women of Nunavik, Quebec. 24th

International Papillomavirus Conference, Beijing, China,

November 2007.

250. Rosberger Z, DiDio P, Rosen NO, Knäuper B, Morrison E, Tabing R, Krawczyk A, Mayrand MH, Franco EL.

Age Differences in Knowledge and Attitudes about HPV and Cervical Cancer Risk. 24th

International

Papillomavirus Conference, Beijing, China, November 2007.

251. Stoler M, Ferenczy A, Ronnett B, Kurman R, Franco E, Liaw K-L, Saah A, Radha R, Barr E. The Accuracy of

Colposcopic Biopsy: A Report from the Gardasil Clinical Trials Pathology Panel. 24th International

Papillomavirus Conference, Beijing, China, November 2007.

252. Mayrand MH(§), Trottier H, Duarte-Franco E, Rodrigues I, Walter SD, Coutlee F, Ratnam S, Franco EL.

Modelling the sensitivity and specificity of PAP and HPV DNA testing in screening for cervical cancer

precursors: Results from the CCCaST study. 24th International Papillomavirus Conference, Beijing, China,

November 2007.


87

253. Ramanakumar AV, Parent ME, Siemiatycki J. Exposures in painting related occupations and risk of lung

cancer among men: results from two case-control studies in Montreal. Canadian Society for Epidemiology and

Biostatistics meeting, May - June, 2007, Toronto.

254. Rosen NO, Knäuper B, DiDio P, Morrison E, Tabing R, Mayrand MH, Franco EL, Rosberger Z. Providing

information about health threats: How uncertainty mediates the degree of distress. 9th Annual Meeting of the

Society for Personality and Social Psychology, Albuquerque, USA, February 2008.

255. Stoler M, Ferenczy A, Ronnett B, Kurman R, Franco E, Liaw K-L, Saah A, Radha R, Barr E. The Accuracy of

Colposcopic Biopsy: A Report from the Gardasil Clinical Trials Pathology Panel. United States and Canadian

Academy of Pathology Annual Meeting, Denver, USA, March 2008.

256. Dang-Tan T, Trottier H, Mery LS, Morrison HI, Barr RD, Greenberg ML, Franco EL. Delays in diagnosis and

treatment among children and adolescents with cancer in Canada. 18th World Congress of Epidemiology,

International Epidemiological Association, Porto Alegre, Brazil, September 2008.

257. Dang-Tan T, Trottier H, Mery LS, Morrison HI, Barr RD, Greenberg ML, Franco EL. Determinants of delays

in cancer care in children with leukemia. 18th World Congress of Epidemiology, International Epidemiological

Association, Porto Alegre, Brazil, September 2008.

258. Tomita LY, Longato-Filho A, Costa MC, Andreoli MA, Villa LL, Franco EL, Cardoso MA. Diet and serum

micronutrients in relation to cervical neoplasia and cancer among low-income Brazilian women. 18th World

Congress of Epidemiology, International Epidemiological Association, Porto Alegre, Brazil, September 2008.

259. Burchell AN(§), Hanley J, Tellier PP, Coutlée F, Franco EL. Evidence of hpv transmission among couples

who recently initiated a sexual relationship: results from the hitch cohort study. 18th World Congress of

Epidemiology, International Epidemiological Association, Porto Alegre, Brazil, September 2008.

260. Ramanakumar AV(§),Thomann P, Trevisan A, Trottier H, Villa LL, Franco EL. Paradoxically positive

association between seropositivity for neutralizing antibodies against human papillomavirus (hpv) type 16 and

risk of cervical hpv-16 infection in women attending cervical cancer screening. 18th World Congress of

Epidemiology, International Epidemiological Association, Porto Alegre, Brazil, September 2008.

261. Burchell AN(§), Trottier H, Platt R, Prado JCM, Sobrinho JS, Costa MC, Villa LL, Franco EL. Risk factors

for incident infection with oncogenic types of human papillomavirus among Brazilian women. 18th World

Congress of Epidemiology, International Epidemiological Association, Porto Alegre, Brazil, September 2008.

262. Fortino A, Koshiol J, Franco E, Pimenta J, Poole C, Smith JS. Human papillomavirus persistence patterns in

women worldwide: a meta-analysis. EUROGIN 2008 Congress ‘Joining Forces for Cervical Cancer

Prevention’, Nice, France, November 2008.

263. Mayrand MH(§), Duarte-Franco E, Rodrigues I, Walter SD, Coutlée F, Ratnam S, Franco EL. Insights from

the longitudinal component of the the Canadian cervical cancer screening trial (CCCaST). EUROGIN 2008

Congress ‘Joining Forces for Cervical Cancer Prevention’, Nice, France, November 2008.

264. Burchell AN(§), Hanley J, Tellier PP, Coutlée F, Franco EL. Risk factors for hpv-16 among young men and

women in a new sexual relationship. EUROGIN 2008 Congress ‘Joining Forces for Cervical Cancer

Prevention’, Nice, France, November 2008.

265. Sénécal M, Maunsell E, Brisson M, Franco E, Ferenczy A, Ratnam S, Coutlée F, Palefsky J, Mansi J.

Psychosocial burden associated with abnormal cervical Pap test results and external ano-genital warts.

EUROGIN 2008 Congress ‘Joining Forces for Cervical Cancer Prevention’, Nice, France, November 2008.

266. Sauthier P, Davies P, Mayrand MH, Provencher D, Petignat P, Drouin P, Gauthier P, Dupuis MJ, Michon B,

Ouellet S, Lussier C, Franco E, Coutlée F. Hybrid capture 2 (hc2), amplicor hpv (mwp hpv) and linear array

(la) tests for the triage of women with ascus to colposcopy. EUROGIN 2008 Congress ‘Joining Forces for

Cervical Cancer Prevention’, Nice, France, November 2008.

267. Ramanakumar AV(§), Sangwa-Lugoma G, Mahmud S, Lorincz A, Ferenczy A, Liaras J, Franco EL.

Prevalence and determinants of human papillomavirus infection in women from Kinshasa, Congo. EUROGIN

2008 Congress ‘Joining Forces for Cervical Cancer Prevention’, Nice, France, November 2008.

268. van Niekerk D, Ogilvie G, Krajden M, Martin R, Stuart G, Peacock S, Ehlen T, Smith L, Franco E, Coldman

A. A randomised controlled trial of hpv testing for cervical cancer screening “hpv focal study”. EUROGIN

2008 Congress ‘Joining Forces for Cervical Cancer Prevention’, Nice, France, November 2008.

269. Trottier H, Ferreira S, Prado JCM, Sobrinho JS, Costa MC, Villa LL, Franco E. HPV in older women is

associated with new sexual partners. 25th

International Papillomavirus Conference, Malmo, Sweden, May

2009.

270. Burchell A(§), Hanley J, Tellier P, Coutlée F, Franco E. Probability of hpv transmission among newly-formed

couples. 25th

International Papillomavirus Conference, Malmo, Sweden, May 2009.


88

271. de Pokomandy A(§), Rouleau D, Ghattas G, Vézina S, Côté P, Macleod J, Allaire G, Trottier H, Franco E,

Coutlée F. Predictors of high-grade anal dysplasia in hiv-seropositive men. 25th


Conference, Malmo, Sweden, May 2009.

272. Ogilvie G, van Niekerk D, Krajden M, Martin R, Stuart G, Peacock S, Ehlen T, Smith L, Franco E, Coldman

A. Evaluating primary hpv testing in a Canadian organized screening program. 25th

International

Papillomavirus Conference, Malmo, Sweden, May 2009.

273. Trevisan A(§), Schlecht NF, Ramana - Kumar AV, Franco E, Villa LL. Physical state and clearance of hpv16

infection. 25th


274. Trevisan A(§), Schlecht NF, Ramana - Kumar AV, Villa LL, Franco E. HPV-16 viral load measurements and

duration of infection. 25th


275. Cornut G, Gagnon S, Hankins C, Money D, Pourreaux K, Franco E, Coutlée F. L1 polymorphism of hpv types

related to hpv-16. 25th


276. Burchell A(§), Hanley J, Tellier P, Coutlée F, Franco E. Prevalence and Between-Partner Concordance of

Human Papillomavirus (HPV) Infection Among Couples in a New Sexual Relationship. 18th

Congress of the

International Society for STD Research, London, UK, June 2009.

277. Ehlen T, Ogilvie G, van Niekerk D, Krajden M, Martin R, Stuart G, Peacock S, Smith L, Franco E, Coldman

A. Primary Hpv Testing in a Canadian Organized Screening Program. EUROGIN 2010 Congress, Monte-

Carlo, Monaco, February 2010.

278. Burchell AN(§), Tellier PP, Coutlée F, Hanley J, Franco EL. The effect of hpv vaccination on infection in

partnerships. EUROGIN 2010 Congress, Monte-Carlo, Monaco, February 2010.

279. Sirjoosingh C(§), Ramanakumar AV, Franco EL. Socioeconomic disparities in cervical cancer survival in the

United States. EUROGIN 2010 Congress, Monte-Carlo, Monaco, February 2010.

280. Ramanakumar VA(§), Richardson H, Tellier PP, Coutlée F, Franco EL. Viral load of hpv 16, 18, 31, 45 and

infection clearance. EUROGIN 2010 Congress, Monte-Carlo, Monaco, February 2010.

281. Burchell AN(§), Tellier PP, Coutlée F, Hanley J, Franco EL. Transmission of male hpv infection. EUROGIN

2010 Congress, Monte-Carlo, Monaco, February 2010.

282. Ferguson RB(§), Ramanakumar A, Richardson H, Coutlée F, Roger M, Franco EL. The role of hla e and g

alleles in susceptibility to hpv infection. EUROGIN 2010 Congress, Monte-Carlo, Monaco, February 2010.

283. Drolet M, Brisson M, Maunsell E, Ferenczy A, Franco EL, Ratnam S, Coutlée F, Palefsky JM, Blanchette C,

Mansi JA. Quality of life lost following an abnormal cervical cytology result: a prospective 3-month study.

EUROGIN 2010 Congress, Monte-Carlo, Monaco, February 2010.


Mansi JA. Loss of quality of life associated with genital warts: a prospective 6-month study. EUROGIN 2010

Congress, Monte-Carlo, Monaco, February 2010.

285. Tota J(§), Ramanakumar A, Villa LL, Franco EL. Cervical hpv dna detection in relation to menstrual phase.

EUROGIN 2010 Congress, Monte-Carlo, Monaco, February 2010.


Mansi JA. Impact d'un résultat anormal au test de Papanicolaou sur la qualité de vie. EUROGIN 2010

Congress, Monte-Carlo, Monaco, February 2010.

287. de Pokomandy A(§), Rouleau D, Ghattas G, Trottier H, Vézina S, Coté P, Macleod J, Allaire G, Franco EL,

Coutlée F. Highly active antiretroviral therapy (HAART) protects against Anal Intraepithelial Neoplasia 2/3 in

HIV-seropositive men in Montreal. 26th

International Papillomavirus Conference, Montreal, Canada, July

2010.

288. Bennett R, Coutlée F, Roger M, Franco E, Brassard P. Incidence, persistence, and determinants of HPV

infection in a population of Inuit women in Nunavik, Quebec. 26th


Montreal, Canada, July 2010.

289. Sirjoosingh C(§), Ramanakumar A, Harper S, Strumpf E, Portelance L, Ferenczy A, Gilbert L, Franco E.

Racial Disparities in Cervical Cancer Treatment and Survival in the United States. 26th

International

Papillomavirus Conference, Montreal, Canada, July 2010.

290. Alvarez J, de Pokomandy A, Rouleau D, Ghattas G, Trottier H, Franco EL, HIPVIRG Study Group, Coutlée

F. Episomal and integrated HPV-16 loads in anal intraepithelial neoplasia in HIV-seropositive men. 26th

International Papillomavirus Conference, Montreal, Canada, July 2010.

291. Ogilvie G, van Niekerk D, Krajden M, Ehlen T, Martin R, Peacock S, Smith L, Stuart G, Franco E, Coldman

A. Randomized controlled trial of primary HPV testing in a Canadian organized screening program. 26th



89

292. Ceballos K, Ogilvie G, van Niekerk D, Mei W, Cook D, Smith L, Franco E, Coldman A, Krajden M.

Comparison of the Roche cobas 4800 vs. Qiagen hc2 Tests for Detection of High-Risk HPV DNA. 26th


293. Ogilvie G, van Niekerk D, Krajden M, Martin R, Stuart G, Peacock S, Ehlen T, Smith L, Franco E, Coldman

A. Primary HPV Testing in a Canadian Population-based Screening Program. 26th


Conference, Montreal, Canada, July 2010.

294. Drolet M, Brisson M, Maunsell E, Ferenczy A, Franco E, Coutlée F, Palefsky J, Mansi J. Understanding the

psychosocial burden of genital warts in Canada: A prospective 6-month study. 26th

International

Papillomavirus Conference, Montreal, Canada, July 2010.

295. Ramanakumar VA, Thomann P, Trevisan A, Trottier H, Franco EL. Seropositivity for HPV type 16

antibodies and its association with HPV infection and precancerous cervical lesions: Results from the Ludwig-

McGill Cohort Study. 26th


296. Burchell A(§), Tellier PP, Francois C, Hanley J, Franco E. Evidence for the protective effect of condoms

against male-to-female transmission. 26th

International Papillomavirus Conference, Montreal, Canada, July

2010.

297. Legault V, Burchell A, Goggin P, Nicolau B, Forest P, Franco E, Coutlée F. Evaluation of a generic assay for

the screening of pgmy-generated hpv amplicons. 26th

International Papillomavirus Conference, Montreal,

Canada, July 2010.

298. Siegel E, Patel N, Lu B, Lee JH, Craft N, Frenkel K, Villa L, Nyitray A, Franco E, Giuliano A. The

relationship between biomarkers of oxidant load and type-specific human papillomavirus clearance. 26th


299. Cerigo H, Coutlée F, Roger M, Franco EL, Brassard P. HPV detection by self-sampling in Nunavik, Québec:

comparability and preference to provider-sampling. 26th


Canada, July 2010.

300. Drolet M, Brisson M, Maunsell E, Ferenczy A, Franco E, Coutlée F, Ratnam S, Palefsky J, Mansi J.

Predictors of high anxiety following an abnormal cervical cytology result. 26th


Conference, Montreal, Canada, July 2010.

301. Farsi N, Rousseau MC, Schlecht N, Allison P, Franco E, Coutlee F, Nicolau B. Risk factors for Head and

Neck Cancer: Is there a difference by HPV status? 26th


Canada, July 2010.

302. Tota JE(§), Ramana-Kumar A, Coutlee F, Villa LL, Franco EL. HPV Type Replacement: An unlikely

phenomenon. 26th


303. van Niekerk D, Franco E, Krajden M, Martin R, Stuart G, Peacock S, Ehlen T, Smith L, Ogilvie G, Coldman

A. Primary Hpv Testing in a Canadian Population-Based Screening Program. EUROGIN 2011 Congress,

Lisbon, Portugal, May 2011.

304. Chevarie-Davis M(§), Ramanakumar AV, Ferreira S, Villa LL, Ferenczy A, Franco E. Hpv Dna Testing and

Cytology as Predictors of Histologically Confirmed Cervical Disease: Evidence from the Ludwig-McGill

Cohort. EUROGIN 2011 Congress, Lisbon, Portugal, May 2011.

305. deVries M(§), Agnihotram RV, Koushik A, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F,

Franco EL. The role of cofactors in progression of cervical precancerous lesions. EUROGIN 2011 Congress,

Lisbon, Portugal, May 2011.

306. Richardson LA(§), Ramanakumar AV, Fontaine D, Ratnam S, Mayrand MH, Coutlée F, Franco EL, on

behalf of CCCaST study group. Hpv Testing with Cytology Triage in Cervical Screening: Influence of

Revealed Versus Concealed Hpv Status. EUROGIN 2011 Congress, Lisbon, Portugal, May 2011.

307. Smith MA(§), Tellier PP, Coutlée F, Franco EL, Richardson H. Occurrence and Dynamics of Hpv

Coinfections Among Montreal University Students. EUROGIN 2011 Congress, Lisbon, Portugal, May 2011.

308. Cerigo H, Coutlée F, Roger M, Franco E, Brassard P. Inuit Women’s Acceptance and Preference of Hpv Self-

Sampling In Nunavik, Quebec. EUROGIN 2011 Congress, Lisbon, Portugal, May 2011.

309. Siegel E, Patel N, Galan L, Lu B, Lee JH, Nyitray A, Huang X, Villa L, Franco E, Giuliano A. Biomarkers of

iron storage and type specific human papillomavirus clearance. 27th International Papillomavirus Conference,

Berlin, Germany, September 2011.

310. Ogilvie G, van Niekirk D, Krajden M, Ceballos K, Ehlen TG, Martin RE, Smith L, Stuart G, Franco EL,

Coldman AJ. HPV FOCAL: round 1 result of cervical cancer screening trial. 27th International Papillomavirus

Conference, Berlin, Germany, September 2011.

311. Brassard P, Cerigo H, Coutlée F, Franco E. Predictors of cervical cancer screening among Inuit women in

Nunavik. 27th International Papillomavirus Conference, Berlin, Germany, September 2011.


90

312. Richardson LA(§), Ramanakumar AV, Franco EL, for the PEACHS Study Consortium. Influence of

revealed HR-HPV status on Pap cytology triage performance. 27th International Papillomavirus Conference,

Berlin, Germany, September 2011.

313. Chevarie-Davis M(§), Ramanakumar AV, Ferreira S, Ferenczy A, Villa LL, Franco E. Cervical lesion risk

prediction with HPV DNA testing and cytology. 27th International Papillomavirus Conference, Berlin,

Germany, September 2011.

314. Tota J(§), Burchell A, Tellier P, Coutlée F, Franco EL. Carrageenan-gel against transmission of cervical HPV:

The CATCH trial. 27th International Papillomavirus Conference, Berlin, Germany, September 2011.

315. Mahmud S, Lugoma G, Nasr SH, Liaras J, Kayembe PK, Tozin R, Drouin P, Lorincz A, Ferenczy A, Franco

EL. HPV testing vs. Cytology for cervical cancer screening in Congo. 27th International Papillomavirus


316. Tota J(§), Agnihotram RV, Coutlée F, Villa LL, Richardson H, Burchell A, Koushik A, Mayrand MH,

Franco EL. Epidemiologic approach to evaluate potential for HPV type replacement post-vaccination. 27th

International Papillomavirus Conference, Berlin, Germany, September 2011.

317. Rousseau MC, Farsi N, Allison P, Abraham P, Netuveli G, Soman A, Franco E, Coutlee F, Schlecht N,

Nicolau B. Head and neck cancer and HPV: Indian-Canadian comparison. 27th International Papillomavirus


318. Cook D, Ceballos K, vanNiekerk D, Ogilvie G, Chow R, Mei W, Smith L, Franco E, Coldman A, Krajden M.

Roche cobas® 4800 vs. Qiagen hc2® high-risk HPV DNA detection. 27th International Papillomavirus


319. Ramanakumar AV, Naud P, Roteli-Martins CM, Carvalho N, Borba P, Teixeira JC, Blatter M, Schuind A,

Dubin G, Franco EL, for the HPV-007 study group. HPV infection incidence and duration in previously

unexposed women. 27th International Papillomavirus Conference, Berlin, Germany, September 2011.

320. Franco E, Burchell A, Coutlée F, Tellier P, Hanley J. Genital transmission of human papillomavirus in

recently-formed, heterosexual couples. 27th International Papillomavirus Conference, Berlin, Germany,

September 2011.

321. deVries M(§), Agnihotram RV, Koushik A, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlee F,

Franco EL. Environmental factors and progression of cervical precancerous lesions. 27th International

Papillomavirus Conference, Berlin, Germany, September 2011.

Documents

The Cancer Research Society Division of Epidemiology fileThe Cancer Research Society Division of Epidemiology Department of Oncology McGill University REPORT OF ACTIVITIES 1995-2011